

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D		A2	(11) International Publication Number: WO 98/55454
			(43) International Publication Date: 10 December 1998 (10.12.98)
(21) International Application Number: PCT/JP98/02482		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 4 June 1998 (04.06.98)			
(30) Priority Data: 9/148325 5 June 1997 (05.06.97) JP			
(71) Applicant (for all designated States except US): TAKEDA CHEMICAL INDUSTRIES, LTD. [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP).			
(72) Inventors; and		Published	
(75) Inventors/Applicants (for US only): OHKAWA, Shigenori [JP/JP]; 45-20, Makamicho 6-chome, Takatsuki-shi, Osaka 569-1121 (JP). SETOH, Masaki [JP/JP]; 18-D73-302, Tsukumodai 5-chome, Saita-shi, Osaka 565-0862 (JP). KAKIHANA, Mitsuru [JP/JP]; 4-2, Tsukushigaoka 9-chome, Kita-ku, Kobe-shi, Hyogo 651-1212 (JP). OKURA, Masahiro [JP/JP]; 6-3-A, Shibuya 2-chome, Ikeda-shi, Osaka 563-0028 (JP).		Without international search report and to be republished upon receipt of that report.	
(74) Agents: ASAHIKA, Tadao et al.; Osaka Plant of Takeda Chemical Industries, Ltd., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-0024 (JP).			

(54) Title: HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE



(57) Abstract

A compound of formula (I): wherein R¹ and R² each is H or a hydrocarbon group which may be substituted, or R¹ and R² form a 3- to 8-membered carbo or heterocyclic ring which may be substituted; R³ is H, a lower alkyl which may be substituted or an aromatic group which may be substituted; R⁴ is (1) an aromatic group which may be substituted, (2) an aliphatic hydrocarbon group substituted by an aromatic group which may be substituted, which hydrocarbon group may be further substituted or (3) an acyl; X and Y each is oxygen or sulfur which may be oxidized; and ring A is a benzene ring which may be further substituted, or a salt thereof, is useful for an agent for suppressing neurodegeneration.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NB	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LJ	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

DESCRIPTION

Heterocyclic Compounds, Their Production and Use

TECHNICAL FIELD

5 The present invention relates to heterocyclic compounds, their production and use, and the compounds suppress cell toxicities caused by β -amyloid protein, protect nerve cell, and are useful for preventing and/or treating neurodegenerative diseases by
10 protecting nerve cell from other inducers of cell death.

BACKGROUND ART

Neurodegenerative diseases are progressive disorders that cause fatal damage of nerve cell death.
15 As principal neurodegenerative diseases, known are Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's chorea, peripheral nervous system disorders such as typically diabetic neuropathy, etc. Most of those are related to aging, and, in fact, cases that present the symptoms of those diseases increase with aging. However, middle-aged and even young-aged cases may often present the symptoms of those diseases.

20 As a result of studies relating to the structure and function of brains, the roles of neurotransmitters and neurotrophins are being gradually clarified, but most part of the causes of neurodegenerative diseases are still unknown. Only for Parkinson's disease, the relation between it and a specific neurotransmitter, dopamine has been clarified. L-dopa, which is a precursor of dopamine, is used as a medicine for Parkinson's disease. L-dopa relieves the neuropathic manifestation of Parkinson's disease, and maintains function. However, L-dopa could not suppress the progress of neurodegeneration in cases of Parkinson's disease, and it gradually loses its potency with the
25
30
35

progress of the manifestation of the disease, or that is, with the degeneration and death of dopamine-based nerve cells. Alzheimer's disease results in the degeneration and death of many types of nerve cells
5 such as acetylcholine-based nerve cells and monoamine-based nerve cells. For this disease, some cholinesterase inhibitors are commercially available and some others are in the development stage. However, those are still within the range of symptomatic
10 treatment for temporarily relieving the neuropathic manifestation of Alzheimer's disease, like L-dopa for Parkinson's disease.

As has been mentioned above, no medicines have been reported for protecting nerve cells from the
15 toxicity of factors causing cell death thereby to suppress the progress of neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.

It is said that the cell death in neurodegenerative diseases is caused by the toxicity of factors that are intrinsic to the respective diseases.
20 For Alzheimer's disease, for example, it is believed that the intrinsic β -amyloid in the disease is a factor to cause cell death. β -amyloid is a protein seen in the brains of cases of Alzheimer's disease, and this constitutes senile lentigines that are characteristic
25 of the disease in neuropathology, and is composed of from 40 to 43 amino acids. It has been clarified that, when β -amyloid is added to the primary culture of hippocampus nerve cells, this kills the cells (see
30 Science, Vol. 245, pp. 417-420, 1989); and it has been reported that the coagulation of β -amyloid is indispensable for the expression of its toxicity (see Neurobiology of Aging, Vol. 13, pp. 587-590, 1992; and Journal of Molecular Biology, Vol. 218, pp. 149-163,
35 1991). For the toxicity expression mechanism of β -

amyloid, the following (1) to (4) may be taken into consideration: (1) β -amyloid forms ion channels, through which calcium ions run into nerve cells. (2) β -amyloid promotes the generation of free radicals.


5 (3) β -amyloid activates tau-protein kinase I (TPK-I) whereby phosphorylation of tau is promoted. (4) β -amyloid activates microglia, which thereby secretes neurotoxin. However, no one has as yet obtained the conclusion.

10 Recently, it has been clarified that neurotrophins such as IGF-1 (insulin-like growth factor) and NGF (nerve growth factor) inhibit the apoptosis of nerve cells by β -amyloid or the like, and that, for its mechanism, the apoptosis inhibition is related to the
15 inhibition of TPK-I/GSK-3 β (glycogen synthase kinase 3) through activation of PI-3 kinase (see J. Neurosci., Vol. 11, pp. 2552-2563, 1991; Science, Vol. 267, pp. 2003-2006, 1995; and J. Biol. Chem., Vol. 272, pp. 154-161, 1997). When PI-3 kinase is inhibited by β -amyloid
20 and TPK-I/GSK-3 β is activated, then pyruvate dehydrogenase (PDH) is inhibited, while having an influence on the synthesis of acetylcholine, to thereby lower the acetylcholine content. This is supported by the decrease in the acetylcholine content of the brains
25 of cases of Alzheimer's disease. On the contrary, when PI-3 kinase is activated, then it is expected that not only the nerve cell death is prevented but also the intracerebral acetylcholine content is increased to improve the nervous system condition. In addition, it
30 is also expected that the inhibition of TPK-I/GSK-3 β results in the increase in the intracerebral glucose utilization which is lowered in cases of Alzheimer's disease (see J. Biol. Chem., Vol. 269, pp. 3568-3573, 1994; and Endocrinology, Vol. 125, pp. 314-320, 1989).

Accordingly, low-molecular compounds having good permeability to the brain and having neurotrophic action may inhibit nerve cell death in cases of neurodegenerative diseases such as Alzheimer's disease,
5 while improving the nervous system condition in those cases.


Known are the following dihydrobenzofuran compounds which are effective for neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's
10 disease, etc.).

1) A compound of the formula:



wherein R is a lower alkyl, R⁰ is hydrogen or an acyl;
R¹ and R² are the same or different and are a lower
15 alkyl which may be substituted, or R¹ and R², taken
together, are a butadienylene which may be substituted;
R³ and R⁴ each is hydrogen or an alkyl which may be
substituted, or R³ and R⁴, taken together, are a
20 polymethylene; R⁵ is a lower alkyl, an aromatic group
or heterocyclic group which may be substituted (EP-A-
273647, JP-A-1-272578).

2) A compound of the formula:




wherein R¹ and R² are the same or different and are a
25 hydrogen atom, an acyl, an alkoxy carbonyl, an
optionally substituted aliphatic group or an optionally
substituted aromatic group; R³, R⁴ and R⁵ are the same
or different and are an optionally acylated hydroxy, an
optionally substituted amino, an optionally substituted

alkoxy or an optionally substituted aliphatic group, or two of R³, R⁴ and R⁵ may be linked together to form an optionally substituted carbocyclic group; R⁶ and R⁷ are the same or different and are an optionally substituted aliphatic group, provided that at least one of R⁶ and R⁷ has methylene at α-position; and R⁸ and R⁹ are the same or different and are a hydrogen atom, an optionally substituted aliphatic group or an optionally substituted aromatic group, or a salt thereof (EP-A-10 483772, JP-A-5-140142).

Also known are the following benzofuran compounds and dihydrobenzofuran compounds.


3) A compound of the formula:



15 wherein A is -O-, -S(O)m-, -N(R¹¹)-, -CH₂CH₂- , or -CH=CH-; m is 0, 1, or 2; X is a bond or C₁₋₄ alkylidenyl; R² is a group of the formula: -NR⁴R⁵ wherein R⁴ and R⁵ are independently C₁₋₆ alkyl, etc.); R is hydroxy, halo, C₃₋₈ cycloalkyl, C₂₋₇ alkanoyloxy, C₁₋₆ alkoxy, phenyl, etc.; R¹ is hydroxy, halo, hydrogen, C₃₋₈ cycloalkyl, C₂₋₇ alkanoyloxy, C₁₋₆ alkoxy, phenyl, etc., or a pharmaceutically acceptable salt, which is useful for the prevention and treatment of physiological disorder associated with an β-amyloid such as Alzheimer's disease and Down's syndrome (WO 95/17095).


25 4) A compound of the formula:

6




wherein R¹ is hydrogen or a lower alkyl; R² is a methyl substituted by carboxy, alkoxy carbonyl, cyano, halogen, aryl or heterocyclic group, or C₂₋₁₅ chain-like hydrocarbon residue having no lower alkyl at α-position which may be substituted by carboxy, alkoxy carbonyl, cyano, halogen, aryl or a heterocyclic group; R³ is a lower alkyl; R⁴ is hydrogen of an acyl; R⁵ and R⁶ each is a lower alkyl of a lower alkoxy, or R⁵ and R⁶, taken together, are butadienylene, or a salt thereof, which has 5- or 12-lipoxygenase inhibiting actions (EP-A-345593, JP-A-2-76869).

5) A compound of the formula:



wherein R¹ is hydrogen or a lower alkyl; n is 1 to 6; X is sulfur which may be oxidized, oxygen or imino which may be substituted; R² is methyl or an organic residue bonded through methylene, methylene or quaternary carbon; R³ is a lower alkyl; R⁴ is hydrogen or an acyl; R⁵ and R⁶ each is a lower alkoxy or a lower alkyl, or R⁵ and R⁶, taken together, are butadienylene, or a salt thereof, which has a 5-lipoxygenase inhibiting action (EP-A-345592, JP-A-2-76870).


6) A compound of the formula:



wherein R is hydrogen or methyl; R¹ and R² each are methyl or ethyl, or R¹ and R² taken together are a saturated heterocyclic group; and X is bromo, chloro, 5 fluoro or hydrogen, or a pharmaceutically acceptable salt thereof, which is useful for inhibiting bone loss (EP-A-722726).


Known are the following indole compounds.

7) A compound of the formula:



10 wherein R₁ is -X(CH₂)_nAr, -X(CH₂)_nR₈ etc., R₂ is hydrogen or Ar etc., P₁ is -X(CH₂)_nR₆, P₂ is -X(CH₂)_nR₈ etc., R₃ is hydrogen, R₁₁, OH, C₁₋₈ alkoxy, S(O)q R₁₁, N(R₆)₂, Br, F, I, Cl, CF₃, NHCOR₆, -R₁₁CO₂R₇, -XR₉-Y, XY or -X(CH₂)_nR₈, 15 wherein methylene of the -X(CH₂)_nR₈ may be unsubstituted or substituted by one more -(CH₂)_nAr, R₈ is hydrogen, R₁₁ etc., R₉ is C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, phenyl, etc., R₁₁ is C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, etc., X is (CH₂)_n, O, S(O)q, Y is CH₃ or -X(CH₂)_nAr, Ar 20 is phenyl, naphthyl, etc., q is 0, 1 or 2, n is an integer of 0 to 6, or a pharmaceutically acceptable salt thereof, which is useful for antagonizing endothelin receptors and treating cerebrovascular diseases (WO 94/14434, JP-A-8-504826).

8) A compound of the formula:




wherein one of R and R₀ is ,

and the other is C₁₋₆ alkyl, C₃₋₆ cycloalkyl or phenyl-
 5 (CH₂)_m-wherein R₄, R₅ and R_{5a} are hydrogen, etc.; m is 1,
 2 or 3; R₂ is hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₁₋₄
 alkoxy, phenoxy, benzyloxy, etc.; R₃ is hydrogen, C₁₋₃
 alkyl, C₁₋₃ alkoxy, phenoxy, benzyloxy, etc.; X is
 - (CH₂)_n - or -CH=CH-; n is 0, 1, 2 or 3; R₆ is hydrogen
 10 or C₁₋₃ alkyl, or a salt thereof, which has cholesterol
 biosyntheses inhibiting activity (WO 84/02131).

DISCLOSURE OF INVENTION

We, the present inventors have studied various
 15 compounds and, as a result, have succeeded in the
 creation of a novel compound of the formula:



wherein R¹ and R² each represents a hydrogen atom or a hydrocarbon group which may be substituted, or
 20 R¹ and R² form, taken together with the adjacent carbon atom, a 3- to 8-membered carbo or heterocyclic ring which may be substituted;
 R³ represents a hydrogen atom, a lower alkyl which may be substituted or an aromatic group which may be substituted;
 25 R⁴ represents (1) an aromatic group which may be substituted, (2) an aliphatic hydrocarbon group

substituted by an aromatic group which may be substituted, which hydrocarbon group may be further substituted or (3) an acyl;

5 X and Y each represents an oxygen atom or a sulfur atom which may be oxidized;


----- represents a single bond or a double bond; and ring A represents a benzene ring which may be further substituted apart from the group of the formula: -X-R⁴ wherein each symbol is as defined above,

10 provided that when X and Y are oxygen atoms and ----- is a single bond, R⁴ is not an acyl, or a salt thereof [hereinafter sometimes referred to briefly as compound (I)], which compound is structurally characterized in that the benzene ring

15 which is condensed with a 5-membered heterocyclic ring is substituted by a group of the formula: -X-R⁴ wherein each symbol is as defined above.

We have found for the first time that compound (I), being based on its specific chemical structure, and a

20 compound of the formula:



wherein R^{4a} represents an aromatic group which may be substituted, an aliphatic hydrocarbon group which may be substituted or an acyl;

25 Xa represents an oxygen atom or a sulfur atom which may be oxidized;

Y_a represents an oxygen atom, a sulfur atom which may be oxidized or an imino which may be substituted;

----- represents a single bond or a double bond;

30 ring Aa represents a benzene ring which may be further substituted apart from (i) the group of the formula: -Xa-R^{4a} wherein each symbol is as defined above, and (ii) an amino which may be substituted,

and the other symbols are defied as above,
provided that when X_a and Y_a are oxygen atoms and
--- is a single bond, R⁴ is not an acyl, or a salt
thereof [hereinafter sometimes referred to briefly as
5 compound (Ia)], have an unexpected, excellent
suppressive effect on neurodegeneration, low toxicity,
excellent permeability to the brain and are therefore
satisfactory as medicines for suppressing
neurodegeneration. Compound (I) is within the scope of
10 compound (Ia). On the basis of these findings, the
inventors have completed the present invention.

Specifically, the present invention relates to:

- 1) compound (I);
- 15 2) a compound of the above 1), wherein R¹ and R² each
is (i) a hydrogen atom or
(ii) a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆
cycloalkyl or C₆₋₁₄ aryl group which may be substituted
by 1 to 5 substituents selected from the group
20 consisting of (1) halogen atoms, (2) C₁₋₃ alkylenedioxy,
(3) nitro, (4) cyano, (5) optionally halogenated C₁₋₆
alkyl, (6) optionally halogenated C₂₋₆ alkenyl, (7)
optionally halogenated C₂₋₆ alkynyl, (8) optionally
halogenated C₃₋₆ cycloalkyl, (9) C₆₋₁₄ aryl, (10)
25 optionally halogenated C₁₋₆ alkoxy, (11) optionally
halogenated C₁₋₆ alkylthio, (12) hydroxy, (13) amino,
(14) mono-C₁₋₆ alkylamino, (15) mono-C₆₋₁₄ arylamino, (16)
di-C₁₋₆ alkylamino, (17) di-C₆₋₁₄ arylamino, (18) acyl
selected from the group consisting of formyl, carboxy,
30 carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl,
C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-
carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-
carbonyl, 5- or 6-membered heterocycle carbonyl, mono-
35 C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-
carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆
alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and
C₆₋₁₄ arylsulfinyl, (19) acylamino selected from the

group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (20) acyloxy selected from the group consisting of C₁₋₆

5 alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy, (21) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the

10 group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (22) 5- to 10-membered aromatic heterocyclic group and (23) sulfo, or R¹ and R² form, taken together with the adjacent carbon atom, a C₃₋₈ cycloalkane or a 3- to 8-membered

15 heterocyclic ring, each of which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl, C₇₋₁₆ aralkyl, amino, mono-C₁₋₆ alkylamino, mono-C₆₋₁₄ arylamino, di-C₁₋₆ alkylamino, di-C₆₋₁₄ arylamino and 5- to 10-membered aromatic

20 heterocyclic group;

R³ is (i) a hydrogen atom,

(ii) a C₁₋₆ alkyl which may be substituted by 1 to 5 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₃ alkylenedioxy, (3) nitro, (4)

25 cyano, (5) optionally halogenated C₁₋₆ alkyl, (6) optionally halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) C₆₋₁₄ aryl, (10) optionally halogenated C₁₋₆ alkoxy, (11) optionally halogenated C₁₋₆ alkylthio,

30 (12) hydroxy, (13) amino, (14) mono-C₁₋₆ alkylamino, (15) mono-C₆₋₁₄ arylamino, (16) di-C₁₋₆ alkylamino, (17) di-C₆₋₁₄ arylamino, (18) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆

alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (19) acylamino selected from the group consisting of 5 formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (20) 10 acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy, (21) 15 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (22) 5- to 10-membered aromatic heterocyclic group and (23) sulfo, or 20 (iii) a C₆₋₁₄ aryl or a 5- to 14-membered aromatic heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, each of 25 which may be substituted by 1 to 3 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₃ alkylenedioxy, (3) nitro, (4) cyano, (5) optionally halogenated C₁₋₆ alkyl, (6) optionally halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) 30 optionally halogenated C₁₋₆ alkoxy, (10) optionally halogenated C₁₋₆ alkylthio, (11) hydroxy, (12) amino, (13) mono-C₁₋₆ alkylamino, (14) di-C₁₋₆ alkylamino, (15) 35 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (16) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-

carbonyl, 5- or 6-membered heterocycle carbonyl, mono-
C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-
carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆
alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and
5 C₆₋₁₄ arylsulfinyl, (17) acylamino selected from the
group consisting of formylamino, C₁₋₆ alkyl-carboxamido,
C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆
alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (18)
acyloxy selected from the group consisting of C₁₋₆
10 alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-
carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-
carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy,
(19) sulfo, (20) C₆₋₁₄ aryl and (21) C₆₋₁₄ aryloxy;
R⁴ is (i) a C₆₋₁₄ aryl or a 5- to 14-membered aromatic
15 heterocyclic group containing 1 to 4 hetero atoms
selected from the group consisting of nitrogen, sulfur
and oxygen atoms in addition to carbon atoms, each of
which may be substituted by 1 to 3 substituents
selected from the group consisting of (1) halogen atoms,
20 (2) C₁₋₃ alkylenedioxy, (3) nitro, (4) cyano, (5)
optionally halogenated C₁₋₆ alkyl, (6) optionally
halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆
alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9)
optionally halogenated C₁₋₆ alkoxy, (10) optionally
25 halogenated C₁₋₆ alkylthio, (11) hydroxy, (12) amino,
(13) mono-C₁₋₆ alkylamino, (14) di-C₁₋₆ alkylamino, (15)
5- to 7-membered saturated cyclic amino which may be
substituted by 1 to 3 substituents selected from the
group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-
30 membered aromatic heterocyclic group, (16) acyl
selected from the group consisting of formyl, carboxy,
carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl,
C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-
carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-
35 carbonyl, 5- or 6-membered heterocycle carbonyl, mono-
C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-
carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆

alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (17) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆

5 alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (18) acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy,

10 (19) sulfo, (20) C₆₋₁₄ aryl and (21) C₆₋₁₄ aryloxy,

(ii) an aliphatic hydrocarbon group selected from the group consisting of C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl and C₃₋₆ cycloalkyl, which hydrocarbon group substituted by 1 to 3 C₆₋₁₄ aryl or 5- to 14-membered aromatic heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, each of which may be substituted by 1 to 3 substituents selected from the group consisting of (1) halogen atoms,

15 (2) C₁₋₃ alkylenedioxy, (3) nitro, (4) cyano, (5) optionally halogenated C₁₋₆ alkyl, (6) optionally halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) optionally halogenated C₁₋₆ alkoxy, (10) optionally halogenated C₁₋₆ alkylthio, (11) hydroxy, (12) amino,

20 (13) mono-C₁₋₆ alkylamino, (14) di-C₁₋₆ alkylamino, (15) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-

25 membered aromatic heterocyclic group, (16) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-

30 carbonyl, 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆

alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (17) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (18) acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy, (19) sulfo, (20) C₆₋₁₄ aryl and (21) C₆₋₁₄ aryloxy, which hydrocarbon group may be further substituted by 1 to 5 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₃ alkylenedioxy, (3) nitro, (4) cyano, (5) optionally halogenated C₁₋₆ alkyl, (6) optionally halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) C₆₋₁₄ aryl, (10) optionally halogenated C₁₋₆ alkoxy, (11) optionally halogenated C₁₋₆ alkylthio, (12) hydroxy, (13) amino, (14) mono-C₁₋₆ alkylamino, (15) mono-C₆₋₁₄ arylamino, (16) di-C₁₋₆ alkylamino, (17) di-C₆₋₁₄ arylamino, (18) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (19) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (20) acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy,

(21) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (22) 5- to 10-membered aromatic heterocyclic group and (23) sulfo, or
5 (iii) an acyl of the formula: -(C=O)-R⁵, -(C=O)-OR⁵, -(C=O)-NR⁵R⁶, -(C=S)-NHR⁵, -SO₂-R^{5a} or -SO-R^{5a} wherein R⁵ is (a) a hydrogen atom,
10 (b) a C₆₋₁₄ aryl or a 5- to 14-membered aromatic heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, each of which may be substituted by 1 to 3 substituents selected from the group consisting of (1) halogen atoms,
15 (2) C₁₋₃ alkylenedioxy, (3) nitro, (4) cyano, (5) optionally halogenated C₁₋₆ alkyl, (6) optionally halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) optionally halogenated C₁₋₆ alkoxy, (10) optionally
20 halogenated C₁₋₆ alkylthio, (11) hydroxy, (12) amino, (13) mono-C₁₋₆ alkylamino, (14) di-C₁₋₆ alkylamino, (15) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (16) acyl
25 selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-
30 carbonyl, 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (17) acylamino selected from the
35 group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (18)

acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy,

5 (19) sulfo, (20) C₆₋₁₄ aryl and (21) C₆₋₁₄ aryloxy, or
(c) a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₆ cycloalkyl group which may be substituted by 1 to 5 substituents selected from the group consisting of (1) C₆₋₁₄ aryl or 5- to 14-membered aromatic heterocyclic

10 group containing 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, each of which may be substituted by 1 to 3 substituents selected from the group consisting of (1') halogen atoms, (2') C₁₋₃ alkylenedioxy, (3') nitro, (4') cyano, (5') optionally halogenated C₁₋₆ alkyl, (6') optionally halogenated C₂₋₆ alkenyl, (7') optionally halogenated C₂₋₆ alkynyl, (8') optionally halogenated C₃₋₆ cycloalkyl, (9') optionally halogenated C₁₋₆ alkoxy, (10') optionally halogenated C₁₋₆ alkylthio, (11') hydroxy, (12') amino, (13') mono-C₁₋₆ alkylamino, (14') di-C₁₋₆ alkylamino, (15') 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-

15 membered aromatic heterocyclic group, (16') acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-

20 carbonyl, 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (17') acylamino selected from the

25 group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (18')

acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy,

5 (19') sulfo, (20') C₆₋₁₄ aryl and (21') C₆₋₁₄ aryloxy, (2) halogen atoms, (3) C₁₋₃ alkyleneoxy, (4) nitro, (5) cyano, (6) optionally halogenated C₁₋₆ alkyl, (7) optionally halogenated C₂₋₆ alkenyl, (8) optionally halogenated C₂₋₆ alkynyl, (9) optionally halogenated C₃₋₆ cycloalkyl, (10) optionally halogenated C₁₋₆ alkoxy,

10 (11) optionally halogenated C₁₋₆ alkylthio, (12) hydroxy, (13) amino, (14) mono-C₁₋₆ alkylamino, (15) di-C₁₋₆ alkylamino, (16) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents

15 selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (17) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆

20 aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄

25 arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (18) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (19)

30 acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy and (20) sulfo;

35 R^{5a} is (a) a C₆₋₁₄ aryl or a 5- to 14-membered aromatic heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur

and oxygen atoms in addition to carbon atoms, each of which may be substituted by 1 to 3 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₃ alkylenedioxy, (3) nitro, (4) cyano, (5)

5 optionally halogenated C₁₋₆ alkyl, (6) optionally halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) optionally halogenated C₁₋₆ alkoxy, (10) optionally halogenated C₁₋₆ alkylthio, (11) hydroxy, (12) amino,

10 (13) mono-C₁₋₆ alkylamino, (14) di-C₁₋₆ alkylamino, (15) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (16) acyl

15 selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono-

20 C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (17) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido,

25 C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (18) acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-

30 carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy, (19) sulfo, (20) C₆₋₁₄ aryl and (21) C₆₋₁₄ aryloxy, or

35 (b) a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₆ cycloalkyl group which may be substituted by 1 to 5 substituents selected from the group consisting of (1) a C₆₋₁₄ aryl or 5- to 14-membered aromatic heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms

in addition to carbon atoms, each of which may be substituted by 1 to 3 substituents selected from the group consisting of (1') halogen atoms, (2') C₁₋₃ alkylenedioxy, (3') nitro, (4') cyano, (5') optionally 5 halogenated C₁₋₆ alkyl, (6') optionally halogenated C₂₋₆ alkenyl, (7') optionally halogenated C₂₋₆ alkynyl, (8') optionally halogenated C₃₋₆ cycloalkyl, (9') optionally halogenated C₁₋₆ alkoxy, (10') optionally halogenated C₁₋₆ alkylthio, (11') hydroxy, (12') amino, (13') mono-C₁₋₆ 10 alkylamino, (14') di-C₁₋₆ alkylamino, (15') 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (16') acyl 15 selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono- 20 C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (17') acylamino selected from the 25 group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (18') acyloxy selected from the group consisting of C₁₋₆ 30 alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy, (19') sulfo, (20') C₆₋₁₄ aryl and (21') C₆₋₁₄ aryloxy, (2) halogen atoms, (3) C₁₋₃ alkylenedioxy, (4) nitro, (5) cyano, (6) optionally halogenated C₁₋₆ alkyl, (7) optionally 35 halogenated C₂₋₆ alkenyl, (8) optionally halogenated C₂₋₆ alkynyl, (9) optionally halogenated C₃₋₆ cycloalkyl, (10) optionally halogenated C₁₋₆ alkoxy, (11) optionally halogenated C₁₋₆ alkylthio, (12) hydroxy,

(13) amino, (14) mono-C₁₋₆ alkylamino, (15) di-C₁₋₆ alkylamino, (16) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group,

5 (17) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆

10 aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl,

15 (18) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (19)

acyloxy selected from the group consisting of C₁₋₆

20 alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy and (20) sulfo; and

R⁶ is a hydrogen atom or a C₁₋₆ alkyl; and

25 ring A is a benzene ring which may be further substituted by 1 to 3 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₃ alkylenedioxy, (3) nitro, (4) cyano, (5) optionally halogenated C₁₋₆ alkyl, (6) optionally halogenated C₂₋₆

30 alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) optionally halogenated C₁₋₆ alkoxy, (10) optionally halogenated C₁₋₆ alkylthio, (11) hydroxy, (12) amino, (13) mono-C₁₋₆ alkylamino, (14) di-C₁₋₆ alkylamino, (15) 5- to 7-

35 membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-

membered aromatic heterocyclic group, (16) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (17) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (18) acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy, (19) sulfo, (20) C₆₋₁₄ aryl and (21) C₆₋₁₄ aryloxy.

3) a compound of the above 1), wherein R¹ and R² each is a C₁₋₆ alkyl which may be substituted, or R¹ and R² form, taken together with the adjacent carbon atom, a 3- to 8-membered carbo or heterocyclic ring which may be substituted;

4) a compound of the above 1), R³ is an aromatic group which may be substituted;


5) a compound of the above 1), wherein R⁴ is (i) an aliphatic hydrocarbon group substituted by an aromatic group which may be substituted, which hydrocarbon group may be further substituted or (ii) an acyl;

6) a compound of the above 1), wherein X is an oxygen atom;

7) a compound of the above 1), wherein Y is an oxygen atom;

8) a compound of the above 7), wherein a group of the formula: -X-R⁴ is substituted on the 5-position of the benzofuran ring;

9) a compound of the above 1), which is a compound of the formula:



wherein each symbol is as defined above, or a salt
5 thereof;

10) a compound of the above 1), wherein R¹ and R² each
is a C₁₋₆ alkyl which may be substituted by 1 to 3
substituents selected from the group consisting of (1)
C₆₋₁₄ aryl, (2) C₁₋₆ alkoxy, (3) C₁₋₆ alkylthio, (4)
10 hydroxy, (5) amino, (6) mono-C₁₋₆ alkylamino, (7) mono-
C₆₋₁₄ arylamino, (8) di-C₁₋₆ alkylamino, (9) di-C₆₋₁₄
arylamino, (10) carboxy, (11) C₁₋₆ alkylsulfonyl, (12)
C₆₋₁₄ arylsulfonyl, (13) C₁₋₆ alkylsulfinyl, (14) C₆₋₁₄
arylsulfinyl and (15) 5- to 7-membered saturated cyclic
15 amino which may be substituted by 1 to 3 substituents
selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄
aryl and 5- to 10-membered aromatic group, or
R¹ and R² form, taken together with the adjacent carbon
atom, a 3- to 8-membered carbo or heterocyclic ring
20 which may be substituted by 1 to 3 substituents
selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄
aryl, C₇₋₁₆ aralkyl and 5- to 10-membered aromatic
heterocyclic group;
R³ is a phenyl, 1-naphthyl, 2-naphthyl, 2-thienyl, 3-
25 thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl,
3-quinolyl, 1-isoquinolyl, 1-indolyl, 2-indolyl or 2-
benzothiazolyl group, each of which may be substituted
by 1 to 3 substituents selected from the group
consisting of (1) halogen atoms, (2) C₁₋₆ alkyl, (3) C₁₋₆
alkoxy, (4) mono-C₁₋₆ alkylamino, (5) di-C₁₋₆ alkylamino
30 and (6) 5- to 7-membered saturated cyclic amino which
may be substituted by 1 to 3 substituents selected from
the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to

10-membered aromatic group;

R⁴ is (i) C₁₋₆ alkyl substituted by a phenyl, 1-naphthyl, 2-naphthyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 1-isoquinolyl, 1-indolyl, 2-indolyl or 2-benzothiazolyl group, each of which may be substituted by 1 to 3 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₆ alkyl, (3) C₁₋₆ alkoxy, (4) hydroxy, (5) amino, (6) mono-C₁₋₆ alkylamino, (7) di-C₁₋₆ alkylamino, (8) carboxy and (9) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic group, which C₁₋₆ alkyl may be further substituted by carboxy or C₁₋₆ alkoxy-carbonyl, or

(ii) a C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₆₋₁₄ aryl-carbonyl or C₇₋₁₆ aralkyl-carbonyl group, each of which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino and carboxy;

X is an oxygen atom;

Y is an oxygen atom; and

ring A is a benzene ring which may be further substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆ alkoxy, amino, mono-C₁₋₆ alkylamino and di-C₁₋₆ alkylamino;

30 11) a compound of the above 1), wherein R¹ and R² each is a C₁₋₆ alkyl which may be substituted by 1 to 3 substituents selected from the group consisting of C₆₋₁₄ aryl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, mono-C₆₋₁₄ arylamino, di-C₁₋₆ alkylamino, di-C₆₋₁₄ arylamino, carboxy, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, or

R^1 and R^2 form, taken together with the adjacent carbon atom, a piperidine which may be substituted by 1 to 3 substituents selected from the group consisting of C_{1-6} alkyl, C_{6-14} aryl and C_{7-16} aralkyl;

5 R^3 is a phenyl which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C_{1-6} alkyl, C_{1-6} alkoxy, amino, mono- C_{1-6} alkylamino and di- C_{1-6} alkylamino;

10 R^4 is (i) C_{1-6} alkyl substituted by a phenyl or pyridyl, each of which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, amino, mono- C_{1-6} alkylamino, di- C_{1-6} alkylamino and carboxy, or

15 (ii) an acyl of the formula: $-(C=O)-R^5'$ wherein R^5' is a phenyl or phenyl- C_{1-6} alkyl, each of which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, amino, mono- C_{1-6} alkylamino, di- C_{1-6} alkylamino and carboxy;


20 X is an oxygen atom;

Y is an oxygen atom; and

ring A is a benzene ring which may be further substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, optionally

25 halogenated C_{1-6} alkyl, optionally halogenated C_{1-6} alkoxy, amino, mono- C_{1-6} alkylamino and di- C_{1-6} alkylamino;


12) a compound of the above 1) which is a compound of the formula:



30

wherein R^1 and R^2 each is C_{1-6} alkyl which may be substituted by 6-membered saturated cyclic amino substituted by a phenyl, or

- R¹ and R² form, taken together with the adjacent carbon atom, a piperidine substituted by a C₁₋₆ alkyl or a C₇₋₁₆ aralkyl;
- R³ is (i) a hydrogen atom, or
- 5 (ii) a phenyl which may be substituted by 1 to 3 substituents selected from the group consisting of (1) C₁₋₆ alkyl, (2) di-C₁₋₆ alkylamino and (3) 6-membered saturated cyclic amino which may be substituted by a C₁₋₆ alkyl,
- 10 R⁴ is (i) a phenyl which may be substituted by 1 to 3 substituents selected from the group consisting of nitro and C₁₋₆ alkyl-carboxamido, (ii) a C₁₋₆ alkyl or C₂₋₆ alkenyl group substituted by 1 to 3 of phenyl, quinolyl or pyridyl, each of which may be substituted by 1 to 3 substituents selected from the group
- 15 consisting of C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxy-carbonyl, C₁₋₆ alkylsulfonyl and C₁₋₆ alkylsulfinyl, which C₁₋₆ alkyl or C₂₋₆ alkenyl group may be further substituted by a phenyl, carboxy or C₁₋₆ alkoxy-carbonyl,
- 20 or
- (iii) an acyl of the formula: -(C=O)-R^{5''}
- wherein R^{5''} is phenyl substituted by a C₁₋₆ alkoxy; and ring A' is a benzene ring which may be further substituted by 1 to 3 C₁₋₆ alkyl;
- 25 13) a compound of the above 1) which is 3-(4-isopropylphenyl)-5-(4-methoxybenzyloxy)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran,
- 30 3-(4-isopropylphenyl)-2,4,6,7-tetramethylbenzofuran-5-yl 4-methoxybenzoate,
- 3-(4-isopropylphenyl)-5-(4-methoxybenzyloxy)-2,4,6,7-tetramethylbenzofuran,
- 3-(4-isopropylphenyl)-5-(4-methoxybenzyloxy)-1',4,6,7-tetramethylspiro[benzofuran-2(3H),4'-piperidine],
- or a salt thereof;
- 35 14) a process for producing of compound (I), which comprises reacting a compound of the formula:



- wherein each symbol is as defined above, or a salt thereof with a compound of the formula: R⁴-L wherein L represents a leaving group and R⁴ is as defined above,
 5 or salt thereof;
- 15) a pharmaceutical composition which comprises compound (I);
- 16) a composition of the above 15) which is an agent for suppressing neurodegeneration;
- 10 17) a composition of the above 15) which is an agent for suppressing β-amyloid toxicity;
- 18) a composition of the above 15) which is an agent for preventing and/or treating neurodegenerative diseases;
- 15 19) an agent for preventing and/or treating neurodegenerative diseases which comprises compound (Ia);
- 20 20) an agent of the above 19) which is an agent for suppressing β-amyloid toxicity;
- 21) an agent of the above 19) which is an agent for preventing and/or treating neurodegenerative diseases;
- 22) a method for suppressing neurodegeneration in mammal, which comprises administering to said mammal an effective amount of compound (Ia) with a
 25 pharmaceutically acceptable excipient, carrier or diluent;
- 23) use of compound (Ia) for manufacturing a pharmaceutical composition for suppressing neurodegeneration; and so forth.

30

In the formulae, the "hydrocarbon group" of the "hydrocarbon group which may be substituted" for R¹ or R² includes, for example, an acyclic or cyclic

hydrocarbon group such as alkyl, alkenyl, alkynyl, cycloalkyl, aryl, etc. Among them, C₁₋₁₆ acyclic or cyclic hydrocarbon group is preferable.

The preferred "alkyl" is for example C₁₋₆ alkyl
5 such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.

The preferred "alkenyl" is for example C₂₋₆ alkenyl such as vinyl, allyl, isopropenyl, butenyl, isobutenyl, sec-butenyl, etc.

10 The preferred "alkynyl" is for example C₂₋₆ alkynyl such as ethynyl, propargyl, butynyl, 1-hexynyl, etc.

The preferred "cycloalkyl" is for example C₃₋₆ cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.

15 The preferred "aryl" is for example C₆₋₁₄ aryl such as phenyl, 1-naphthyl, 2-naphthyl, biphenylyl, 2-anthryl, etc.

Examples of the "substituents" of the "hydrocarbon group which may be substituted" include halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.), C₁₋₃ alkylatedioxy (e.g., methylenedioxy, ethylenedioxy, etc.), nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₂₋₆ alkenyl, optionally halogenated C₂₋₆ alkynyl, optionally halogenated C₃₋₆ cycloalkyl, C₆₋₁₄ aryl (e.g., phenyl, 1-naphthyl, 2-naphthyl, biphenylyl, 2-anthryl, etc.), optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino (e.g., methylamino, ethylamino, etc.), mono-C₆₋₁₄ arylamino (e.g., phenylamino, 1-naphthylamino, 2-naphthylamino, etc.), di-C₁₋₆ alkylamino (e.g., dimethylamino, diethylamino, etc.), di-C₆₋₁₄ arylamino (e.g., diphenylamino, etc.), acyl, acylamino, acyloxy, 5- to 7-membered saturated cyclic amino which may be substituted, 5- to 10-membered aromatic heterocyclic group (e.g., 2- or 3-thienyl, 2-, 3- or 4-pyridyl, 2-, 3-, 4-, 5- or 8-quinolyl, 1-, 3-, 4- or 5-isoquinolyl,

1-, 2- or 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl, benzo[b]furanyl, etc.), sulfo, and so forth.

The "hydrocarbon group" may have 1 to 5, 5 preferably 1 to 3 substituents as mentioned above at possible positions of the hydrocarbon group and, when the number of substituents is two or more, those substituents may be the same as or different from one another.

10 The above-mentioned "optionally halogenated C₁₋₆ alkyl" includes, for example, C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.) which may have 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.). Concretely mentioned is methyl, chloromethyl, difluoromethyl, trichloromethyl, trifluoromethyl, ethyl, 2-bromoethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, propyl, 3,3,3-trifluoropropyl, isopropyl, butyl, 4,4,4-trifluorobutyl, 15 isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 5,5,5-trifluoropentyl, hexyl, 6,6,6-trifluorohexyl, etc.

20 The above-mentioned "optionally halogenated C₂₋₆ alkenyl" includes, for example, C₂₋₆ alkenyl (e.g., vinyl, allyl, isopropenyl, butenyl, isobutenyl, sec-butenyl, etc.) which may have 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.). Concretely mentioned is vinyl, allyl, isopropenyl, butenyl, isobutenyl, sec-butenyl, 3,3,3-trifluoro-1-propenyl, 4,4,4-trifluoro-1-but enyl, etc.

25 The above-mentioned "optionally halogenated C₂₋₆ alkynyl" includes, for example, C₂₋₆ alkynyl (e.g., ethynyl, propargyl, butynyl, 1-hexynyl, etc.) which may have 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.). Concretely mentioned is ethynyl, propargyl, butynyl, 1-hexynyl, 3,3,3-trifluoro-1-propynyl, 4,4,4-trifluoro-1-butynyl,

etc.

- The above-mentioned "optionally halogenated C₃₋₆ cycloalkyl" includes, for example, C₃₋₆ cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.) which may have 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.). Concretely mentioned is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4,4-dichlorocyclohexyl, 2,2,3,3-tetrafluorocyclopentyl, 4-chlorocyclohexyl, etc.
- 10 The above-mentioned "optionally halogenated C₁₋₆ alkoxy" includes, for example, C₁₋₆ alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy, etc.) which may have 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.). Concretely mentioned is methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, propoxy, isopropoxy, butoxy, 4,4,4-trifluorobutoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy, etc.
- 15 20 The above-mentioned "optionally halogenated C₁₋₆ alkylthio" includes, for example, C₁₋₆ alkylthio (e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, sec-butylthio, tert-butylthio, etc.) which may have 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.). Concretely mentioned is methylthio, difluoromethylthio, trifluoromethylthio, ethylthio, propylthio, isopropylthio, butylthio, 4,4,4-trifluorobutylthio, pentylthio, hexylthio, etc.
- 25 30 The above-mentioned "acyl" includes, for example, formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl (e.g., acetyl, propionyl, etc.), C₃₋₆ cycloalkyl-carbonyl (e.g., cyclopropylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, etc.), C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, etc.), C₆₋₁₀ aryl-carbonyl (e.g., benzoyl, 1-naphthoyl, 2-naphthoyl, etc.), C₇₋₁₆ aralkyl-

carbonyl (e.g., phenylacetyl, phenylpropionyl, etc.), C₆₋₁₄ aryloxy-carbonyl (e.g., phenoxy carbonyl, etc.), C₇₋₁₆ aralkyloxy-carbonyl (e.g., benzyloxycarbonyl, phenethyloxycarbonyl, etc.), 5- or 6-membered heterocycle carbonyl (e.g., nicotinoyl, isonicotinoyl, 2-thenoyl, 3-thenoyl, 2-furoyl, 3-furoyl, morpholinocarbonyl, thiomorpholinocarbonyl, piperidinocarbonyl, 1-pyrrolidinyl carbonyl, etc.), mono-C₁₋₆ alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, etc.), di-C₁₋₆ alkyl-carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, etc.), C₆₋₁₄ aryl-carbamoyl (e.g., phenylcarbamoyl, 1-naphthylcarbamoyl, 2-naphthylcarbamoyl, etc.), 5- or 6-membered heterocycle carbamoyl (e.g., 2-pyridylcarbamoyl, 3-pyridylcarbamoyl, 4-pyridylcarbamoyl, 2-thienylcarbamoyl, 3-thienylcarbamoyl, etc.), C₁₋₆ alkylsulfonyl (e.g., methylsulfonyl, ethylsulfonyl, etc.), C₆₋₁₄ arylsulfonyl (e.g., phenylsulfonyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl, etc.), C₁₋₆ alkylsulfinyl (e.g., methylsulfinyl, ethylsulfinyl, etc.), C₆₋₁₄ arylsulfinyl (e.g., phenylsulfinyl, 1-naphthylsulfinyl, 2-naphthylsulfinyl, etc.), and so forth.

The above-mentioned "acylamino" includes, for example, formylamino, C₁₋₆ alkyl-carboxamido (e.g., acetamido, etc.), C₆₋₁₄ aryl-carboxamido (e.g., phenylcarboxamido, naphthylcarboxamido, etc.), C₁₋₆ alkoxy-carboxamido (e.g., methoxycarboxamido, ethoxycarboxamido, propoxycarboxamido, butoxycarboxamido, etc.), C₁₋₆ alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino, etc.), C₆₋₁₄ arylsulfonylamino (e.g., phenylsulfonylamino, 2-naphthylsulfonylamino, 1-naphthylsulfonylamino, etc.), and so forth.

The above-mentioned "acyloxy" includes, for example, C₁₋₆ alkyl-carbonyloxy (e.g., acetoxy, propionyloxy, etc.), C₆₋₁₄ aryl-carbonyloxy (e.g.,

- benzoyloxy, naphthylcarbonyloxy, etc.), C₁₋₆ alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy, etc.), mono-C₁₋₆ alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy, etc.), di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy, diethylcarbamoyloxy, etc.), C₆₋₁₄ aryl-carbamoyloxy (e.g., phenylcarbamoyloxy, naphthylcarbamoyloxy, etc.), nicotinoyloxy, and so forth.
- 10 The above-mentioned "5- to 7-membered saturated cyclic amino" of the "5- to 7-membered saturated cyclic amino which may be substituted" includes, for example, morpholino, thiomorpholino, piperazin-1-yl, piperidino, pyrrolidin-1-yl, etc. The "substituents" of the "5- to 15 7-membered saturated cyclic amino which may be substituted" include, for example, 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.), C₆₋₁₄ aryl (e.g., phenyl, 1-naphthyl, 2-naphthyl, biphenylyl, 2-anthryl, etc.) and 5- to 10-membered aromatic heterocyclic group (e.g., 2- or 3-thienyl, 2-, 3- or 4-pyridyl, 2-, 3-, 4-, 5- or 8-quinolyl, 1-, 3-, 4- or 5-isoquinolyl, 1-, 2- or 3-indolyl, 2-benzothiazolyl, 2-25 benzo[b]thienyl, benzo[b]furanyl, etc.).
- 20 The "3- to 8-membered carbocyclic ring" of the "3- to 8-membered carbocyclic ring which may be substituted" formed by R¹ and R² includes, for example, C₃₋₈ cycloalkane such as cyclopropane, cyclobutane, cyclopentane, cyclohexane, etc.
- 25 The "3- to 8-membered heterocyclic ring" of the "3- to 8-membered heterocyclic ring which may be substituted" formed by R¹ and R² includes, for example, aziridine, azetidine, morpholine, thiomorpholine, 30 piperazine, piperidine, pyrrolidine, hexamethyleneimine, heptamethyleneimine, hexahydropyrimidine, etc.

The "substituents" of the "3- to 8-membered carbo or heterocyclic ring which may be substituted" formed by R¹ and R² include, for example, 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl (e.g., 5 methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.), C₆₋₁₄ aryl (e.g., phenyl, 1-naphthyl, 2-naphthyl, biphenylyl, 2-anthryl, etc.), C₇₋₁₆ aryl (e.g., benzyl, phenethyl, diphenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl, 10 2,2-diphenylethyl, etc.), amino, mono-C₁₋₆ alkylamino (e.g., methylamino, ethylamino, etc.), mono-C₆₋₁₄ arylamino (e.g., phenylamino, 1-naphthylamino, 2-naphthylamino, etc.), di-C₁₋₆ alkylamino (e.g., dimethylamino, diethylamino, etc.), di-C₆₋₁₄ arylamino (e.g., diphenylamino, etc.) and 15 5- to 10-membered aromatic heterocyclic group (e.g., 2- or 3-thienyl, 2-, 3- or 4-pyridyl, 2-, 3-, 4-, 5- or 8-quinolyl, 1-, 3-, 4- or 5-isoquinolyl, 1-, 2- or 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl, benzo[b]furanyl, 20 etc.).

The "lower alkyl" of the "lower alkyl which may be substituted" for R³ includes, for example, C₁₋₆ alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.

25 The "substituents" of the "lower alkyl which may be substituted" for R³ and their number are the same as those mentioned above for the "substituents" of the "hydrocarbon group which may be substituted" for R¹ or R².

30 The "aromatic group" of the "aromatic group which may be substituted" for R³ includes, for example, an aromatic hydrocarbon group, an aromatic heterocyclic group, and so forth.

35 The "aromatic hydrocarbon group" includes, for example, a C₆₋₁₄ monocyclic or fused polycyclic (e.g., bi- or tri-cyclic) aromatic hydrocarbon group, etc.

Concretely mentioned is C₆₋₁₄ aryl such as phenyl, 1-naphthyl, 2-naphthyl, biphenylyl, 2-anthryl, etc.

The "aromatic heterocyclic group" includes, for example, 5- to 14-membered, preferably 5- to 10-membered aromatic heterocyclic group containing one or more (e.g., 1 to 4) hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, etc. Concretely mentioned is a monovalent group formed by removing an optional hydrogen atom from an aromatic heterocyclic ring such as thiophene, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b]thiophene, furan, isoindolidine, xanthrene, phenoxythiin, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indole, isoindole, 1H-indazole, purine, 4H-quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, carbazole, β-carboline, phenanthridine, acridine, phenazine, thiazole, isothiazole, phenothiazine, oxazole, isoxazole, furazan, phenoxyazine, etc.; or a ring as formed through condensation of the above aromatic heterocyclic ring, preferably monocyclic ring, with one or more, preferably one or two aromatic rings (e.g., benzene ring, etc.), etc.

The preferred example of the "aromatic heterocyclic group" is a 5- or 6-membered aromatic heterocyclic group which may be fused with one benzene ring. Concretely mentioned is 2-, 3- or 4-pyridyl, 2-, 3-, 4-, 5- or 8-quinolyl, 1-, 3-, 4- or 5-isoquinolyl, 1-, 2- or 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl, benzo[b]furanyl, 2- or 3-thienyl, etc. More preferred is 2- or 3-thienyl, 2-, 3- or 4-pyridyl, 2- or 3-quinolyl, 1-isoquinolyl, 1- or 2-indolyl, 2-benzothiazolyl, etc.

The "substituents" of the "aromatic heterocyclic

group which may be substituted" include, for example, halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.), C₁₋₃ alkylenedioxy (e.g., methylenedioxy, ethylenedioxy, etc.), nitro, cyano, optionally halogenated C₁₋₆ alkyl, 5 optionally halogenated C₂₋₆ alkenyl, optionally halogenated C₂₋₆ alkynyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino (e.g., methylamino, ethylamino, 10 propylamino, isopropylamino, butylamino, etc.), di-C₁₋₆ alkylamino (e.g., dimethylamino, diethylamino, dipropylamino, dibutylamino, ethylmethyleamino, etc.), 5- to 7-membered saturated cyclic amino which may be substituted, acyl, acylamino, acyloxy, sulfo, C₆₋₁₄ aryl 15 (e.g., phenyl, 1-naphthyl, 2-naphthyl, etc.), C₆₋₁₄ aryloxy (e.g., phenoxy, naphthoxy, etc.), and so forth.

The "aromatic group" may have 1 to 3 substituents as mentioned above at possible positions of the 20 aromatic group and, when the number of substituents is two or more, those substituents may be the same as or different from one another.

The above-mentioned "optionally halogenated C₁₋₆ alkyl", "optionally halogenated C₂₋₆ alkenyl", 25 "optionally halogenated C₂₋₆ alkynyl", "optionally halogenated C₃₋₆ cycloalkyl", "optionally halogenated C₁₋₆ alkoxy", "optionally halogenated C₁₋₆ alkylthio", "5- to 7-membered saturated cyclic amino which may be substituted", "acyl", "acylamino" and "acyloxy" include, 30 for example, those described in detail in the foregoing referring to the "substituents" of the "hydrocarbon group which may be substituted" for R¹ or R², respectively.

35 Preferred example of the "aromatic group which may be substituted" for R³ is a phenyl, 2-, 3- or 4-pyridyl, 2- or 3-quinolyl or 1-isoquinolyl group, each of which

may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₂₋₆ alkenyl, optionally 5 halogenated C₂₋₆ alkynyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, 5- to 7-membered saturated cyclic amino which may be 10 substituted, acyl, acylamino, acyloxy, sulfo, C₆₋₁₄ aryl and C₆₋₁₄ aryloxy.

The "aromatic group which may be substituted" for R⁴ includes, for example, 1 to 3, preferably 1 or 2 of the "aromatic group which may be substituted" for R³ 15 above mentioned.

The "aliphatic hydrocarbon group" of the "aliphatic hydrocarbon group substituted by an aromatic group which may be substituted, which hydrocarbon group may be further substituted" for R⁴ includes, for 20 example, alkyl, alkenyl, alkynyl, cycloalkyl, and so forth. Among others, preferred are C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl and C₃₋₁₀ cycloalkyl.

The "alkyl" is preferably, for example, C₁₋₆ alkyl such as methyl, ethyl, propyl, isopropyl, butyl, 25 isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.

The "alkenyl" is preferably, for example, C₂₋₆ alkenyl such as vinyl, allyl, isopropenyl, butenyl, isobutenyl, sec-butenyl, etc.

The "alkynyl" is preferably, for example, C₂₋₆ alkynyl such as ethynyl, propargyl, butynyl, 1-hexynyl, etc.

The "cycloalkyl" is preferably, for example, C₃₋₆ cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.

35 Among others, preferred is C₁₋₆ alkyl.

The "aromatic group which may be substituted" which the above "aliphatic hydrocarbon group" have,

includes, for example, 1 to 3 of the "aromatic group which may be substituted" for R³.

Preferred example of the above "aromatic group which may be substituted" is a phenyl, 2-, 3- or 4-pyridyl, 2- or 3-quinolyl or 1-isoquinolyl group, each of which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₂₋₆ alkenyl, 10 optionally halogenated C₂₋₆ alkynyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, 5- to 7-membered saturated cyclic amino which may be 15 substituted, acyl, acylamino, acyloxy, sulfo, C₆₋₁₄ aryl and C₆₋₁₄ aryloxy.

The "substituents" which the above "aliphatic hydrocarbon group" may further have, and their number are the same as those mentioned above for the 20 "substituents" of the "hydrocarbon group which may be substituted" for R¹ or R².

Among them, preferred are acyl such as carboxy, C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, etc.

25 The "acyl" for R⁴ includes, for example, an acyl of the formula: -(C=O)-R⁵, -(C=O)-OR⁵, -(C=O)-NR⁵R⁶, -(C=S)-NHR⁵, -SO₂-R^{5a} or -SO-R^{5a} wherein R⁵ is a hydrogen atom, an aromatic group which may be substituted or an aliphatic hydrocarbon group which may be substituted; 30 R^{5a} is an aromatic group which may be substituted or an aliphatic hydrocarbon group which may be substituted; and R⁶ is a hydrogen atom or C₁₋₆ alkyl.

The "aromatic group which may be substituted" for R⁵ or R^{5a} includes, for example, the "aromatic group 35 which may be substituted" for R³ above.

The "aliphatic hydrocarbon group" of the "aliphatic hydrocarbon group which may be substituted"

for R⁵ or R^{5a} includes, for example, the "aliphatic hydrocarbon group" of the "aliphatic hydrocarbon group substituted by an aromatic group which may be substituted, which hydrocarbon group may be further substituted" for R⁴ above.

The "substituents" of the "aliphatic hydrocarbon group which may be substituted" for R⁵ or R^{5a} include, for example, (1) the "aromatic group which may be substituted" of the "aliphatic hydrocarbon group substituted by an aromatic group which may be substituted, which hydrocarbon group may be further substituted" for R⁴ above, (2) halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.), (3) C₁₋₃ alkylenedioxy (e.g., methylenedioxy, ethylenedioxy, etc.), (4) nitro, (5) cyano, (6) optionally halogenated C₁₋₆ alkyl, (7) optionally halogenated C₂₋₆ alkenyl, (8) optionally halogenated C₂₋₆ alkynyl, (9) optionally halogenated C₃₋₆ cycloalkyl, (10) optionally halogenated C₁₋₆ alkoxy, (11) optionally halogenated C₁₋₆ alkylthio, (12) hydroxy, (13) amino, (14) mono-C₁₋₆ alkylamino (e.g., methylamino, ethylamino, etc.), (15) di-C₁₋₆ alkylamino (e.g., dimethylamino, diethylamino, etc.), (16) 5- to 7-membered saturated cyclic amino which may be substituted, (17) acyl, (18) acylamino, (19) acyloxy, (20) sulfo, and so forth.

The above-mentioned "optionally halogenated C₁₋₆ alkyl", "optionally halogenated C₂₋₆ alkenyl", "optionally halogenated C₂₋₆ alkynyl", "optionally halogenated C₃₋₆ cycloalkyl", "optionally halogenated C₁₋₆ alkoxy", "optionally halogenated C₁₋₆ alkylthio", "5- to 7-membered saturated cyclic amino which may be substituted", "acyl", "acylamino" and "acyloxy" include, for example, those described in detail in the foregoing referring to the "substituents" of the "hydrocarbon group which may be substituted" for R¹ or R², respectively.

The "aliphatic hydrocarbon group" may have 1 to 5, preferably 1 to 3 substituents as mentioned above at possible positions of the aliphatic hydrocarbon group and, when the number of substituents is two or more, 5 those substituents may be the same as or different from one another.

Preferably, R⁵ and R^{5a} each is an aromatic group which may be substituted.

10 The "C₁₋₆ alkyl" for R⁶ includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.

The "sulfur atom which may be oxidized" for X or Y includes S, SO and SO₂.

15 The "substituents" which ring A may have apart from the group of the formula: -X-R⁴, include, for example, the "substituents" of the "aromatic group which may be substituted" for R³ above. Ring A may have 1 to 3 substituents as mentioned above at possible positions of the ring and, when the number of 20 substituents is two or more, those substituents may be the same as or different from one another.

25 Preferably, the "substituents" which ring A may have apart from the group of the formula: -X-R⁴, include, for example, halogen atoms, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₂₋₆ alkenyl, optionally halogenated C₂₋₆ alkynyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, acyl, 30 acyloxy, sulfo, C₆₋₁₄ aryl, C₆₋₁₄ aryloxy, and so forth.

The "aromatic group which may be substituted" and the "acyl" for R^{4a} include, for example, the "aromatic group which may be substituted" and the "acyl" for R⁴, respectively.

35 The "aliphatic hydrocarbon group which may be substituted" for R^{4a} includes, for example, the "aliphatic hydrocarbon group which may be substituted"

for R⁵ or R^{5a}.

The "sulfur atom which may be oxidized" for Xa or Ya is same as the "sulfur atom which may be oxidized" for X above.

5 The "substituents" of the "imino which may be substituted" for Ya includes, for example, a hydrocarbon group which may be substituted, an acyl, and so forth.

10 The above "hydrocarbon group which may be substituted" includes, for example, the "hydrocarbon group which may be substituted" for R¹ or R².

15 The above "acyl" includes, for example, that described in detail in the foregoing referring to the "substituents" of the "hydrocarbon group which may be substituted" for R¹ or R².

20 The preferred examples of the "imino which may be substituted" for Ya includes imino, C₁₋₆ alkylimino (e.g., methylimino, ethylimino, etc.), C₆₋₁₄ arylimino (e.g., phenylimino, 1-naphthylimino, 2-naphthylimino, etc.), C₇₋₁₆ aralkylimino (e.g., benzylimino, etc.), etc.

25 The "substituents" which ring Aa may have apart from the group of the formula: -Xa-R^{4a}, include any substituent apart from an amino which may be substituted, for example, halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.), C₁₋₃ alkylenedioxy (e.g., methylenedioxy, ethylenedioxy, etc.), nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₂₋₆ alkenyl, optionally halogenated C₂₋₆ alkynyl, optionally halogenated C₃₋₆ cycloalkyl, 30 optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, acyl, acyloxy, sulfo, and so forth.

35 The above-mentioned "optionally halogenated C₁₋₆ alkyl", "optionally halogenated C₂₋₆ alkenyl", "optionally halogenated C₂₋₆ alkynyl", "optionally halogenated C₃₋₆ cycloalkyl", "optionally halogenated C₁₋₆ alkoxy", "optionally halogenated C₁₋₆ alkylthio",

"acyl" and "acyloxy" include, for example, those described in detail in the foregoing referring to the "substituents" of the "hydrocarbon group which may be substituted" for R¹ or R², respectively.

5 Ring Aa may have 1 to 3 substituents as mentioned above at possible positions of the ring and, when the number of substituents is two or more, those substituents may be the same as or different from one another.

10 In the above formulae, preferably, R¹ and R² each is a C₁₋₆ alkyl which may be substituted, or R¹ and R² form, taken together with the adjacent carbon atom, a 3- to 8-membered carbo or heterocyclic ring which may be substituted.


15 Preferably, R³ is an aromatic group which may be substituted.

20 Preferably, R⁴ and R^{4a} each is (1) an aliphatic hydrocarbon group substituted by an aromatic group which may be substituted, which hydrocarbon group may be further substituted or (2) an acyl.


Preferably, X and Xa each is an oxygen atom.

Preferably, Y and Ya each is an oxygen atom.

25 The group of the formula: -X-R⁴ is preferably substituted on the 5-position of the basic skeleton as follows.



30 The group of the formula: -Xa-R^{4a} is preferably substituted on the 5-position of the basic skeleton as follows.




In compound (I), preferred is a compound wherein
 R^1 and R^2 each is a C_{1-6} alkyl which may be substituted by
5 1 to 3 substituents selected from the group consisting
of (1) C_{6-14} aryl, (2) C_{1-6} alkoxy, (3) C_{1-6} alkylthio, (4)
hydroxy, (5) amino, (6) mono- C_{1-6} alkylamino, (7) mono-
 C_{6-14} arylamino, (8) di- C_{1-6} alkylamino, (9) di- C_{6-14}
arylamino, (10) carboxy, (11) C_{1-6} alkylsulfonyl, (12)
10 C_{6-14} arylsulfonyl, (13) C_{1-6} alkylsulfinyl, (14) C_{6-14}
arylsulfinyl and (15) 5- to 7-membered saturated cyclic
amino which may be substituted by 1 to 3 substituents
selected form the group consisting of C_{1-6} alkyl, C_{6-14}
aryl and 5- to 10-membered aromatic group, or
15 R^1 and R^2 form, taken together with the adjacent carbon
atom, a 3- to 8-membered carbo or heterocyclic ring
which may be substituted by 1 to 3 substituents
selected form the group consisting of C_{1-6} alkyl, C_{6-14}
aryl, C_{7-16} aralkyl and 5- to 10-membered aromatic
20 heterocyclic group;
 R^3 is a phenyl, 1-naphthyl, 2-naphthyl, 2-thienyl, 3-
thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl,
3-quinolyl, 1-isoquinolyl, 1-indolyl, 2-indolyl or 2-
benzothiazolyl group, each of which may be substituted
25 by 1 to 3 substituents selected from the group
consisting of (1) halogen atoms, (2) C_{1-6} alkyl, (3) C_{1-6}
alkoxy, (4) mono- C_{1-6} alkylamino, (5) di- C_{1-6} alkylamino
and (6) 5- to 7-membered saturated cyclic amino which
may be substituted by 1 to 3 substituents selected form
30 the group consisting of C_{1-6} alkyl, C_{6-14} aryl and 5- to
10-membered aromatic group;
 R^4 is (i) C_{1-6} alkyl substituted by a phenyl, 1-naphthyl,
2-naphthyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl,

4-pyridyl, 2-quinolyl, 3-quinolyl, 1-isoquinolyl, 1-indolyl, 2-indolyl or 2-benzothiazolyl group, each of which may be substituted by 1 to 3 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₆ alkyl, (3) C₁₋₆ alkoxy, (4) hydroxy, (5) amino, (6) mono-C₁₋₆ alkylamino, (7) di-C₁₋₆ alkylamino, (8) carboxy and (9) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic group, which C₁₋₆ alkyl may be further substituted by carboxy or C₁₋₆ alkoxy-carbonyl, or
(ii) a C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₆₋₁₄ aryl-carbonyl or C₇₋₁₆ aralkyl-carbonyl group, each of which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino and carboxy;
X is an oxygen atom;
20 Y is an oxygen atom; and
ring A is a benzene ring which may be further substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆ alkoxy, amino, mono-C₁₋₆ alkylamino and di-C₁₋₆ alkylamino.

More preferred is a compound wherein R¹ and R² each is a C₁₋₆ alkyl which may be substituted by 1 to 3 substituents selected from the group consisting of C₆₋₁₄ aryl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, mono-C₆₋₁₄ arylamino, di-C₁₋₆ alkylamino, di-C₆₋₁₄ arylamino, carboxy, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, or
35 R¹ and R² form, taken together with the adjacent carbon atom, a piperidine which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆

- alkyl, C₆₋₁₄ aryl and C₇₋₁₆ aralkyl;
- R³ is a phenyl which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl, C₁₋₆ alkoxy, amino, mono-C₁₋₆ alkylamino and di-C₁₋₆ alkylamino;
- 5 R⁴ is (i) C₁₋₆ alkyl substituted by a phenyl or pyridyl, each of which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino and carboxy, or
- 10 (ii) an acyl of the formula: -(C=O)-R^{5'} wherein R^{5'} is a phenyl or phenyl-C₁₋₆ alkyl, each of which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino and carboxy;
- 15 X is an oxygen atom;
- Y is an oxygen atom; and
- ring A is a benzene ring which may be further substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆ alkoxy, amino, mono-C₁₋₆ alkylamino and di-C₁₋₆ alkylamino.
- 20 Furthermore the compound of the following formula is also preferred.



- wherein R¹ and R² each is C₁₋₆ alkyl which may be substituted by 6-membered saturated cyclic amino substituted by a phenyl, or
- 30 R¹ and R² form, taken together with the adjacent carbon atom, a piperidine substituted by a C₁₋₆ alkyl or a C₇₋₁₆ aralkyl;

R³ is (i) a hydrogen atom, or
(ii) a phenyl which may be substituted by 1 to 3
substituents selected from the group consisting of (1)
C₁₋₆ alkyl, (2) di-C₁₋₆ alkylamino and (3) 6-membered
5 saturated cyclic amino which may be substituted by a
C₁₋₆ alkyl,
R⁴ is (i) a phenyl which may be substituted by 1 to 3
substituents selected from the group consisting of
nitro and C₁₋₆ alkyl-carboxamido, (ii) a C₁₋₆ alkyl or C₂₋₆
10 alkenyl group substituted by 1 to 3 of phenyl,
quinolyl or pyridyl, each of which may be substituted
by 1 to 3 substituents selected from the group
consisting of C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxy-
carbonyl, C₁₋₆ alkylsulfonyl and C₁₋₆ alkylsulfinyl,
15 which C₁₋₆ alkyl or C₂₋₆ alkenyl group may be further
substituted by a phenyl, carboxy or C₁₋₆ alkoxy-carbonyl,
or
(iii) an acyl of the formula: -(C=O)-R^{5''}
wherein R^{5''} is phenyl substituted by a C₁₋₆ alkoxy; and
20 ring A' is a benzene ring which may be further
substituted by 1 to 3 C₁₋₆ alkyl.

In compound (Ia), preferred is a compound wherein
R¹ and R² each is a C₁₋₆ alkyl which may be substituted by
25 1 to 3 substituents selected from the group consisting
of (1) C₆₋₁₄ aryl, (2) C₁₋₆ alkoxy, (3) C₁₋₆ alkylthio, (4)
hydroxy, (5) amino, (6) mono-C₁₋₆ alkylamino, (7) mono-
C₆₋₁₄ arylamino, (8) di-C₁₋₆ alkylamino, (9) di-C₆₋₁₄
arylamino, (10) carboxy, (11) C₁₋₆ alkylsulfonyl, (12)
30 C₆₋₁₄ arylsulfonyl, (13) C₁₋₆ alkylsulfinyl, (14) C₆₋₁₄
arylsulfinyl and (15) 5- to 7-membered saturated cyclic
amino which may be substituted by 1 to 3 substituents
selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄
aryl and 5- to 10-membered aromatic group, or
35 R¹ and R² form, taken together with the adjacent carbon
atom, a 3- to 8-membered carbo or heterocyclic ring

which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl, C₇₋₁₆ aralkyl and 5- to 10-membered aromatic heterocyclic group;

- 5 R³ is a phenyl, 1-naphthyl, 2-naphthyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 1-isoquinolyl, 1-indolyl, 2-indolyl or 2-benzothiazolyl group, each of which may be substituted by 1 to 3 substituents selected from the group
- 10 consisting of (1) halogen atoms, (2) C₁₋₆ alkyl, (3) C₁₋₆ alkoxy, (4) mono-C₁₋₆ alkylamino, (5) di-C₁₋₆ alkylamino and (6) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 15 10-membered aromatic group;
- 15 R^{4a} is (i) C₁₋₆ alkyl substituted by a phenyl, 1-naphthyl, 2-naphthyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 1-isoquinolyl, 1-indolyl, 2-indolyl or 2-benzothiazolyl group, each of 20 which may be substituted by 1 to 3 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₆ alkyl, (3) C₁₋₆ alkoxy, (4) hydroxy, (5) amino, (6) mono-C₁₋₆ alkylamino, (7) di-C₁₋₆ alkylamino, (8) carboxy and (9) 5- to 7-membered saturated cyclic amino 25 20 which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic group, which C₁₋₆ alkyl may be further substituted by carboxy or C₁₋₆ alkoxy-carbonyl, or
- 30 (ii) a C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₆₋₁₄ aryl-carbonyl or C₇₋₁₆ aralkyl-carbonyl group, each of 35 which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino and carboxy;
- Xa is an oxygen atom;

Ya is an oxygen atom; and
ring Aa is a benzene ring which may be further
substituted by 1 to 3 substituents selected from the
group consisting of halogen atoms, optionally
5 halogenated C₁₋₆ alkyl and optionally halogenated C₁₋₆
alkoxy.

More preferred is a compound wherein R¹ and R² each
is a C₁₋₆ alkyl which may be substituted by 1 to 3
substituents selected from the group consisting of C₆₋₁₄
10 aryl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, hydroxy, amino, mono-
C₁₋₆ alkylamino, mono-C₆₋₁₄ arylamino, di-C₁₋₆ alkylamino,
di-C₆₋₁₄ arylamino, carboxy, C₁₋₆ alkylsulfonyl, C₆₋₁₄
arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl,
or

15 R¹ and R² form, taken together with the adjacent carbon
atom, a piperidine which may be substituted by 1 to 3
substituents selected from the group consisting of C₁₋₆
alkyl, C₆₋₁₄ aryl and C₇₋₁₆ aralkyl;

R³ is a phenyl which may be substituted by 1 to 3
20 substituents selected from the group consisting of
halogen atoms, C₁₋₆ alkyl, C₁₋₆ alkoxy, amino, mono-C₁₋₆
alkylamino and di-C₁₋₆ alkylamino;

R^{4a} is (i) C₁₋₆ alkyl substituted by a phenyl or pyridyl,
each of which may be substituted by 1 to 3 substituents
25 selected from the group consisting of halogen atoms,
C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, amino, mono-C₁₋₆
alkylamino, di-C₁₋₆ alkylamino and carboxy, or
(ii) an acyl of the formula: -(C=O)-R^{5'} wherein R^{5'} is
a phenyl or phenyl-C₁₋₆ alkyl, each of which may be
30 substituted by 1 to 3 substituents selected from the
group consisting of halogen atoms, C₁₋₆ alkyl, C₁₋₆
alkoxy, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆
alkylamino and carboxy;

Xa is an oxygen atom;

35 Ya is an oxygen atom; and
ring Aa is a benzene ring which may be further

substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, optionally halogenated C₁₋₆ alkyl and optionally halogenated C₁₋₆ alkoxy.

5

As compound (I) or (Ia), concretely mentioned are 3-(4-isopropylphenyl)-5-(4-methoxybenzyloxy)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran,
3-(4-isopropylphenyl)-2,4,6,7-tetramethylbenzofuran-5-
10 yl 4-methoxybenzoate,
3-(4-isopropylphenyl)-5-(4-methoxybenzyloxy)-2,4,6,7-tetramethylbenzofuran,
3-(4-isopropylphenyl)-5-(4-methoxybenzyloxy)-1',4,6,7-tetramethylspiro[benzofuran-2(3H),4'-piperidine],
15 3-(4-isopropylphenyl)-5-(3-pyridylmethyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran,
and salts thereof.

More Preferred examples are
3-(4-isopropylphenyl)-5-(4-methoxybenzyloxy)-2,2,4,6,7-
20 pentamethyl-2,3-dihydrobenzofuran,
3-(4-isopropylphenyl)-2,4,6,7-tetramethylbenzofuran-5-
yl 4-methoxybenzoate,
3-(4-isopropylphenyl)-5-(4-methoxybenzyloxy)-2,4,6,7-tetramethylbenzofuran,
25 3-(4-isopropylphenyl)-5-(4-methoxybenzyloxy)-1',4,6,7-tetramethylspiro[benzofuran-2(3H),4'-piperidine],
and salts thereof.

Salts of compound (I) or compound (Ia) include,
30 for example, metal salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, etc. Preferred examples of metal salts include alkali metal salts such as sodium salts, potassium salts; alkaline earth metal salts such as calcium salts, magnesium salts, barium salts; aluminium salts, etc. Preferred examples of salts with organic bases include

salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N,N-dibenzylethylenediamine, etc.

Preferred examples of salts with inorganic acids

5 include hydrochlorides, hydrobromides, nitrates, sulfates, phosphates, etc. Preferred examples of salts with organic acids include formates, acetates, trifluoroacetates, fumarates, oxalates, tartrates, maleates, citrates, succinates, malates,

10 methanesulfonates, benzenesulfonates, p-toluenesulfonates, etc. Preferred examples of salts with basic amino acids include salts with arginine, lysine, ornithine, etc. Preferred examples of salts with acidic amino acids include aspartates, glutamates,

15 etc.

Among others, more preferred are pharmaceutically acceptable salts. For example, for compound (I) or (Ia) having an acidic functional group in the molecule, mentioned are their inorganic salts, such as alkali metal salts (e.g., sodium salts, potassium salts, etc.), and alkaline earth metal salts (e.g., calcium salts, magnesium salts, barium salts, etc.), ammonium salts, etc.; and for compound (I) or (Ia) having a basic functional group in the molecule, mentioned are their inorganic salts such as hydrochlorides, sulfates, phosphates, hydrobromides etc., and organic salts such as acetates, maleates, fumarates, succinates, methanesulfonates, p-toluenesulfonates, citrates, tartrates, etc.

30


Process for producing compound (I) and compound (Ia) is mentioned below.

Compound (I) of the present invention can be produced in any *per se* known manner, for example, 35 according to the methods disclosed in EP-A-273647, JP-A-1-272578, EP-A-483772, JP-A-5-140142, EP-A-345593, JP-A-2-76869, EP-A-345592 and JP-A-2-76870, or

analogous methods thereto, as well as according to the methods of the following process. Compound (Ia) can be produced in the same manner as in the production of compound (I), or in any other *per se* known manner, for example, according to the methods disclosed in WO 94/14434, JP-A-8-504826 and WO 84/02131, or analogous methods thereto.

10 Each symbol in the compounds in the following process is same as defined above. Compounds (II) and (III) described in the following process include their salts. For their salts, for example, referred to are the same as the salts of compound (I).

Process 1



15

Compound (I) is produced by reacting compound (II) with a compound of the formula: R⁴-L wherein L represents a leaving group and R⁴ is as defined above [compound (III)].

20 The "leaving group" for L includes, for example, hydroxy, halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.), optionally halogenated C₁₋₅ alkylsulfonyloxy (e.g., methanesulfonyloxy, ethanesulfonyloxy, trichloromethanesulfonyloxy, etc.), C₆₋₁₀ arylsulfonyloxy which may be substituted. The "C₆₋₁₀ arylsulfonyloxy which may be substituted" includes, for example, C₆₋₁₀ arylsulfonyloxy (e.g. phenylsulfonyloxy, naphthylsulfonyloxy, etc.) which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkoxy and nitro. Concretely mentioned is benzenesulfonyloxy, m-

nitrobenzenesulfonyloxy and p-toluenesulfonyloxy, and so forth.

(1) Hereinunder mentioned is the case where R⁴ is "an aromatic group which may be substituted" or "an aliphatic hydrocarbon group substituted by an aromatic group which may be substituted, which hydrocarbon group may be further substituted".

Compound (II) is reacted with compound (III) optionally in the presence of a base.

10 The amount of compound (III) to be reacted is from 1.0 to 5.0 mol or so, preferably from 1.0 to 2.0 mol or so, relative to one mol of compound (II).

15 The "base" includes, for example, basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogencarbonate, etc.; aromatic amines such as pyridine, lutidine, etc.; tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylpyrrolidine, N-methylmorpholine, etc.; alkali metal hydrides such as sodium hydride, potassium hydride, etc.; metal amides such as sodium amide, lithium diisopropylamide, lithium hexamethyldisilazide, etc.; metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide, etc. The amount of the base to be used is from 1.0 to 5.0 mol or so, preferably from 1.0 to 2.0 mol or so, relative to one mol of compound (II).

20 In this reaction, advantageously used is a solvent inert to the reaction. There is no particular limitation on the kind of solvent that can be used unless the reaction is interfered with. For example, preferably used are alcohols such as methanol, ethanol, propanol, etc.; ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, etc.; hydrocarbons such as benzene, toluene, cyclohexane, hexane, etc.; amides such as N,N-dimethylformamide,

N,N-dimethylacetamide, etc.; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; nitriles such as acetonitrile, propionitrile, etc.; sulfoxides such 5 as dimethylsulfoxide, etc.; and mixtures of those solvents.

The reaction time is generally from 30 minutes to 48 hours, preferably from 1 hour to 24 hours. The reaction temperature is generally from -20 to 200°C, 10 preferably from 0 to 150°C.

In place of the reaction mentioned above, also employable herein is Mitsunobu reaction (see Synthesis, pp. 1-27, 1981).

15 In this reaction, compound (II) is reacted with compound (III) wherein L is OH in the presence of an azodicarboxylate compound (e.g., diethylazo dicarboxylate, etc.) and a phosphine compound (e.g., triphenylphosphine, tributylphosphine, etc.).

20 The amount of compound (III) wherein L is OH to be reacted is from 1.0 to 5.0 mol or so, preferably from 1.0 to 2.0 mol or so, relative to one mol of compound (II).

25 The amount of the "azodicarboxylate compound" and that of the "phosphine compound" to be used are from 1.0 to 5.0 mol or so, preferably from 1.0 to 2.0 mol or so, relative to one mol of compound (II), respectively.

30 In this reaction, advantageously used is a solvent inert to the reaction. There is no particular limitation on the kind of solvent that can be used unless the reaction is interfered with. For example, preferably used are ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, etc.; hydrocarbons such as benzene, toluene, cyclohexane, 35 hexane, etc.; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, etc.; halogenated hydrocarbons such as dichloromethane, chloroform, carbon

tetrachloride, 1,2-dichloroethane, etc.; nitriles such as acetonitrile, propionitrile, etc.; sulfoxides such as dimethylsulfoxide, etc.; and mixtures of those solvents.

5 The reaction time is generally from 5 minutes to 48 hours, preferably from 30 minutes to 24 hours. The reaction temperature is generally from -20 to 200°C, preferably from 0 to 100°C.

10 (2) The case where R⁴ is "an acyl" is mentioned below.

Compound (II) is reacted with compound (III) optionally in the presence of a base or acid.

15 The amount of compound (III) to be reacted is from 1.0 to 5.0 mol or so, preferably from 1.0 to 2.0 mol or so, relative to one mol of compound (II).

The "base" includes, for example, aromatic amines such as triethylamine, pyridine, etc.

20 The "acid" includes, for example, methanesulfonic acid, p-toluenesulfonic acid, camphor-sulfonic acid, etc.

The amount of the "base" to be used is from 1.0 to 10 equivalents or so, preferably from 0.8 to 2 equivalents or so, relative to compound (II).

25 The amount of the "acid" to be used is from 0.1 to 10 equivalents or so, preferably from 0.8 to 3 equivalents or so, relative to compound (II).

This reaction is advantageously effected in the absence of a solvent or in the presence of a solvent inert to the reaction. There is no particular limitation on the kind of solvent that can be used unless the reaction is interfered with. For example, preferably used are ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, etc.; hydrocarbons such as benzene, toluene, cyclohexane, hexane, etc.; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, etc.; halogenated hydrocarbons

such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; nitriles such as acetonitrile, propionitrile, etc.; sulfoxides such as dimethylsulfoxide, etc.; nitrogen-containing aromatic hydrocarbons such as pyridine, lutidine, quinoline, etc.; and mixtures of those solvents.

The reaction temperature is generally from -20 to 150°C or so, preferably from 0 to 100°C. The reaction time is generally from 5 minutes to 24 hours, preferably from 10 minutes to 5 hours.


The product (I) as produced in the manner mentioned above may be applied to the next reaction while it is still crude in the reaction mixture, or may be isolated from the reaction mixture in any ordinary manner. This can be easily purified through separation means such as recrystallization, distillation, chromatography and the like.

Compound (II) can be produced in any *per se* known manner, for example, by the methods disclosed in EP-A-273647, JP-A-1-272578, EP-A-483772, JP-A-5-140142, EP-A-345593, JP-A-2-76869, EP-A-345592, JP-A-2-76870 and JP-A-57-122080, or analogous methods thereto.

Compound (III) can be purchased from a commercial market or produced in any *per se* known manner.

In the case that Compound (II) is a benzofuran [compound (IIa)], it can be also obtained according to the methods of the following process.

Process 2



In above formulae, L' represents a leaving group, R⁷ represents a hydrogen atom or a group formed by removing a methylene from R¹ and hal represents halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc).

The "leaving group" for L' includes, for example, hydroxy, halogen atoms (e.g. fluoro, chloro, bromo, iodo, etc.), C₁₋₆ alkylsulfonyloxy (e.g. 5 methanesulfonyloxy, ethanesulfonyloxy, etc.), C₆₋₁₀ arylsulfonyloxy which may be substituted, etc. The "C₆₋₁₀ arylsulfonyloxy which may be substituted" includes, 10 for example, C₆₋₁₀ arylsulfonyloxy (e.g. phenylsulfonyloxy, naphthylsulfonyloxy, etc.) which may 15 be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkoxy and nitro. Concretely mentioned is benzenesulfonyloxy, m-nitrobenzenesulfonyloxy, p-toluenesulfonyloxy, and so forth.

Compound (IV) can be purchased from a commercial market or produced in any *per se* known manner.

Compound (VI) can be produced by reacting a phenolate anion, which is produced by treating compound 5 (IV) with a base, and a compound of the formula: R⁷-CHL'-CH=CH-R³ [compound (V)].

The "base" includes, for example, inorganic bases such as alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, etc.; alkali metal 10 alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide, etc.; alkali metal hydrides such as sodium hydride, potassium hydride, etc.; metal amides such as sodium amide, lithium diisopropylamide, lithium hexamethyldisilazide, etc.; and basic salts 15 such as potassium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium acetate, etc. The amount of the base is generally about from 0.5 to 5 mol, preferably about 1 to 3 mol, per mol of compound (IV).

This reaction is advantageously effected in the 20 presence of a solvent inert to the reaction. There is no particular limitation on the kind of solvent that can be used unless the reaction is interfered with. For example, preferably used are alcohols such as 25 methanol, ethanol, propanol, etc.; hydrocarbons such as cyclohexane, hexane, benzene, toluene, xylene, etc.; ethers such as tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diethyl ether, diisopropyl ether, etc.; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoric triamide, etc.; 30 sulfoxides such as dimethyl sulfoxide etc.; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ketones such as acetone, methyl ethyl ketone, etc.; water; and mixtures of these solvents.

35 The reaction time is generally from 10 minutes to 8 hours, preferably from 30 minutes to 3 hours. The reaction temperature is generally from 0 to 120°C,

preferably from 25 to 100°C.

The reaction product can be directly used, either as the reaction mixture as such or in a partially purified form, in the next reaction. If desired, 5 however, the product compound can be isolated from the reaction mixture in the routine manner and expediently purified by the conventional purification procedure (e.g. recrystallization, distillation, chromatography, etc.).

10

Compound (VII) can be produced by subjecting compound (VI) to Claisen rearrangement.

This reaction is advantageously effected in the absence of a solvent or in the presence of a solvent 15 inert to the reaction. There is no particular limitation on the kind of solvent that can be used unless the reaction is interfered with. For example, preferably used are alcohols such as methanol, ethanol, propanol, etc.; hydrocarbons such as cyclohexane, 20 hexane, benzene, toluene, xylene, mesitylene etc.; ethers such as tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diethyl ether, diisopropyl ether, etc.; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoric triamide, etc.; 25 sulfoxides such as dimethyl sulfoxide etc.; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; and mixtures of these solvents.

If desired, this reaction can be conducted with 30 acid catalyst.

The "acid catalyst" includes, for example, Lewis acid such as aluminium chloride, boron trifluoride etc. The amount of the acid catalyst is generally from about 0.1 to 20 mol, preferably from about 0.1 to 5 mol, per 35 mol of compound (VI).

The reaction time is generally from 10 minutes to 8 hours, preferably from 30 minutes to 3 hours. The

reaction temperature is from generally -70 to 300°C, preferably from 150 to 250°C.

Thus obtained compound can be submitted to the next reaction either as the reaction mixture or after 5 partial purification, but can be easily isolated by *per se* known method and purified by the routine purification procedures such as recrystallization, distillation, chromatography, etc.

10 Compound (VIII) can also be produced by treating compound (VII) with a halogenation reagent.

The "halogenation reagent" includes, for example, halogens such as bromine, chlorine, iodine, etc.; imides such as N-bromosuccinimide, etc.; halogen 15 adducts such as benzyltrimethylammonium dichloroiodate, benzyltrimethylammonium tribromide, etc.

The amount of the halogenation reagent is from about 1.0 to 5.0 mol, preferably from about 1.0 to 2.0 mol, per mol of compound (VII).

20 This reaction is advantageously effected in the presence of a solvent inert to the reaction. There is no particular limitation on the kind of solvent that can be used unless the reaction is interfered with. For example, preferably used are ethers such as diethyl 25 ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, etc.; alcohols such as methanol, ethanol, propanol, etc.; hydrocarbons such as benzene, toluene, cyclohexane, hexane, etc.; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, etc.; 30 halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; nitriles such as acetonitrile, propionitrile, etc.; sulfoxides such as dimethyl sulfoxide etc.; organic acids such as acetic acid, propionic acid, 35 etc.; nitroalkanes such as nitromethane, etc.; aromatic amines such as pyridine, lutidine, quinoline, etc.; and mixtures of these solvents.

This reaction can be conducted with a base or a radical initiator, or under light exposure, where necessary.

The "base" includes, for example, basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, sodium, acetate, potassium acetate, etc; aromatic amines such as pyridine, lutidine, etc.; tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylpyrrolidine, N-methylmorpholine, etc. The amount of the bases is from about 0.8 to 10 mol, per mol of compound (VII).

The "radical initiator" includes, for example, benzoyl peroxide, azobisisobutyronitrile, etc. The amount of the radical initiator is from about 0.01 to 1 mol, per mol of compound (VII).

In the case of the light exposure, halogen lamp can be used.

The reaction temperature is about from -50 to 150°C, preferably from 0 to 100°C. The reaction time is generally from 5 minutes to 24 hours, preferably from 10 minutes to 12 hours.

Thus obtained compound can be submitted to the next reaction either as the reaction mixture or after partial purification, but can be easily isolated by *per se* known method and purified by the routine purification procedures such as recrystallization, distillation, chromatography, etc.

Compound (IIa) can be produced by treating compound (VIII) with a base.

The "base" includes, for example, inorganic bases such as alkali metal hydroxides e.g., sodium hydroxide, potassium hydroxide, etc.; organic bases such as triethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene,

pyridine, etc.; alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide, etc.; alkali metal hydrides such as sodium hydride, potassium hydride, etc.; metal amides such as sodium 5 amide, lithium diisopropylamide, lithium hexamethyldisilazide, etc.; basic salts such as potassium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium acetate, etc.

10 The amount of the base is generally from about 0.5 to 10 mol, preferably about from 1 to 5 mol, per mole of compound (VIII).

15 This reaction is advantageously effected in the presence of a solvent inert to the reaction. There is no particular limitation on the kind of solvent that can be used unless the reaction is interfered with.
For example, preferably used are alcohols such as methanol, ethanol, propanol, etc.; hydrocarbons such as cyclohexane, hexane, benzene, toluene, xylene, etc.; ethers such as tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diethyl ether, diisopropyl ether, etc.; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoric triamide, etc.; sulfoxides such as dimethyl sulfoxide etc.; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ketones such as acetone, methyl ethyl ketone, etc.; water; and mixtures of these solvents.

20 30 The reaction time is generally from 10 minutes to 24 hours, preferably from 30 minutes to 12 hours. The reaction temperature is generally from 0 to 120°C, preferably from 25 to 100°C.

35 Thus obtained compound can be submitted to the next reaction either as the reaction mixture or after partial purification, but can be easily isolated by *per se* known method and purified by the routine purification procedures such as recrystallization, distillation, chromatography, etc.

In the above-mentioned reactions where the starting compounds are substituted by any of amino, carboxy or hydroxy, those groups may be protected by ordinary protective groups which are generally used in peptide chemistry. The protective groups may be removed after the reaction to give the intended products.

The amino-protecting group includes, for example, formyl, C₁₋₆ alkyl-carbonyl (e.g., acetyl, propionyl, etc.) which may be substituted, phenylcarbonyl which may be substituted, C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, etc.) which may be substituted, phenoxy carbonyl which may be substituted, C₇₋₁₀ aralkyloxy-carbonyl (e.g., benzyloxycarbonyl, etc.) which may be substituted, trityl which may be substituted, phthaloyl which may be substituted, etc. These substituents include, for example, halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.), C₁₋₆ alkyl-carbonyl (e.g., acetyl, propionyl, valeryl, etc.), nitro, etc. The number of those substituents is 1 to 3.

The carboxy-protecting group includes, for example, C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, etc.) which may be substituted, phenyl which may be substituted, trityl which may be substituted, silyl which may be substituted, etc. These substituents include, for example, halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.), formyl, C₁₋₆ alkyl-carbonyl (e.g., acetyl, propionyl, butylcarbonyl, etc.), nitro, C₁₋₆ alkyl (e.g., methyl, ethyl, tert-butyl, etc.), C₆₋₁₀ aryl (e.g., phenyl, naphthyl, etc.), etc. The number of those substituents is 1 to 3.

The hydroxy-protecting group includes, for example, C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, etc.) which may be substituted, phenyl which may be substituted, C₇₋₁₁ aralkyl (e.g., benzyl, etc.) which may be substituted, formyl which

- may be substituted, C₁₋₆ alkyl-carbonyl (e.g., acetyl, propionyl, etc.) which may be substituted, phenyloxycarbonyl which may be substituted, C₇₋₁₁ aralkyl-oxycarbonyl (e.g., benzylloxycarbonyl, etc.)
- 5 which may be substituted, tetrahydropyranyl which may be substituted, tetrahydrofuryl which may be substituted, silyl which may be substituted, etc. Those substituents include, for example, halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.), C₁₋₆ alkyl (e.g., methyl, ethyl, tert-butyl, etc.), C₇₋₁₁ aralkyl (e.g., benzyl, etc.), C₆₋₁₀ aryl (e.g., phenyl, naphthyl, etc.), nitro, etc. The number of those substituents is 10 1 to 4.
- 15 Those protective groups may be removed by any *per se* known methods or analogous methods thereto, such as methods using acids, bases, ultraviolet rays, hydrazine, phenylhydrazine, sodium N-methyldithiocarbamate, tetrabutylammonium fluoride, palladium acetate, etc.; and reduction, etc.
- 20 The starting compounds for compound (I) include their salts, which are not specifically defined provided that the reaction with those salts gives the intended products. The above salts include, for example, the salts of compound (I) above.
- 25 For configurational isomers (E- and Z-forms) of compound (I), they may be isolated and purified through any ordinary separation means of, for example, extraction, recrystallization, distillation, chromatography and the like, to give pure products in 30 any time when the isomers are formed. By the methods described in "Shin Jikken Kagaku Kouza (New Edition of Lectures of Experimental Chemistry)" 14, edited by the Chemical Society of Japan, pp. 251-253, and in Fourth Edition of "Shin Jikken Kagaku Kouza (Lectures of Experimental Chemistry)" 19, edited by the Chemical Society of Japan, pp. 273-274, or analogous methods thereto, the products of compound (I) being produced

are specifically isomerized at the position of the double bond by heating, or with acid catalysts, transition metal catalysts or radical species catalysts, or through exposure to light, or with strong base 5 catalysts or the like, to thereby obtain the intended pure isomers.

Compound (I) includes stereoisomers, depending on the type of the substituents therein, and both single isomers and mixtures of different isomers are within 10 the scope of the present invention.

Compounds (I) and (Ia) may be in any form of their hydrates and non-hydrates.

In any case, products formed in the reaction mixtures may be subjected to deprotection, acylation, 15 alkylation, hydrogenation, oxidation, reduction, chain extension, substituents-exchange reaction and combined reactions thereof, to obtain compound (I).

Where the products are formed in their free form in the reaction, they may be converted into their salts 20 in any ordinary manner. Where they are formed in the form of their salts, they may be converted into free compounds or other salts in any ordinary manner. The thus-obtained compound (I) may be isolated and purified from the reaction mixtures through any ordinary means 25 of, for example, trans-solvation, concentration, solvent extraction, fractionation, crystallization, recrystallization, chromatography and the like.

Where compound (I) exists in the reaction mixtures in the form of its configurational isomers, 30 diastereomers, conformers or the like, they may be optionally isolated into single isomer through the separation and isolation means mentioned above. Where compound (I) is in the form of its racemates, they may be resolved into d- and l-forms through any ordinary 35 optical resolution.

As compound (I) of the present invention and compound (Ia) have an suppressive effect on neurodegeneration, an activity of suppressing nerve cell death to be caused by β -amyloid, and an activity of neurotrophic factors, while having low toxicity and few side effects, they are useful as medicines.

Compound (I) of the present invention and compound (Ia) act on mammals (e.g., mouse, rat, hamster, rabbit, feline, canine, bovine, sheep, monkey, human, etc.) as neurodegeneration inhibitors and neurotrophic factor-like substances, or as β -amyloid toxicity inhibitors, and suppress the nerve cell death in those mammals. In addition, as having an activity of activating cholinergic neurons (e.g., elevation of choline acetyltransferase activity, etc.), compounds (I) and (Ia) increase the acetylcholine content of subjects to which they are administered while activating the function of the central nervous systems of the subjects. Accordingly, compounds (I) and (Ia) are effective for neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's chorea, etc.), peripheral nervous system disorders (e.g., diabetic neuropathy, etc.) and the like, and are used as medicines for preventing and/or treating those diseases and disorders.

As their toxicity is low, compound (I) of the present invention and compound (Ia) are, either directly as they are or after having been formulated into pharmaceutical compositions along with pharmaceutically acceptable carriers in any *per se* known manner, for example, into tablets (including sugar-coated tablets, film-coated tablets), powders, granules, capsules (including soft capsules), liquid preparations, injections, suppositories, sustained release preparations, cataplasms, chewing gums, etc., safely administered orally or parenterally (e.g.,

locally, rectally, intravenously, etc.). In the pharmaceutical composition of the present invention, the amount of compound (I) or (Ia) is from 0.01 to 100 % by weight or so of the total weight of the composition. The dose of the composition varies, depending on the subject to which the composition is administered, the administration route employed, the disorder of the subject, etc. For example, for the peroral composition for treating Alzheimer's disease, its dose to adults may be from 0.1 to 20 mg/kg of body weight or so, preferably from 0.2 to 10 mg/kg of body weight or so, more preferably from 0.5 to 10 mg/kg of body weight or so, in terms of the active ingredient of compound (I) or (Ia), and this may be administered once or several times a day. Compounds (I) and (Ia) may be combined with any other active ingredients, for example, cholinesterase inhibitor (e.g., Aricept (donepezil), etc.), brain function activator (e.g., idebenone, vincocetine, etc.), medicine for Parkinson's disease (e.g., L-dopa, etc.), neurotrophic factors, and so forth. For example, compound (I) or (Ia) is mixed with any of those other active ingredients in any known manner, and formulated into one pharmaceutical composition (for example, in the form of tablets, powders, granules, capsules including soft capsules, liquid preparations, injections, suppositories, sustained-release preparations, etc.); or they may be formulated into separate compositions and administered to the same subject simultaneously or at time intervals.

Any ordinary organic and inorganic carrier substances that are generally used in formulating medicines are usable as the carriers for formulating the pharmaceutical compositions of the present invention. For example, employable are ordinary excipients, lubricants, binders, disintegrators, etc. for formulating solid preparations; and solvents, solubilizers, suspending agents, isotonizing agents,

buffers, soothing agents, etc. for formulating liquid preparations. If desired, further employable are other additives such as preservatives, antioxidants, colorants, sweeteners, adsorbents, wetting agents, etc.

5 The excipients include, for example, lactose, white sugar, D-mannitol, starch, corn starch, crystalline cellulose, light silicic anhydride, etc.

The lubricants include, for example, magnesium stearate, calcium stearate, talc, colloidal silica, etc.

10 The binders include, for example, crystalline cellulose, white sugar, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, starch, sucrose, gelatin, methyl cellulose, carboxymethyl cellulose sodium, etc.

15 The disintegrators include, for example, starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, croscarmellose sodium, carboxymethyl starch sodium, L-hydroxypropyl cellulose, etc.

20 The solvents include, for example, water for injections, alcohol, propylene glycol, macrogol, sesame oil, corn oil, olive oil, etc.

25 The solubilizers include, for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, etc.

30 The suspending agents include, for example, surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glycerin monostearate, etc.; hydrophilic polymers such as polyvinyl alcohol, polyvinyl pyrrolidone, carboxymethyl cellulose sodium, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, etc.

35 The isotonizing agents include, for example, glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol, etc.

The buffers include, for example, liquid buffers of phosphates, acetates, carbonates, citrates, etc.

The soothing agents include, for example, benzyl alcohol, etc.

5 The preservatives include, for example, parahydroxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, etc.

The antioxidants include, for example, sulfites, ascorbic acid, etc.

10

BEST MODE FOR CARRYING OUT THE INVENTION

The invention will be described in more detail hereinunder, with reference to the following Reference Examples, Examples, Formulation Examples and Experimental Examples, which, however, are to concretely illustrate some embodiments of the invention and are not intended to restrict the scope of the invention. Various changes and modifications can be made within the range that does not deviate the scope of the invention.

20 "Room temperature" as referred to in the following Reference Examples and Examples is meant to indicate a temperature falling between 10°C and 35°C. Unless otherwise specifically indicated, "%" is by weight.

25 The meanings of the abbreviations used hereinunder are as follows:

s: singlet

d: doublet

t: triplet

30 q: quartet

septet : septet

m: multiplet

br: broad

J: coupling constant

35 Hz: Hertz

CDCl₃: deuterated chloroform

d_6 -DMSO: deuterated dimethylsulfoxide

1H -NMR: proton nuclear magnetic resonance spectrum

Examples

5 Reference Example 1

Methyl α -bromophenylacetate

Concentrated sulfuric acid (0.5 mL) was added to a solution of α -bromophenylacetic acid (3.00 g, 13.9 mmol) in ethanol (30 mL) at room temperature, and the mixture was heated under reflux for 1 hour. The reaction mixture was cooled, and extracted twice with ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium hydrogencarbonate, then dried over magnesium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (2.50 g, yield 79 %). This was oily.

1H -NMR ($CDCl_3$) δ : 3.78 (3H, s), 5.36 (1H, s), 7.29-7.42 (3H, m), 7.48-7.61 (2H, m).

20

Reference Example 2

1-Bromo-4-(4-morpholinyl)benzene

Bromine (10.8 g, 67.4 mmol) was added to a solution of 4-(4-morpholinyl)benzene (10.0 g, 61.3 mmol) in ethanol (100 mL) at 0°C, and the mixture was stirred for 1 hour at room temperature. Water (100 mL) was poured into the reaction mixture, which was then extracted twice with ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium hydrogencarbonate and water, then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized from ethyl acetate-hexane to obtain the title compound (10.7 g, yield 72 %).

35 m.p.: 118-120°C.

¹H-NMR (CDCl₃) δ: 2.98-3.22 (4H, m), 3.71-3.92 (4H, m), 6.72-6.83 (2H, m), 7.31-7.42 (2H, m).

Reference Example 3

5 1-Bromo-4-(4-methyl-1-piperazinyl)benzene

Sodium hydride (60 % liquid paraffin dispersion, 2.70 g, 67.8 mmol) was added to a solution of 1-phenylpiperazine (10.0 g, 61.6 mmol) in N,N-dimethylformamide (80 mL) at 0°C, and the mixture was 10 stirred for 10 minutes at the same temperature. To the reaction mixture was added iodomethane (8.74 g, 67.8 mmol), and the mixture was stirred for 30 minutes at room temperature. The reaction mixture was poured into water (80 mL), and extracted twice with ethyl acetate. 15 The organic layers were combined, washed with water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized from hexane-isopropyl ether to obtain 1-methyl-4-phenylpiperazine (7.40 g). Bromine (7.00 g, 20 43.8 mmol) was added to a solution of this compound in ethanol (80 mL) at 0°C, and the mixture was stirred for 1 hour at room temperature. Water (80 mL) was poured into the reaction mixture, which was then extracted twice with ethyl acetate. The organic layer was 25 combined, washed with an aqueous saturated sodium hydrogencarbonate and water, then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized from ethyl acetate-hexane to obtain the title compound (8.1 g, yield 52%).

m.p.: 78-80°C.

¹H-NMR (CDCl₃) δ: 2.35 (3H, s), 2.52-2.63 (4H, m), 3.13-3.26 (4H, m), 6.78 (2H, d, J = 8.8 Hz), 7.33 (2H, d, J = 8.8 Hz).

2-Methyl-1-[4-(4-morpholinyl)phenyl]propan-1-one

n-Butyllithium (1.6 M, 25.8 mL, 41.3 mmol) was added to a solution of 1-bromo-4-(4-morpholinyl)benzene (10.0 g, 41.3 mmol) in tetrahydrofuran (100 mL) at - 5 78°C, and the mixture was stirred for 20 minutes at the same temperature. To the reaction mixture was added N-isobutyrylpropyleneimine (5.77 g, 45.4 mmol), and the mixture was stirred for 30 minutes at room temperature. Water (40 mL) was poured into the reaction mixture, 10 which was then extracted twice with ethyl acetate. The organic layers were combined, washed with water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized from hexane to obtain the title compound (6.50 g, yield 15 67 %).

m.p.: 75-77°C.

¹H-NMR (CDCl₃) δ: 1.19 (6H, d, J = 7.0 Hz), 3.22-3.33 (4H, m), 3.50 (1H, septet, J = 7.0 Hz), 3.81-3.92 (4H, m), 6.81-6.92 (2H, m), 7.85-8.95 (2H, m).

20

Reference Example 5**2-Methyl-1-[4-(4-methyl-1-piperazinyl)phenyl]propan-1-one**

Using 1-bromo-4-(4-methyl-1-piperazinyl)benzene 25 the title compound was obtained in the same manner as in Reference Example 4.

Yield: 81 %.

m.p.: 74-76°C (from methanol).

¹H-NMR (CDCl₃) δ: 1.19 (6H, d, J = 6.6 Hz), 2.35 (3H, s), 30 2.46-2.63 (4H, m), 3.32-3.41 (4H, m), 3.50 (1H, septet, J = 7.0 Hz), 6.84-6.92 (2H, m), 7.85-7.95 (2H, m).

Reference Example 6**1-(2,5-Dimethoxy-3,4,6-trimethylphenyl)-2-methyl-1-[4-(4-morpholinyl)phenyl]propan-1-ol**

n-Butyllithium (1.6 M, 18.1 mL, 29.0 mmol) was added to a solution of 1-bromo-2,5-dimethoxy-3,4,6-trimethylbenzene (7.52 g, 29.0 mmol) in tetrahydrofuran (50 mL) at -78°C, and the mixture was stirred for 20 minutes at the same temperature. To the reaction mixture was added 2-methyl-1-[4-(4-morpholinyl)phenyl]propan-1-one (6.15 g, 26.4 mmol), and the mixture was stirred for 30 minutes at room temperature. Water (40 mL) was poured into the reaction mixture, which was then extracted three times with ethyl acetate. The organic layers were combined, washed with water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized from ethanol to obtain the title compound (8.40 g, yield 90%).

m.p.: 191-193°C.

¹H-NMR (CDCl₃) δ: 0.87-1.10 (6H, m), 2.11 (3H, s), 2.18 (3H, s), 2.45 (3H, s), 2.80-3.18 (8H, m), 3.62 (3H, s), 3.75-3.90 (4H, m), 6.41 (1H, br s), 6.82 (2H, d, J = 8.8 Hz), 7.34 (2H, d, J = 8.8 Hz).

Reference Example 7

1-(2,5-Dimethoxy-3,4,6-trimethylphenyl)-2-methyl-1-[4-(4-methyl-1-piperazinyl)phenyl]propan-1-ol

Using 2-methyl-1-[4-(4-methyl-1-piperazinyl)phenyl]propan-1-one, the title compound was obtained in the same manner as in Reference Example 6. Yield: 43%.

m.p.: 114-116°C (from methanol).

¹H-NMR (CDCl₃) δ: 0.97 (6H, t, J = 6.6 Hz), 2.11 (3H, s), 2.18 (3H, s), 2.34 (3H, s), 2.45 (3H, s), 2.50-2.62 (4H, m), 2.76-3.00 (1H, m), 3.02 (3H, s), 3.10-3.28 (4H, m), 3.62 (3H, s), 6.40 (1H, br s), 6.84 (2H, d, J = 8.8 Hz), 7.33 (2H, d, J = 8.8 Hz).

3-(4-Isopropylphenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-5-ol

n-Butyllithium (1.6 M, 20.8 mL, 33.2 mmol) was added to a solution of 1-bromo-2,5-dimethoxybenzene

5 (7.2 g, 33.2 mmol) in tetrahydrofuran (20 mL) at -78°C, and the mixture was stirred for 20 minutes at the same temperature. To the reaction mixture was added 1-(4-isopropylphenyl)-2-methylpropan-1-one (5.70 g, 30.0 mmol), and the mixture was stirred for 30 minutes at

10 room temperature. Water (30 mL) was poured into the reaction mixture, which was then extracted three times with ethyl acetate. The organic layers were combined, washed with water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. A

15 mixture of the residue and 48 % hydrobromic acid (30 mL) was heated under reflux for 24 hours in an argon atmosphere. After cooled, water (30 mL) was added to the reaction mixture, which was then extracted twice with ethyl acetate. The organic layers were combined, washed with water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized from isopropyl ether-hexane to obtain the title compound (2.1 g, yield 70 %).

m.p.: 102-104°C.

25 $^1\text{H-NMR}$ (CDCl_3) δ : 0.96 (3H, s), 1.25 (6H, d, $J = 7.0$ Hz), 1.57 (3H, s), 2.90 (1H, septet, $J = 7.0$ Hz), 4.28 (1H, s), 4.67 (1H, s), 6.53-6.85 (3H, m), 7.02 (2H, d, $J = 8.0$ Hz), 7.16 (2H, d, $J = 8.0$ Hz).

30 Reference Example 9

2,2,4,6,7-Pentamethyl-3-[4-(4-morpholinyl)phenyl]-2,3-dihydrobenzofuran-5-ol

A mixture of 1-(2,5-dimethoxy-3,4,6-trimethylphenyl)-2-methyl-1-[4-(4-

35 morpholinyl)phenyl]propan-1-ol (8.00 g, 19.3 mmol) and 48 % hydrobromic acid (100 mL) was heated under reflux

for 3 hours in an argon atmosphere. After cooled, an aqueous saturated sodium hydrogencarbonate (30 mL) was added to the reaction mixture, which was then extracted twice with ethyl acetate. The organic layers were
5 combined, washed with water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized from isopropyl ether-hexane to obtain the title compound (6.40 g, yield 90 %).

10 m.p.: 91-93°C.

$^1\text{H-NMR}$ (CDCl_3) δ : 1.00 (3H, s), 1.46 (3H, s), 1.82 (3H, s), 2.15 (3H, s), 2.17 (3H, s), 2.98-3.24 (4H, m), 3.71-3.99 (4H, m), 4.04 (1H, s), 4.18 (1H, s), 6.44-7.10 (4H, m).

15

Reference Example 10

2,2,4,6,7-Pentamethyl-3-[4-(4-methyl-1-piperazinyl)phenyl]-2,3-dihydrobenzofuran-5-ol

Using 1-(2,5-dimethoxy-3,4,6-trimethylphenyl)-2-methyl-1-[4-(4-methyl-1-piperazinyl)phenyl]propan-1-ol
20 the title compound was obtained in the same manner as in Reference Example 9.

Yield: 55 %.

m.p.: 159-161°C (from ethyl acetate-hexane).

25 $^1\text{H-NMR}$ (CDCl_3) δ : 1.00 (3H, s), 1.46 (3H, s), 1.81 (3H, s), 2.17 (6H, s), 2.34 (3H, s), 2.48-2.65 (4H, m), 3.08-3.22 (4H, m), 4.03 (1H, s), 6.58-7.20 (4H, m), 1H not confirmed.

30 Reference Example 11

1-(4-Isopropylphenyl)propan-1-ol

Propionyl chloride (11.6 g, 125 mmol) was dropwise added to a suspension of aluminium chloride (16.7 g, 125 mmol) and cumene (18.0 g, 150 mmol) in carbon
35 disulfide (30 mL) at -5°C, and the mixture was stirred for 30 minutes at room temperature. The reaction

mixture was poured into water with ice, and the organic layer was separated, washed with an aqueous saturated sodium hydrogencarbonate and water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to obtain 1-(4-isopropylphenyl)propan-1-one (24.7 g). Sodium borohydride (1.29 g, 34.2 mmol) was added to a solution of the thus-obtained compound (13.0 g, 68.4 mmol) in ethanol (80 mL) with cooling with ice, and the mixture was stirred for 30 minutes at room temperature. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (11.5 g, yield 79 %). This was oily.

¹H-NMR (CDCl₃) δ: 0.91 (3H, t, J = 7.4 Hz), 1.25 (6H, d, J = 7.0 Hz), 1.63-1.92 (2H, m), 1.94 (1H, br s), 2.90 (1H, septet, J = 7.0 Hz), 4.47-4.61 (1H, m), 7.16-7.29 (4H, m).

20

Reference Example 12

2-[1-(4-Isopropylphenyl)propyl]-3,5,6-trimethyl-1,4-benzoquinone

Boron trifluoride/ethyl ether complex (1.30 g, 9.33 mmol) was dropwise added to a suspension of 1-(4-isopropylphenyl)propan-1-ol (5.00 g, 28.0 mmol) and trimethylhydroquinone (4.30 g, 28.0 mmol) in 1,2-dichloroethane (100 mL) at 60°C in a nitrogen atmosphere, and the mixture was stirred for 3 hours at the same temperature. After cooled, the reaction mixture was washed with an aqueous solution of iron(III) chloride and water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (hexane/ethyl acetate = 30/1) to obtain the title compound (5.40 g, yield 62 %).

m.p.: 61-63°C (from methanol).

¹H-NMR (CDCl₃) δ: 0.91 (3H, t, J = 7.4 Hz), 1.22 (6H, d, J = 6.8 Hz), 1.83-2.11 (11H, m), 2.85 (1H, septet, J = 6.8 Hz), 4.02-4.23 (1H, m), 7.02-4.24 (4H, m).

5

Reference Example 13

3-(4-Isopropylphenyl)-2,4,6,7-tetramethylbenzofuran-5-ol

A solution of 2-[1-(4-isopropylphenyl)propyl]-3,5,6-trimethyl-1,4-benzoquinone (1.00 g, 0.324 mmol) in ethanol (1.00 liter) was stirred for 5 hours while cooling it with ice-water to keep the solution at room temperature and while exposing it to light from 400 W Bromcinelight Deluxe (manufactured by LPL Co.). The solvent was removed under reduced pressure, and the residue was subjected to silica gel column chromatography (hexane/ethyl acetate = 20/1) to obtain the title compound (0.90 g, yield 90%). This was oily.

¹H-NMR (CDCl₃) δ: 1.31 (6H, d, J = 7.0 Hz), 1.98 (3H, s), 2.28 (3H, s), 2.30 (3H, s), 2.43 (3H, s), 2.97 (1H, septet, J = 7.0 Hz), 4.43 (1H, s), 7.26 (4H, s).

Reference Example 14

2,3,6-Trimethyl-4-[(3-phenyl-2-propenyl)oxy]phenyl acetate

To a solution of 4-hydroxy-2,3,6-trimethylphenyl acetate (10.0 g, 51.5 mmol) in N,N-dimethylformamide (100 mL) was added 1-chloro-3-phenyl-2-propene (7.86 g, 51.5 mmol) and potassium carbonate (7.10 g, 51.5 mmol) and the mixture was stirred under an argon atmosphere at 60°C for 2 hours. This reaction mixture was poured into water and extracted twice with ethyl acetate. The combined extract was washed with water, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was crystallized from methanol to obtain the title compound (13.0 g, yield 81%).

m.p.: 104-107°C.

¹H-NMR (CDCl₃) δ: 2.06 (3H, s), 2.13 (3H, s), 2.18 (3H, s), 2.34 (3H, s), 4.66 (2H, dd, J = 5.6, 1.2 Hz), 6.43 (1H, dt, J = 16.2, 5.6 Hz), 5.63 (1H, s), 6.74 (1H, d, J = 16.2 Hz), 7.24-7.46 (5H, m).

Reference Example 15

4-Hydroxy-2,3,6-trimethyl-5-(1-phenyl-2-propenyl)phenyl acetate

A solution of 2,3,6-trimethyl-4-[(3-phenyl-2-propenyl)oxy]phenyl acetate (10.0 g, 32.2 mmol) in N,N-dimethylaniline (70 mL) was stirred under an argon atmosphere at 200°C for 3 h. After the reaction mixture was cooled, it was diluted with ethyl acetate, washed with 2N hydrochloric acid, and water, and dried over magnesium sulfate, and concentrated under reduced pressure. The residue was recrystallized from ethyl acetate-hexane to obtain the title compound (7.80 g, yield 78 %).

m.p.: 136-138°C.

¹H-NMR (CDCl₃) δ: 2.06 (6H, s), 2.11 (3H, s), 2.33 (3H, s), 4.83-5.18 (2H, m), 5.36 (1H, d, J = 10.0 Hz), 6.32-6.58 (1H, m), 7.18-7.37 (5H, m), 1H not confirmed.

Reference Example 16

2,4,6,7-Tetramethyl-3-phenylbenzofuran-5-yl acetate

To a suspension of 4-hydroxy-2,3,6-trimethyl-5-(1-phenyl-2-propenyl)phenyl acetate (5.10 g, 16.4 mmol) and calcium carbonate (2.13 g, 21.3 mmol) in tetrahydrofuran (20 mL) and methanol (20 mL) was added benzyltrimethylammonium dichloroiodate (6.28 g, 18.0 mmol) slowly. The mixture was stirred at room temperature for 30 minutes. The insoluble material was removed by filtration and the filtrate was concentrated under reduced pressure. To the residue was added ethyl acetate and water. The organic layer was separated and

the aqueous layer was extracted twice with ethyl acetate. The combined organic layer was washed with 10% aqueous sodium hydrogen sulfite, water, an aqueous saturated solution of sodium bicarbonate and brine.

5 The organic layer was dried over magnesium sulfate, treated with activated carbon, filtrated and the filtrate was concentrated in vacuo to provide 5.30 g of 2-iodomethyl-4,6,7-trimethyl-3-phenyl-2,3-dihydrobenzofuran-5-yl acetate. A mixture of this

10 compound (5.30 g, 12.1 mmol) and 1,8-diazabicyclo[5.4.0]-7-undecene (9.0 m, 60.0 mmol) in toluene (20 mL) was stirred under an argon atmosphere at 100°C for 3 hours. To that mixture was added water, and the mixture was extracted with ethyl acetate. The

15 extract was washed with 2N hydrochloric acid, and water, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 20/1) to obtain the title compound (4.0 g, yield 79 %). This

20 was oily.

¹H-NMR (CDCl₃) δ: 1.85 (3H, s), 2.15 (3H, s), 2.30 (3H, s), 2.33 (3H, s), 2.44 (3H, s), 7.32-7.48 (5H, m).

Reference Example 17

25 2,4,6,7-Tetramethyl-3-phenylbenzofuran-5-ol
To a solution of 2,4,6,7-tetramethyl-3-phenylbenzofuran-5-yl acetate (4.00 g, 13.0 mmol) in a mixture of tetrahydrofuran (32 mL) and methanol (8 mL) was added 8N sodium hydroxide solution (2.0 mL) dropwise and the mixture was stirred at 40°C for 1 hour. The solvent was then distilled off under reduced pressure. To the residue was added 2N hydrochloric acid, and the mixture was extracted with ethyl acetate. The extract was washed with water and brine, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was recrystallized from isopropyl

ether-hexane to obtain the title compound (3.0 g, yield 87 %).

m.p.: 102-104°C.

¹H-NMR (CDCl₃) δ: 1.96 (3H, s), 2.28 (3H, s), 2.29 (3H, s), 2.44 (3H, s), 4.42 (1H, s), 7.28-7.43 (5H, m).

Reference Example 18

1-(2,4-Dimethoxyphenyl)-1-(4-isopropylphenyl)-2-methylpropan-1-ol

10 Using 1-bromo-2,4-dimethoxybenzene and 1-(4-isopropylphenyl)-2-methylpropan-1-one the title compound was obtained in the same manner as in Reference Example 6. Yield 56 %.

m.p.: 80-81°C (from methanol).

15 ¹H-NMR(CDCl₃) δ: 0.75 (3H, d, J = 6.6 Hz), 1.08 (3H, d, J = 6.6 Hz), 1.20 (6H, d, J = 7.0 Hz), 2.66 (1H, septet, J = 7.0 Hz), 2.80 (1H, septet, J = 6.6 Hz), 3.48 (3H, s), 3.79 (3H, s), 4.71 (1H, s), 6.39-6.40 (1H, m), 6.50-6.56 (1H, m), 7.04-7.08 (2H, m), 7.19-7.23 (2H, m), 20 7.40-7.44 (1H, m).

Reference Example 19

3-(4-Isopropylphenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-6-ol

25 A mixture of 1-(2,4-dimethoxyphenyl)-1-(4-isopropylphenyl)-2-methylpropan-1-ol (5.58 g, 17.0 mmol) and 48 % hydrobromic acid (30 mL) was heated under reflux for 24 hours in an argon atmosphere.

After the reaction mixture was cooled, an aqueous 30 saturated sodium hydrogencarbonate was added to the mixture, which was then extracted twice with ethyl acetate. The organic layers were combined, washed with brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was 35 subjected to silica gel column chromatography (hexane/ethyl acetate = 20/1 to 10/1) to obtain the title

compound (2.43 g, yield 51 %).

m.p.: 114-115°C (from hexane).

5 ¹H-NMR(CDCl₃) δ: 0.95 (3H, s), 1.24 (6H, d, J = 7.0 Hz),
1.57 (3H, s), 2.89 (1H, septet, J = 7.0 Hz), 4.25 (1H,
s), 6.15 (1H, br), 6.34-6.38 (2H, m), 6.84-6.88 (1H, m),
6.99-7.03 (2H, m), 7.13-7.17 (2H, m).

Reference Example 20

4-(4-Isopropylbenzoyl)piperidine

10 To 1-acetylisonipecotic acid (41.74 g, 243.8 mmol)
was added thionyl chloride (200 mL), and the resulting
mixture was stirred for 30 minutes. The mixture was
diluted with petroleum ether. The precipitated solid
was collected and washed with petroleum ether to afford
15 1-acetylisonipecotyl chloride. This was added to a
stirring mixture of cumene (120 mL) and aluminium
chloride (69.6 g, 522 mmol) and the resulting mixture
was stirred at 110°C for 1 hour. The mixture was
poured into ice, and extracted twice with ethyl acetate.
20 The organic layers were combined, washed with brine,
dried over magnesium sulfate, filtered, and
concentrated under reduced pressure. To the residue
was added concentrated hydrochloric acid (100 mL), and
the mixture was refluxed for 12 hours. The mixture was
25 cooled to room temperature and was washed twice with
diethyl ether. The aqueous solution was made basic
with 8N sodium hydroxide solution and then extracted
twice with ethyl acetate. The organic layers were
combined, washed with an aqueous saturated sodium
30 hydrogencarbonate, dried over magnesium sulfate,
filtered, and concentrated under reduced pressure. The
residue was crystallized from ethyl acetate-hexane to
obtain the title compound (23.5 g, yield 41 %).
m.p.: 55-57°C.
35 ¹H-NMR(CDCl₃) δ: 1.27 (6H, d, J = 6.8 Hz), 1.57-2.70 (5H,
m), 2.70-2.83 (2H, m), 2.97 (1H, septet, J = 6.8 Hz),

3.16-3.22 (2H, m), 3.34-3.46 (1H, m), 7.30-7.34 (2H, m),
7.87-7.91 (2H, m).

Reference Example 21

5 1-Benzyl-4-(4-isopropylbenzoyl)piperidine

To a solution of 4-(4-isopropylbenzoyl)piperidine in N,N-dimethylformamide (100 mL), potassium carbonate (9.60 g, 69.5 mmol) and benzyl bromide (8.50 g, 71.5 mmol) were added, and the resulting mixture was stirred
10 for 20 hours at room temperature. The mixture was poured into water, and extracted twice with ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium hydrogencarbonate, dried over magnesium sulfate, filtered, and concentrated
15 under reduced pressure. The residue was crystallized from hexane to obtain the title compound (13.53 g, yield 66 %).

m.p.: 76-77°C.

20 $^1\text{H-NMR}(\text{CDCl}_3)$ δ: 1.26 (6H, d, J = 7.0 Hz), 1.79-1.90 (4H, m), 2.07-2.20 (2H, m), 2.92-2.99 (3H, m), 3.15-3.30 (1H, m), 3.55 (2H, s), 7.24-7.32 (7H, m), 7.85-7.89 (2H, m).

Reference Example 22

25 (1-Benzyl-4-piperidyl)(2,5-dimethoxy-3,4,6-trimethylphenyl)(4-isopropylphenyl)methanol

n-Butyllithium (1.6 M, 12.0 mL, 19.2 mmol) was added to a solution of 1-bromo-2,5-dimethoxy-3,4,6-trimethylbenzene (4.89 g, 18.87 mmol) in tetrahydrofuran (100 mL) at -78°C, and the mixture was stirred for 30 minutes at the same temperature. To the reaction mixture was added 1-benzyl-4-(4-isopropylbenzoyl)piperidine (5.02 g, 15.6 mmol). The mixture was stirred for 30 minutes at the same temperature, then poured into the water, and extracted twice with ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium

hydrogencarbonate, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized from ethyl acetate-hexane to obtain the title compound (6.54 g. yield 83 %).

5 m.p.: 105-108°C.

¹H-NMR(CDCl₃) δ: 1.19 (6H, d, J = 6.6 Hz), 1.2-1.5 (2H, m), 1.8-2.0 (4H, m), 2.09 (3H, s), 2.17 (3H, s), 2.39 (3H, s), 2.4-2.5 (1H, m), 2.78-2.88 (3H, m), 2.97 (3H, s), 3.51 (2H, s), 3.60 (3H, s), 6.37 (1H, br), 7.08-10 7.12 (2H, m), 7.26-7.34 (7H, m).

Reference Example 23

1'-Benzyl-3-(4-isopropylphenyl)-4,6,7-trimethylspiro[benzofuran-2(3H),4'-piperidine]-5-ol

15 To a solution of (1-benzyl-4-piperidyl)(2,5-dimethoxy-3,4,6-trimethylphenyl)(4-isopropylphenyl)methanol (6.41 g, 12.8 mmol) in acetic acid (50 mL) was added 48% hydrobromic acid (60 mL), and the mixture was heated under reflux for 15 hours in
20 an argon atmosphere. The reaction mixture was cooled to room temperature, made basic with 8N sodium hydroxide solution, and extracted twice with ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium hydrogencarbonate, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized from ethyl acetate-hexane to obtain the title compound (4.44 g, yield 76 %).

m.p.: 190-192°C.

30 ¹H-NMR(CDCl₃) δ: 1.19 (6H, d, J = 7.0 Hz), 1.21-1.41 (2H, m), 1.71-2.00 (5H, m), 2.17 (3H, s), 2.20 (3H, s), 2.27-2.90 (5H, m), 2.97 (3H, s), 3.54 (2H, s), 4.02 (1H, s), 6.6-7.1 (4H, m), 7.20-7.32 (5H, m), 1H not confirmed.

3-(4-Isopropylphenyl)-4,6,7-trimethylspiro[benzofuran-2(3H),4'-piperidine]-5-ol hydrochloride

To a solution of 1'-benzyl-3-(4-isopropylphenyl)-4,6,7-trimethylspiro[benzofuran-2(3H),4'-piperidine]-5-ol (3.51 g, 7.70 mmol) and triethylamine (1.1 mL, 7.9 mmol) in chloroform (40 mL) α -chloroethyl chloroformate (2.30 g, 16.1 mmol) was added at 0°C. The mixture was refluxed for 1 hour and concentrated under reduced pressure. The residue was refluxed in methanol (20 mL) for 1 hour and concentrated under reduced pressure. The residue was crystallized from ethanol-ethyl acetate to obtain the title compound (2.80 g, yield 90%).
m.p.: >245°C (dec.)

¹H-NMR(d₆-DMSO) δ : 1.18 (6H, d, J = 6.6 Hz), 1.34 (2H, br), 1.71 (3H, s), 1.97 (2H, br), 2.08 (3H, s), 2.11 (3H, s), 2.8-3.3 (5H, m), 4.26 (1H, s), 6.6-7.2 (4H, m), 7.53 (1H, s), 8.78 (1H, s), 1H not confirmed.

Reference Example 25

3-(4-Isopropylphenyl)-1',4,6,7-tetramethylspiro[benzofuran-2(3H),4'-piperidine]-5-ol

A mixture of 3-(4-isopropylphenyl)-4,6,7-trimethylspiro[benzofuran-2(3H),4'-piperidine]-5-ol hydrochloride (2.80 g, 6.97 mmol), formic acid (30 mL) and 37% formalin (30 mL) was stirred for 15 hours at 100°C. The reaction mixture was cooled to room temperature, made basic with 8N sodium hydroxide solution, and extracted twice with ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium hydrogencarbonate, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (Chromatorex NH DM1020, Fuji Silysia Chemical LTD) (hexane/ethyl acetate = 1/1) to obtain the title compound (2.05 g, yield 77%).
m.p.: 114-117°C (from ethyl acetate-hexane).

¹H-NMR(CDCl₃) δ: 1.18-1.39 (8H, m), 1.72-2.91 (19H, m), 4.02 (1H, m), 6.6-7.1 (4H, m), 1H not confirmed.

Reference Example 26

5 (1-Benzyl-4-piperidyl)(2,5-dimethoxy-3,4,6-trimethylphenyl)methanol
n-Butyllithium (1.6 M, 19.5 mL, 31.2 mmol) was added to a solution of 1-bromo-2,5-dimethoxy-3,4,6-trimethylbenzene (8.00 g, 30.87 mmol) in
10 tetrahydrofuran (80 mL) at -78°C, and the mixture was stirred for 30 minutes at the same temperature. To the reaction mixture was added 1-benzyl-4-formylpiperidine (6.23 g, 30.65 mmol). The mixture was stirred for 30 minutes at room temperature, then poured into water, and extracted twice with ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium hydrogencarbonate, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (ethyl acetate) to obtain the title compound (6.17 g, yield 52 %). This was oily.

1¹H-NMR(CDCl₃) δ: 1.17-2.05 (7H, m), 2.16 (3H, s), 2.17(3H, s), 2.24 (3H, s), 2.79-2.85 (1H, m), 2.98-3.05 (1H, m), 3.48 (2H, s), 3.61 (3H, s), 3.75 (3H, s), 4.59 (1H, m), 7.23-7.32 (5H, m), 1H not confirmed.

Reference Example 27

1'-Benzyl-4,6,7-trimethylspiro[benzofuran-2(3H),4'-piperidine]-5-ol

30 To a solution of (1-benzyl-4-piperidyl)(2,5-dimethoxy-3,4,6-trimethylphenyl)methanol (6.10 g, 15.9 mmol) in acetic acid (30 mL) was added 48% hydrobromic acid (40 mL), and the mixture was heated under reflux for 15 hours in an argon atmosphere. The reaction mixture was cooled to room temperature, made basic with 8N sodium hydroxide solution, and extracted twice with

ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium hydrogencarbonate, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was
5 subjected to silica gel column chromatography (hexane/ethyl acetate = 1/1) to obtain the title compound (4.60 g, yield 86 %). This was amorphous.
¹H-NMR(CDCl₃) δ: 1.71-2.00 (6H, m), 2.10 (3H, s), 2.11 (3H, s), 2.12 (3H, s), 2.58 (2H, m), 2.87 (2H, s), 3.56
10 (2H, s), 7.25-7.38 (5H, m), 1H not confirmed.

Example 1

5-Benzylxy-3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran

15 Sodium hydride (60 % liquid paraffin dispersion, 68 mg, 1.70 mmol) was added to a solution of 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ol (0.5 g, 1.54 mmol) in N,N-dimethylformamide (20 mL) at 0°C, and the mixture was
20 stirred for 10 minutes at the same temperature. To the reaction mixture was added benzyl bromide (290 mg, 1.70 mmol) and the mixture was stirred for further 30 minutes at room temperature. The reaction mixture was poured into water (30 mL), and extracted twice with ethyl acetate. The organic layers were combined,
25 washed with water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized from methanol to obtain the title compound (380 mg, yield 60 %).

30 m.p.: 79-81°C.

¹H-NMR (CDCl₃) δ: 1.01 (3H, s), 1.22 (6H, d, J = 6.8 Hz), 1.50 (3H, s), 1.83 (3H, s), 2.16 (3H, s), 2.24 (3H, s), 2.86 (1H, septet, J = 6.8 Hz), 4.09 (1H, s), 4.70 (2H, s), 6.70-7.00 (2H, br), 7.09 (2H, d, J = 8.4 Hz), 7.30-7.50 (5H, m).

Example 2

5-Benzyl-3-[4-(dimethylamino)phenyl]-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran

Using 3-[4-(dimethylamino)phenyl]-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ol and benzyl bromide, the title compound was obtained in the same manner as in Example 1.

Yield: 40 %.

m.p.: 110-112°C (from methanol).

10 $^1\text{H-NMR}$ (CDCl_3) δ : 1.03 (3H, s), 1.48 (3H, s), 1.87 (3H, s), 2.16 (3H, s), 2.23 (3H, s), 2.91 (6H, s), 4.04 (1H, s), 4.70 (2H, s), 6.48-7.16 (4H, m), 7.20-7.48 (5H, m).

Example 3

15 5-Benzyl-2,4,6,7-tetramethyl-2-(4-phenyl-1-piperazinyl)methyl-2,3-dihydrobenzofuran

Using 2,4,6,7-tetramethyl-2-(4-phenyl-1-piperazinyl)methyl-2,3-dihydrobenzofuran-5-ol and benzyl bromide, the title compound was obtained in the same manner as in Example 1.

20 Yield: 48 %.

m.p.: 120-121°C (from methanol).

25 $^1\text{H-NMR}$ (CDCl_3) δ : 1.47 (3H, s), 2.09 (3H, s), 2.16 (3H, s), 2.20 (3H, s), 2.58-2.92 (7H, m), 3.08-3.22 (5H, m), 4.71 (2H, s), 6.78-6.94 (3H, m), 7.20-7.52 (7H, m).

Example 4

3-(4-Isopropylphenyl)-5-(4-methoxybenzyloxy)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran

30 Using 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ol and 4-methoxybenzyl chloride, the title compound was obtained in the same manner as in Example 1.

35 Yield: 49 %.

m.p.: 95-96°C (from methanol).

¹H-NMR (CDCl₃) δ: 1.00 (3H, s), 1.22 (6H, d, J = 7.0 Hz), 1.49 (3H, s), 1.82 (3H, s), 2.16 (3H, s), 2.23 (3H, s), 2.86 (1H, septet, J = 7.0 Hz), 3.81 (3H, s), 4.08 (1H, s), 4.63 (2H, s), 6.70-7.18 (6H, m), 7.35 (2H, d, J = 5 Hz).

Example 5

3-(4-Isopropylphenyl)-5-(4-methoxybenzyloxy)-2,2-dimethyl-2,3-dihydrobenzofuran

10 Using (4-isopropylphenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-5-ol and 4-methoxybenzyl chloride, the title compound was obtained in the same manner as in Example 1.

Yield: 75 %.

15 m.p.: 124-126°C (from ethyl acetate-hexane).

¹H-NMR (CDCl₃) δ: 0.95 (3H, s), 1.25 (6H, d, J = 7.0 Hz), 1.57 (3H, s), 2.90 (septet, 1H, J = 7.0 Hz), 3.71 (3H, s), 4.30 (1H, s), 4.87 (2H, s), 6.65-7.35 (11H, m).

20 **Example 6**

3-[4-(Dimethylamino)phenyl]-5-(4-methoxybenzyloxy)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran

25 Using 3-[4-(dimethylamino)phenyl]-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ol and 4-methoxybenzyl chloride, the title compound was obtained in the same manner as in Example 1.

Yield: 42 %.

m.p.: 105-107°C (from ethanol).

30 ¹H-NMR (CDCl₃) δ: 1.02 (3H, s), 1.48 (3H, s), 1.84 (3H, s), 2.15 (3H, s), 2.23 (3H, s), 2.92 (6H, s), 3.81 (3H, s), 4.04 (1H, s), 4.58-4.69 (2H, m), 6.54-6.93 (6H, m), 7.30-7.42 (2H, m).

Example 7

35 **5-(4-Methoxybenzyloxy)-3-[4-(4-morpholinyl)phenyl]-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran**

Using 2,2,4,6,7-pentamethyl-3-[4-(4-morpholinyl)phenyl]-2,3-dihydrobenzofuran-5-ol and 4-methoxybenzyl chloride, the title compound was obtained in the same manner as in Example 1.

5 Yield: 38 %.

m.p.: 110-112°C (ethanol).

¹H-NMR (CDCl₃) δ: 1.01 (3H, s), 1.48 (3H, s), 1.83 (3H, s), 2.15 (3H, s), 2.23 (3H, s), 3.02-3.26 (4H, m), 3.71-3.99 (7H, m), 4.05 (1H, s), 4.57-4.90 (2H, m), 10 6.60-7.00 (6H, m), 7.35 (2H, d, J = 6.8 Hz).

Example 8

5-(4-Methoxybenzyloxy)-2,2,4,6,7-pentamethyl-3-[4-(4-methyl-1-piperazinyl)phenyl]-2,3-dihydrobenzofuran

15 Using 2,2,4,6,7-pentamethyl-3-[4-(4-methyl-1-piperazinyl)phenyl]-2,3-dihydrobenzofuran-5-ol and 4-methoxybenzyl chloride, the title compound was obtained in the same manner as in Example 1.

Yield: 42 %.

20 m.p.: 121-122°C (from ethyl ether-hexane).

¹H-NMR (CDCl₃) δ: 1.01 (3H, s), 1.48 (3H, s), 1.83 (3H, s), 2.15 (3H, s), 2.23 (3H, s), 2.34 (3H, s), 2.52-2.63 (4H, m), 3.13-3.24 (4H, m), 3.81 (3H, s), 4.05 (1H, s), 4.58-4.67 (2H, m), 6.60-7.07 (6H, m), 7.35 (2H, d, J = 8.8 Hz).

Example 9

3-(4-Isopropylphenyl)-2,2,4,6,7-pentamethyl-5-(4-methylthiobenzyloxy)-2,3-dihydrobenzofuran

30 Using 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ol and 4-(bromomethyl)phenyl methyl sulfide, the title compound was obtained in the same manner as in Example 1.

Yield: 70 %.

35 m.p.: 118-120°C (from ethanol).

¹H-NMR (CDCl₃) δ: 1.01 (3H, s), 1.22 (6H, d, J = 7.0 Hz), 1.49 (3H, s), 1.82 (3H, s), 2.16 (3H, s), 2.22 (3H, s), 2.48 (3H, s), 2.86 (1H, septet, J = 7.0 Hz), 4.08 (1H, s), 4.65 (2H, s), 6.80-7.02 (2H, br), 7.08 (2H, d, J = 8.0 Hz), 7.25 (2H, d, J = 8.4 Hz), 7.36 (2H, d, J = 8.4 Hz).

Example 10

10 3-(4-Isopropylphenyl)-2,2,4,6,7-pentamethyl-5-[4-(methylsulfinyl)benzyloxy]-2,3-dihydrobenzofuran

Sodium periodate (0.766 g, 3.58 mmol) was added to a solution of 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-5-(4-methylthiobenzyloxy)-2,3-dihydrobenzofuran (1.50 g, 3.26 mmol) in a mixture of ethanol (80 mL) and water (8 mol), and the mixture was heated under reflux for 2 hours. To the reaction mixture were added ethyl acetate and water to separate it into two layers, and the aqueous layer was extracted with ethyl acetate. The organic layers were combined, washed with water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was recrystallized from ethyl acetate-hexane to obtain the title compound (1.23 g, yield 79 %).

25 m.p.: 132-134°C.

¹H-NMR (CDCl₃) δ: 1.02 (3H, s), 1.22 (6H, d, J = 6.8 Hz), 1.50 (3H, s), 1.82 (3H, s), 2.17 (3H, s), 2.23 (3H, s), 2.71, 2.72 (1.5H x2, s x2), 2.86 (1H, septet, J = 6.8 Hz), 4.09 (1H, s), 4.76 (2H, s), 6.71-7.15 (4H, m), 30 7.57-7.69 (4H, m).

Example 11

35 3-(4-Isopropylphenyl)-2,2,4,6,7-pentamethyl-5-[4-(methylsulfonyl)benzyloxy]-2,3-dihydrobenzofuran

Sodium periodate (2.02 g, 9.45 mmol) was added to a solution of 3-(4-isopropylphenyl)-2,2,4,6,7-

pentamethyl-5-[(4-methylsulfinyl)benzyloxy]-2,3-dihydrobenzofuran (1.50 g, 3.15 mmol) in a mixture of ethanol (80 mL) and water (8 mol), and the mixture was heated under reflux for 18 hours. To the reaction mixture were added ethyl acetate and water to separate it into two layers, and the aqueous layer was extracted with ethyl acetate. The organic layers were combined, washed with water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was recrystallized from ethyl acetate-hexane to obtain the title compound (1.05 g, yield 68 %).

m.p.: 161-162°C.

¹H-NMR (CDCl₃) δ: 1.02 (3H, s), 1.22 (6H, d, J = 7.0 Hz), 1.50 (3H, s), 1.82 (3H, s), 2.17 (3H, s), 2.22 (3H, s), 2.87 (1H, septet, J = 7.0 Hz), 3.05 (3H, s), 4.09 (1H, s), 4.80 (2H, s), 6.70-7.13 (4H, m), 7.67 (2H, d, J = 8.4 Hz), 7.95 (2H, d, J = 8.4 Hz).

20 Example 12

3-(4-Isopropylphenyl)-2,2,4,6,7-pentamethyl-5-(3-phenyl-2-propen-1-yloxy)-2,3-dihydrobenzofuran

Using 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ol and 3-bromo-1-phenyl-1-propene, the title compound was obtained in the same manner as in Example 1.

Yield: 71 %.

m.p.: 106-107°C (from methanol).

¹H-NMR (CDCl₃) δ: 1.00 (3H, s), 1.21 (6H, d, J = 7.0 Hz), 1.49 (3H, s), 1.86 (3H, s), 2.16 (3H, s), 2.24 (3H, s), 2.85 (1H, septet, J = 7.0 Hz), 4.08 (1H, s), 4.36 (2H, d, J = 6.0 Hz), 6.42 (1H, dt, J = 15.4, 6.0 Hz), 6.66-7.15 (5H, m), 7.20-7.48 (5H, m).

35 Example 13

3-(4-Isopropylphenyl)-2,2,4,6,7-pentamethyl-5-(2-quinolylmethoxy)-2,3-dihydrobenzofuran hydrochloride
Sodium hydride (60 % liquid paraffin dispersion, 136 mg, 3.39 mmol) was added to a solution of 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ol (1.0 g, 3.08 mmol) in N,N-dimethylformamide (30 mL) at 0°C, and the mixture was stirred for 10 minutes at the same temperature. To the reaction mixture was added 2-(chloromethyl)quinoline hydrochloride (730 mg, 3.39 mmol) and the mixture was stirred for 30 minutes at 80°C. The reaction mixture was poured into water (40 mL), and extracted twice with ethyl acetate. The organic layers were combined, washed with water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. To the residue was added 4 N HCl-ethanol, and the solvent was removed through distillation. The residue was crystallized from ethanol-hexane to obtain the title compound (1.1 g, yield 71 %).

m.p.: 136-139°C.

¹H-NMR (DMSO-d₆) δ: 0.94 (3H, s), 1.18 (6H, d, J = 7.0 Hz), 1.45 (3H, s), 1.78 (3H, s), 2.11 (3H, s), 2.22 (3H, s), 2.85 (1H, septet, J = 7.0 Hz), 4.19 (1H, s), 4.20-4.90 (1H, br), 5.10 (1H, d, J = 15.8 Hz), 5.19 (1H, d, J = 15.8 Hz), 6.65-7.05 (2H, br), 7.13 (2H, d, J = 8.8 Hz), 7.72-7.85 (1H, m), 7.91-8.02 (2H, m), 8.15-8.30 (2H, m), 8.80 (1H, d, J = 8.8 Hz).

Example 14

30 5-(3,3-Diphenylpropyloxy)-3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran
Using 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ol and 3,3-diphenylpropyl methanesulfonate, the title compound was obtained in
35 the same manner as in Example 1. This was oily.
Yield: 55 %.

5 ¹H-NMR (CDCl₃) δ: 0.99 (3H, s), 1.21 (6H, d, J = 7.0 Hz), 1.45 (3H, s), 1.71 (3H, s), 2.08 (3H, s), 2.10 (3H, s), 2.48 (1H, d, J = 6.6 Hz), 2.55 (1H, d, J = 6.6 Hz), 2.76-2.93 (1H, m), 3.60 (2H, t, J = 6.6 Hz), 4.07 (1H, s), 4.25 (1H, t, J = 8.0 Hz), 6.60-7.00 (2H, br), 7.06 (2H, d, J = 7.6 Hz), 7.10-7.34 (10H, m).

Example 15

10 Methyl 4-[[3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl]oxymethyl]benzoate

Using methyl 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ol and methyl 4-(bromomethyl)methylbenzoate, the title compound was obtained in the same manner as in Example 1.

15 Yield: 82 %.

m.p.: 108-110°C (from methanol).

20 ¹H-NMR (CDCl₃) δ: 1.01 (3H, s), 1.22 (6H, d, J = 7.0 Hz), 1.50 (3H, s), 1.82 (3H, s), 2.16 (3H, s), 2.22 (3H, s), 2.86 (1H, septet, J = 7.0 Hz), 3.92 (3H, s), 4.09 (1H, s), 4.76 (2H, s), 6.65-7.00 (2H, br), 7.08 (2H, d, J = 8.0 Hz), 7.51 (2H, d, J = 8.0 Hz), 8.04 (2H, d, J = 8.2 Hz). 07 (1H, s), 4.21-4.37 (4H, m), 6.63-6.98 (2H, br), 7.07 (2H, d, J = 8.0 Hz).

25

Example 16

2,3-dihydrobenzofuran-5-yl]oxy]phenylacetate

30 Using 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ol and methyl α-bromophenylacetate, the title compound was obtained in the same manner as in Example 1. This was oily.

Yield: 82 %.

35 ¹H-NMR (CDCl₃) δ: 0.99 (3H, s), 1.21, 1.23 (6H, each d, J = 7.0 Hz), 1.47 (3H, s), 1.57, 1.60 (3H, each s),

2.00, 2.04 (3H, each s), 2.09, 2.11 (3H, each s), 2.75-
2.98 (1H, m), 3.70, 3.74 (3H, each s), 4.01 (1H, s),
5.07 (1H, s), 6.60-6.95 (2H, br), 7.06 (2H, d, J = 8.0
Hz), 7.24-7.50 (5H, m).

5

Example 17

3-(4-Isopropylphenyl)-2,2,4,6,7-pentamethyl-5-(2-pyridylmethoxy)-2,3-dihydrobenzofuran

Using 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-
10 2,3-dihydrobenzofuran-5-ol and 2-chloromethylpyridine
hydrochloride, the title compound was obtained in the
same manner as in Example 1.

Yield: 17 %.

m.p.: 88-89°C (from methanol).

15 $^1\text{H-NMR}$ (CDCl_3) δ : 1.02 (3H, s), 1.22 (6H, d, J = 7.0 Hz),
1.51 (3H, s), 1.83 (3H, s), 2.17 (3H, s), 2.24 (3H, s),
2.86 (1H, septet, J = 7.0 Hz), 4.10 (1H, s), 4.80 (1H,
d, J = 15.8 Hz), 4.89 (1H, d, J = 15.8 Hz), 6.72-7.02
(2H, br), 7.09 (2H, d, J = 8.2 Hz), 7.15-7.25 (1H, m),
20 7.67-7.81 (2H, m), 8.50-8.58 (1H, m).

Example 18

3-(4-Isopropylphenyl)-2,2,4,6,7-pentamethyl-5-(3-pyridylmethoxy)-2,3-dihydrobenzofuran

25 Using 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-
2,3-dihydrobenzofuran-5-ol and 3-chloromethylpyridine
hydrochloride, the title compound was obtained in the
same manner as in Example 1. This was oily.

Yield: 76 %.

30 $^1\text{H-NMR}$ (CDCl_3) δ : 1.02 (3H, s), 1.22 (6H, d, J = 7.0 Hz),
1.50 (3H, s), 1.82 (3H, s), 2.16 (3H, s), 2.22 (3H, s),
2.86 (1H, septet, J = 7.0 Hz), 4.09 (1H, s), 4.73 (2H,
s), 6.63-7.02 (2H, br), 7.09 (2H, d, J = 8.2 Hz), 7.24
(1H, dd, J = 7.8, 5.0 Hz), 7.78 (1H, d, J = 7.6 Hz),
35 8.56 (1H, d, J = 4.0 Hz), 8.60-8.71 (1H, br).

Example 19

3-(4-Isopropylphenyl)-2,2,4,6,7-pentamethyl-5-(4-pyridylmethoxy)-2,3-dihydrobenzofuran

Using 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-
5 2,3-dihydrobenzofuran-5-ol and 4-chloromethylpyridine
hydrochloride, the title compound was obtained in the
same manner as in Example 1. This was oily.

Yield: 52 %.

¹H-NMR (CDCl₃) δ: 1.02 (3H, s), 1.22 (6H, d, J = 7.0 Hz),
10 1.50 (3H, s), 1.82 (3H, s), 2.16 (3H, s), 2.21 (3H, s),
2.78-2.93 (1H, m), 4.08 (1H, s), 4.73 (2H, s), 6.62-
7.01 (2H, br), 7.09 (2H, d, J = 8.4 Hz), 7.38 (2H, d, J
= 5.8 Hz), 8.60 (2H, d, J = 5.8 Hz).

15 **Example 20**

3-(4-Isopropylphenyl)-5-(2,4-dinitrophenyloxy)-
2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran

Sodium hydride (60 % liquid paraffin dispersion,
270 mg, 6.75 mmol) was added to a solution of 3-(4-
20 isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-ol (2.0 g, 6.16 mmol) in N,N-
dimethylformamide (30 mL) at 0°C, and the mixture was
stirred for 20 minutes at the same temperature. To the
reaction mixture was added 1-chloro-2,4-dinitrobenzene
25 (1.37 g, 6.78 mmol) and the mixture was stirred for 20
minutes at room temperature. The reaction mixture was
poured into water (50 mL), and extracted twice with
ethyl acetate. The organic layers were combined, dried
over magnesium sulfate, filtered, and concentrated
under reduced pressure. The residue was crystallized
30 from ethyl acetate-hexane to obtain the title compound
(1.5 g, yield 50 %).

m.p.: 137-139°C.

¹H-NMR (CDCl₃) δ: 1.04 (3H, s), 1.22 (6H, d, J = 7.0 Hz),
35 1.57 (3H, s), 1.66 (3H, s), 2.03 (3H, s), 2.19 (3H, s),
2.86 (1H, septet, J = 7.0 Hz), 4.13 (1H, s), 6.62-6.95

(3H, m), 7.11 (2H, d, J = 8.0 Hz), 8.26 (1H, dd, J = 9.2, 2.6 Hz), 8.75-8.86 (1H, m).

Example 21

5 5-(2,4-Bisacetylaminophenoxy)-3-(4-isopropylphenyl)-
2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran
 3-(4-Isopropylphenyl)-5-(2,4-dinitrophenyloxy)-
2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran (800 mg,
1.63 mmol) and 10 % palladium-carbon (hydrate) (80 mg)
10 were dispersed in ethanol (40 mL), and the mixture was
stirred in a hydrogen atmosphere at 60°C for 4 hours.
The reaction mixture, from which was removed the
catalyst through filtration, was concentrated under
reduced pressure to obtain 5-(2,4-diaminophenoxy)-3-(4-
15 isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran (710 mg). Acetyl chloride (0.26 mL,
3.63 mmol) was added to a solution of the thus-obtained
compound (710 mg, 1.65 mmol) and triethylamine (290 mg,
1.70 mmol) in chloroform (30 mL) at 0°C, and the
20 mixture was stirred for 1 hour at the same temperature.
The reaction mixture was poured into water (30 mL), and
extracted twice with ethyl acetate. The organic layers
were combined, washed with an aqueous saturated sodium
hydrogencarbonate, dried over magnesium sulfate,
25 filtered, and concentrated under reduced pressure. The
residue was subjected to silica gel column
chromatography (hexane/ethyl acetate = 1/5) to obtain
the title compound (640 mg, yield 76 %). This was
amorphous.

30 ¹H-NMR (CDCl₃) δ: 1.04 (3H, s), 1.22 (6H, d, J = 6.8 Hz),
1.52 (3H, s), 1.64 (3H, s), 2.00 (3H, s), 2.12 (3H, s),
2.18 (3H, s), 2.23 (3H, s), 2.86 (1H, septet, J = 6.8
Hz), 4.11 (1H, s), 6.30 (1H, d, J = 9.2 Hz), 6.60-7.03
(2H, br), 7.05 (2H, d, J = 8.4 Hz), 7.54 (1H, dd, J =
35 9.2, 2.6 Hz), 7.69 (1H, br s), 8.02 (1H, s), 8.21 (1H,
d, J = 2.6 Hz).

Example 22

α -[3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yloxy]phenylacetic acid

5 An aqueous solution of 2 N sodium hydroxide (2.5 mL) was dropwise added to a solution of methyl α -[3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yloxy]phenylacetate (1.20 g, 2.54 mmol) in a mixture of tetrahydrofuran (24 mL) and 10 methanol (6 mL), and the mixture was stirred for 30 minutes at room temperature. The reaction mixture was concentrated under reduced pressure, to which was added 2 N hydrochloric acid. Then, this was extracted twice with ethyl acetate. The organic layers were washed 15 with water, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was recrystallized from hexane to obtain the title compound (0.31 g, yield 27 %), which was a mixture of diastereomers (ratio: 8/1).

20 m.p.: 163-166°C.

$^1\text{H-NMR}$ (CDCl_3) δ : 0.98 (3H, s), 1.12-1.25 (6H, m), 1.41-1.56 (6H, m), 1.92-2.10 (6H, m), 2.87 (1H, septet, J = 6.6 Hz), 3.99 (1H, s), 5.08-5.10 (1H, m), 5.20-6.00 (1H, br), 6.60-7.17 (4H, m), 7.20-7.39 (5H, m).

25

Example 23

α -[3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yloxy]phenylacetic acid

30 The filtrate in Example 22 was concentrated under reduced pressure to obtain the title compound (0.50 g, yield 43 %), which was amorphous and was a mixture of diastereomers (ratio: 1/3).

$^1\text{H-NMR}$ (CDCl_3) δ : 0.98 (3H, s), 1.16-1.26 (6H, m), 1.39-1.56 (6H, m), 1.91-2.10 (6H, m), 2.84 (1H, septet, J =

6.8 Hz), 4.00 (1H, m), 5.07-5.10 (1H, s), 5.40-6.30 (1H, br), 6.50-7.14 (4H, m), 7.20-7.40 (5H, m).

Example 24

5 3-(4-Isopropylphenyl)-2,2,4,6,7-pentamethyl-5-(3-phenyl-1-propyl)oxy-2,3-dihydrobenzofuran

10 3-(4-Isopropylphenyl)-2,2,4,6,7-pentamethyl-5-(3-phenyl-2-propen-1-yl)oxy-2,3-dihydrobenzofuran (800 mg, 1.82 mmol) and 10 % palladium-carbon (hydrate) (80 mg) were suspended in ethanol (20 mL), and the mixture was stirred for 3 hours in a hydrogen atmosphere at room temperature. The catalyst was removed through filtration, and the filtrate was concentrated under reduced pressure. The residue was crystallized from methanol to obtain the title compound (610 mg, yield 76 %).

m.p.: 78-80°C.

15 ¹H-NMR (CDCl₃) δ: 0.99 (3H, s), 1.22 (6H, d, J = 6.8 Hz), 1.48 (3H, s), 1.81 (3H, s), 2.02-2.22 (8H, m), 2.76-2.91 (3H, m), 3.68 (2H, t, J = 6.4 Hz), 4.07 (1H, s), 6.70-6.92 (2H, br), 7.07 (2H, d, J = 8.8 Hz), 7.15-7.32 (5H, m).

Example 25

20 3-(4-Isopropylphenyl)-2,2,4,6,7-pentamethyl-5-(2-phenylethyl)oxy-2,3-dihydrobenzofuran

25 A solution of 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ol (1.0 g, 3.08 mmol), 2-phenylethanol (414 mg, 3.39 mmol), triphenylphosphine (890 mg, 3.39 mmol) and diethyl azodicarboxylate (590 mg, 3.39 mmol) in tetrahydrofuran (20 mL) was stirred for 30 minutes at room temperature. The reaction mixture was concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography (hexane/ethyl acetate = 100/1) to obtain the title compound (150 mg, yield 11 %).

m.p.: 72-74°C (from methanol).

¹H-NMR (CDCl₃) δ: 0.98 (3H, s), 1.21 (6H, d, J = 7.0 Hz), 1.46 (3H, s), 1.72 (3H, s), 2.10 (3H, s), 2.12 (3H, s), 2.83 (1H, septet, J = 7.0 Hz), 3.05 (2H, t, J = 7.0 Hz), 5 3.85 (2H, t, J = 7.0 Hz), 4.03 (1H, s), 6.65-7.00 (2H, br), 7.06 (2H, d, J = 8.0 Hz), 7.15-7.50 (5H, m).

Example 26

3-(4-Isopropylphenyl)-2,4,6,7-tetramethylbenzofuran-5-
10 yl 4-methoxybenzoate

Triethylamine (0.45 mL, 3.21 mmol) was added to a solution of 3-(4-isopropylphenyl)-2,4,6,7-tetramethylbenzofuran-5-ol (0.90 g, 2.92 mmol) and 4-methoxybenzoyl chloride (0.55 g, 3.21 mmol) in chloroform (15 mL) at room temperature, and the mixture was stirred for 3 hours at 60°C. Water (30 mL) was poured into the reaction mixture, which was then extracted twice with ethyl acetate. The organic layers were combined, washed with 1 N hydrochloric acid and saturated sodium hydroxide, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized from ethanol to obtain the title compound (0.52 g, yield 79 %).

m.p.: 113-115°C.

25 ¹H-NMR (CDCl₃) δ: 1.28 (6H, d, J = 6.8 Hz), 1.90 (3H, s), 2.18 (3H, s), 2.33 (3H, s), 2.46 (3H, s), 2.95 (1H, septet, J = 6.8 Hz), 3.89 (3H, s), 6.99 (2H, d, J = 9.0 Hz), 7.25 (4H, s), 8.20 (2H, d, J = 8.8 Hz).

30 **Example 27**

3-(4-Isopropylphenyl)-5-(4-methoxybenzyloxy)-2,4,6,7-tetramethylbenzofuran

Using 3-(4-isopropylphenyl)-2,4,6,7-tetramethylbenzofuran-5-ol and 4-methoxybenzyl chloride, 35 the title compound was obtained in the same manner as in Example 1. This was oily.

Yield: 64 %.

¹H-NMR (CDCl₃) δ: 1.31 (6H, d, J = 6.8 Hz), 2.06 (3H, s), 2.31 (3H, s), 2.34 (3H, s), 2.43 (3H, s), 2.97 (1H, septet, J = 6.8 Hz), 3.82 (3H, s), 4.66 (2H, s), 6.91 (2H, d, J = 8.8 Hz), 7.26 (4H, s), 7.40 (2H, d, J = 8.8 Hz).

Example 28

2,4,6,7-Tetramethyl-3-phenylbenzofuran-5-yl 4-methoxybenzoate

Using 2,4,6,7-tetramethyl-3-phenylbenzofuran-5-ol and 4-methoxybenzoyl chloride, the title compound was obtained in the same manner as in Example 26.

Yield 64%.

m.p.: 152-154°C (from methanol).

¹H-NMR (CDCl₃) δ: 1.88 (3H, s), 2.18 (3H, s), 2.32 (3H, s), 2.46 (3H, s), 3.89 (3H, s), 6.99 (2H, d, J = 9.2 Hz), 7.29-7.43 (5H, m), 8.20 (2H, d, J = 9.2 Hz).

Examples 29

3-(4-Isopropylphenyl)-6-(4-methoxybenzyloxy)-2,2-dimethyl-2,3-dihydrobenzofuran

Sodium hydride (60 % liquid paraffin dispersion, 179.0 mg, 4.48 mmol) was added to a solution of 3-(4-isopropylphenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-6-ol (1.12 g, 4.00 mmol) in N,N-dimethylformamide (15 mL) at 0°C, and the mixture was stirred for 30 minutes at the same temperature. To the reaction mixture was added 4-methoxybenzyl chloride (636.8 mg, 4.07 mmol) and the mixture was stirred for further 30 minutes at room temperature. The reaction mixture was poured into water, and extracted twice with ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium hydrogencarbonate, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was subjected to silica

gel column chromatography (hexane/ethyl acetate = 5/1) to obtain the title compound (1.19 g, yield 74 %).
m.p.: 86-88°C (from hexane).

5 ¹H-NMR(CDCl₃) δ: 0.95 (3H, s), 1.24 (6H, d, J = 7.0 Hz),
1.58 (3H, s), 2.89 (1H, septet, J = 7.0 Hz), 3.82 (3H, s),
4.27 (1H, s), 4.96 (2H, s), 6.47-6.52 (2H, m),
6.90-6.95 (3H, m), 7.02 (2H, d, J = 8.1 Hz), 7.16 (2H, d, J = 8.1 Hz),
7.37 (2H, d, J = 8.8 Hz).

10 Example 30

1 '-Benzyl-3-(4-isopropylphenyl)-5-(4-methoxybenzyloxy)-4,6,7-trimethylspiro[benzofuran-2(3H),4'-piperidine] Sodium hydride (60 % liquid paraffin dispersion, 81.4 mg, 1.81 mmol) was added to a solution of 1'-benzyl-3-(4-isopropylphenyl)-4,6,7-trimethylspiro[benzofuran-2(3H),4'-piperidine]-5-ol (824.0 mg, 1.81 mmol) in N,N-dimethylformamide (15 mL) at 0°C, and the mixture was stirred for 30 minutes at the same temperature. To the reaction mixture was added 4-methoxybenzyl chloride (319.9 mg, 2.04 mmol) and the mixture was stirred for further 30 minutes at room temperature. The reaction mixture was poured into water, and extracted twice with ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium hydrogencarbonate, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (hexane/ethyl acetate = 3/1) to obtain the title compound (539 mg, yield 52 %).

30 This was amorphous.

1 H-NMR(CDCl₃) δ: 1.20 (6H, d, J = 6.8 Hz), 1.27-1.39 (2H, m), 1.81 (3H, s), 1.86-1.96 (2H, m), 2.19 (3H, s), 2.23 (3H, s), 2.35-2.87 (5H, m), 3.52 (2H, s), 3.80 (3H, s), 4.04 (1H, s), 4.62 (2H, s), 6.6-6.9 (4H, m), 7.04-7.08 (2H, m), 7.22-7.36 (7H, m).

Example 31

1'-Benzyl-5-(4-methoxybenzyloxy)-4,6,7-trimethylspiro[benzofuran-2(3H),4'-piperidine]

Sodium hydride (60 % liquid paraffin dispersion, 134.6 mg, 3.37 mmol) was added to a solution of 1'-benzyl-4,6,7-trimethylspiro[benzofuran-2(3H),4'-piperidine]-5-ol (1.01 g, 2.98 mmol) in N,N-dimethylformamide (15 mL) at 0°C, and the mixture was stirred for 30 minutes at the same temperature. To the reaction mixture was added 4-methoxybenzyl chloride (584.9 mg, 3.43 mmol) and the mixture was stirred for further 30 minutes at room temperature. The reaction mixture was poured into water, and extracted twice with ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium hydrogencarbonate, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (hexane/ethyl acetate = 2/1) to obtain the title compound (1.15 g, yield 85 %).
m.p.: 85-86°C (from hexane).

¹H-NMR(CDCl₃) δ: 1.80-2.00 (4H, m), 2.10 (3H, s), 2.15 (3H, s), 2.18 (3H, s), 2.60 (4H, br), 2.87 (2H, s), 3.58 (2H, s), 3.83 (3H, s), 4.62 (2H, s), 6.90-6.95 (2H, m), 7.30-7.43 (7H, m).

Example 32

3-(4-Isopropylphenyl)-5-(4-methoxybenzyloxy)-1',4,6,7-tetramethylspiro[benzofuran-2(3H),4'-piperidine]

Sodium hydride (60 % liquid paraffin dispersion, 64.3 mmol, 1.61 mmol) was added to a solution of 3-(4-isopropylphenyl)-1',4,6,7-tetramethylspiro[benzofuran-2(3H),4'-piperidine]-5-ol (509.0 mg, 1.34 mmol) in N,N-dimethylformamide (25 mL) at 0°C, and the mixture was stirred for 30 minutes at the same temperature. To the reaction mixture was added 4-methoxybenzyl chloride

(244.0 mg, 1.56 mmol) and the mixture was stirred for further 30 minutes at room temperature. The reaction mixture was poured into water, and extracted twice with ethyl acetate. The organic layers were combined, washed 5 with an aqueous saturated sodium hydrogencarbonate, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (Chromatorex NH DM1020, Fuji Silysia Chemical LTD) 10 (hexane/ethyl acetate = 1/1) to obtain the title compound (262 mg, yield 39 %). This was amorphous.
¹H-NMR(CDCl₃) δ: 1.21 (6H, d, J = 7.0 Hz), 1.3-1.4 (2H, m), 1.82 (3H, s), 1.99-2.04 (2H, m), 2.19 (3H, s), 2.23 (3H, s), 2.30 (3H, s), 2.37-2.70 (4H, m), 2.82 (1H, septet, J = 7.0 Hz), 3.81 (3H, s), 4.05 (1H, s), 4.62 (2H, s), 6.6-6.9 (4H, m), 7.05-7.09 (2H, m), 7.33-7.37 (2H, m).

Example 33

20 3-(4-Isopropylphenyl)-1',4,6,7-tetramethyl-5-(4-pyridylmethoxy)spiro[benzofuran-2(3H),4'-piperidine] Sodium hydride (60 % liquid paraffin dispersion, 187.3 mg, 4.98 mmol) was added to a solution of 3-(4-isopropylphenyl)-1',4,6,7-tetramethylspiro[benzofuran-25 2(3H),4'-piperidine]-5-ol (817.7 mg, 2.15 mmol) in N,N-dimethylformamide (30 mL) at 0°C, and the mixture was stirred for 30 minutes at the same temperature. To the reaction mixture was added 4-chloromethylpyridine hydrochloride (364.5 mg, 2.22 mmol) and the mixture was 30 stirred for further 30 minutes at room temperature. The reaction mixture was poured into water, and extracted twice with ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium hydrogencarbonate, dried over magnesium sulfate, 35 filtered, and concentrated under reduced pressure. The residue was subjected to silica gel column


102

chromatography (Chromatorex NH DM1020, Fuji Silysia Chemical LTD) (hexane/ethyl acetate = 4/1) to obtain the title compound (575 mg, yield 57 %).
m.p.: 96-98°C (from hexane).


5 $^1\text{H-NMR}(\text{CDCl}_3)$ δ : 1.21 (6H, d, J = 7.0 Hz), 1.34-1.41 (2H, m), 1.82 (3H, s), 1.92-2.11 (2H, m), 2.19 (3H, s), 2.21 (3H, s), 2.30 (3H, s), 2.37-2.65 (4H, m), 2.85 (1H, septet, J = 7.0 Hz), 4.05 (1H, s), 4.72 (2H, s), 6.6-7.1 (4H, m), 7.36-7.39 (2H, m), 8.58-8.61 (2H, m).

10


The chemical structural formulae of the compounds obtained in these Examples are shown below.



Ex. No.	a	b	c	d	e	f	g	—
1	Me	Me		<chem>*c1ccc(*)cc1</chem>	Me	<chem>*Cc1ccccc1</chem>	Me	Me
2	Me	Me		<chem>*N(c1ccc(*)cc1)C</chem>	Me	<chem>*Cc1ccccc1</chem>	Me	Me
3	Me	<chem>*Cc1ccc(*)cc1</chem>	H	Me	<chem>*Cc1ccccc1</chem>	Me	Me	—
4	Me	Me		<chem>*c1ccc(*)cc1</chem>	Me	<chem>*Oc1ccc(*)cc1</chem>	Me	Me
5	Me	Me		<chem>*c1ccc(*)cc1</chem>	H	<chem>*Oc1ccc(*)cc1</chem>	H	H
6	Me	Me		<chem>*N(c1ccc(*)cc1)C</chem>	Me	<chem>*Oc1ccc(*)cc1</chem>	Me	Me
7	Me	Me	<chem>Oc1ccc(*)cc1</chem>	Me	<chem>*Oc1ccc(*)cc1</chem>	Me	Me	—
8	Me	Me	<chem>*Nc1ccc(*)cc1</chem>	Me	<chem>*Oc1ccc(*)cc1</chem>	Me	Me	—
9	Me	Me		<chem>*c1ccc(*)cc1</chem>	Me	<chem>*S(=O)(=O)c1ccc(*)cc1</chem>	Me	Me
10	Me	Me		<chem>*c1ccc(*)cc1</chem>	Me	<chem>*S(=O)(=O)c1ccc(*)cc1</chem>	Me	Me
11	Me	Me		<chem>*c1ccc(*)cc1</chem>	Me	<chem>*S(=O)(=O)c1ccc(*)cc1</chem>	Me	Me
12	Me	Me		<chem>*c1ccc(*)cc1</chem>	Me	<chem>*Cc1ccccc1</chem>	Me	Me
13	Me	Me		<chem>*c1ccc(*)cc1</chem>	Me	<chem>*Cc1cnc2ccccc2n1</chem>	Me	Me
14	Me	Me		<chem>*c1ccc(*)cc1</chem>	Me	<chem>*Cc1ccccc1Cc2ccccc2</chem>	Me	Me



Ex. No.	a	b	c	d	e	f	g	—
15	Me	Me		Me		Me	Me	—
16	Me	Me		Me		Me	Me	—
17	Me	Me		Me		Me	Me	—
18	Me	Me		Me		Me	Me	—
19	Me	Me		Me		Me	Me	—
20	Me	Me		Me		Me	Me	—
21	Me	Me		Me		Me	Me	—
22	Me	Me		Me		Me	Me	—
23	Me	Me		Me		Me	Me	—
24	Me	Me		Me		Me	Me	—
25	Me	Me		Me		Me	Me	—
26	Me	-		Me		Me	Me	—
27	Me	-		Me		Me	Me	—
28	Me	-		Me		Me	Me	—
29	Me	Me		H	H		H	—



Ex. No.	c	d	e	f	g	h
30		Me		Me	Me	
31	H	Me		Me	Me	
32		Me		Me	Me	Me
33		Me		Me	Me	Me

Formulation Example 1

	(1) Compound obtained in Example 4	50 mg
	(2) Lactose	34 mg
	(3) Corn starch	10.6 mg
5	(4) Corn starch (paste)	5 mg
	(5) Magnesium stearate	0.4 mg
	(6) Calcium carboxymethyl cellulose	20 mg
	Total	120 mg

10 (1) to (6) were mixed in an ordinary manner, and
tabletted into tablets using a tabletting machine.

Experimental Example 1

15 Evaluation of cell protective activity against β -amyloid neurotoxicity in human neuroblastoma SK-N-SH cells

Method**a) Material Used**

20 Human neurblastoma SK-N-SH cells: obtained from American Type Tissue Culture Collection (ATCC).
DMEM/F-12 medium: obtained from Nikken Biological Medicine Laboratory Co.
Ca⁺⁺ and Mg⁺⁺ free phosphate-buffered saline (PBS(-)): obtained form Nikken Biological Medicine Laboratory Co.
25 N2 supplement TM, and EDTA solution: obtained from Gibco BRL Co.
Fetal calf serum, and mixture of penicillin (5000 U/mL) and streptomycin (5 mg/mL): obtained from Bio Whittaker Co.
30 Recombinant human interferon gamma (rhIFN- γ): obtained from Wako Pure Chemical Co.
Alamar Blue TM reagent: obtained from AccuMed International, Inc.
35 Culture flasks: manufactured by Falcon Co.
Collagen-coated, 96-well multi-plate: manufactured

by Iwaki Glass Co.

β -amyloid 25-35: obtained from Bachem AG.

Other reagents: commercially-available special-grade chemicals.

5

b) Test Method

(1) Cultivation of SK-N-SH cells

SK-N-SH cells were sub-cultured in DMEM/F12 medium containing 5 % FCS, 0.5 % N2 supplement TM, 1 % of mixture of penicillin (5000 U/mL) and streptomycin (5 mg/mL), under 10 % CO₂ and 90 % air, using CO₂ incubator. At sub-confluent condition, cells were harvested from culture flask with PBS(-) containing 2.5 mM EDTA, and plated at a density of 1.0 x 10⁴ cells/100 μ l of culture medium/well in collagen-coated 96-well multi-plate. The next day, 80 μ l of culture medium was substituted with DMEM/F12 medium (containing neither FCS nor N2 supplement) containing 1.25 ng/mL of rhIFN- γ , and after 24 hr cultivation cells were used for cell toxicity assay mentioned below.

(2) Measurement of cell protective activity of test compounds against β -amyloid 25-35-induced neurotoxicity

After pretreatment of SK-N-SH cells with rhIFN- γ in collagen-coated 96 well multi-plate, cell toxicity assay was started by addition of β -amyloid 25-35 and test compound. Briefly, 80 μ l of culture medium was removed, and 40 μ l of β -amyloid 25-35 and 40 μ l of test compound were added to cultures at the same time. The final concentrations of β -amyloid 25-35 and test compounds were 10 μ M and 1 μ M, respectively.

The test compound was dissolved at 10 mM in dimethylsulfoxide (DMSO) and diluted in DMEM/F12 medium. β -amyloid 25-35 was dissolved at 5 mM in sterile pure water, and stored at -80°C. Immediately before use,

the stock solution β -amyloid 25-35 was diluted in DMEM/F12 medium and sonicated.

5 (3) Evaluation of cell protective activity of test compound

Cell viability was assessed by the reduction of Alamar Blue™ reagents, 3 days after starting of the cell toxicity assay. Briefly, 20 μ l of culture medium was substituted with 20 μ l of Alamar Blue™ reagents 10 and incubated 4 hours. Absorbances were determined at wavelengths of 570 nm and 600 nm using a plate reader (MTP-32 Micro-plate Reader, manufactured by Corona Co.). Amount of reduced Alamar Blue™ reagents was determined 15 by subtracting absorbance₆₀₀ from absorbance₅₇₀. The cell protective activity of the test compound was estimated according to the following equation:

20 Cell protective activity of compound
 = [(A-B)/(C-B)] x 100 (%)
where;
A: cell viability of the group treated with both the test compound and β -amyloid
B: cell viability of the group treated with β -amyloid only
25 C: cell viability of the control group

Results

Cell viability of the group treated with both the test compound and β -amyloid was compared with that 30 group treated with β -amyloid only using Dunnett's test. Cell viability of each group was determined using at least 4 culture well. The data obtained are shown in the following Table.

Compound of Example	Cell Protecting Activity (%)
1	30.7
2	27.9
3	39.4
7	27.3
12	44.8
14	44.2
25	47.0

These data verify that compound (I) and compound (Ia) well suppress β -amyloid toxicity.


5

INDUSTRIAL APPLICABILITY

Compounds (I) and (Ia) have excellent suppressive effects on neurodegeneration and good permeability to the brain, while having low toxicity, and are therefore 10 useful as medicines for preventing and/or treating neurodegenerative diseases.

CLAIMS

1. A compound of the formula:



- 5 wherein R¹ and R² each represents a hydrogen atom or a hydrocarbon group which may be substituted, or R¹ and R² form, taken together with the adjacent carbon atom, a 3- to 8-membered carbo or heterocyclic ring which may be substituted;
- 10 R³ represents a hydrogen atom, a lower alkyl which may be substituted or an aromatic group which may be substituted;
- R⁴ represents (1) an aromatic group which may be substituted, (2) an aliphatic hydrocarbon group
- 15 substituted by an aromatic group which may be substituted, which hydrocarbon group may be further substituted or (3) an acyl;
- X and Y each represents an oxygen atom or a sulfur atom which may be oxidized;
- 20 ---- represents a single bond or a double bond; and ring A represents a benzene ring which may be further substituted apart from the group of the formula: -X-R⁴ wherein each symbol is as defined above, provided that when X and Y are oxygen atoms and ---- is a single bond, R⁴ is not an acyl,
- 25 or a salt thereof.
2. A compound of Claim 1, wherein R¹ and R² each is
- (i) a hydrogen atom or
- (ii) a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆
- 30 cycloalkyl or C₆₋₁₄ aryl group which may be substituted by 1 to 5 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₃ alkylatedioxy, (3) nitro, (4) cyano, (5) optionally halogenated C₁₋₆ alkyl, (6) optionally halogenated C₂₋₆ alkenyl, (7)

optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) C₆₋₁₄ aryl, (10) optionally halogenated C₁₋₆ alkoxy, (11) optionally halogenated C₁₋₆ alkylthio, (12) hydroxy, (13) amino,
5 (14) mono-C₁₋₆ alkylamino, (15) mono-C₆₋₁₄ arylamino, (16) di-C₁₋₆ alkylamino, (17) di-C₆₋₁₄ arylamino, (18) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 10 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and
15 C₆₋₁₄ arylsulfinyl, (19) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (20) acyloxy selected from the group consisting of C₁₋₆ 20 alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy, (21) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the
25 group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (22) 5- to 10-membered aromatic heterocyclic group and (23) sulfo, or R¹ and R² form, taken together with the adjacent carbon atom, a C₃₋₈ cycloalkane or a 3- to 8-membered heterocyclic ring, each of which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl, C₇₋₁₆ aralkyl, amino, mono-C₁₋₆ alkylamino, mono-C₆₋₁₄ arylamino, di-C₁₋₆ alkylamino, di-C₆₋₁₄ arylamino and 30 5- to 10-membered aromatic heterocyclic group;
35 R³ is (i) a hydrogen atom,

(ii) a C₁₋₆ alkyl which may be substituted by 1 to 5 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₃ alkyleneoxy, (3) nitro, (4) cyano, (5) optionally halogenated C₁₋₆ alkyl, (6)

5 optionally halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) C₆₋₁₄ aryl, (10) optionally halogenated C₁₋₆ alkoxy, (11) optionally halogenated C₁₋₆ alkylthio, (12) hydroxy, (13) amino, (14) mono-C₁₋₆ alkylamino,

10 (15) mono-C₆₋₁₄ arylamino, (16) di-C₁₋₆ alkylamino, (17) di-C₆₋₁₄ arylamino, (18) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-

15 carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl,

20 (19) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (20) acyloxy selected from the group consisting of C₁₋₆

25 alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy, (21) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the

30 group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (22) 5- to 10-membered aromatic heterocyclic group and (23) sulfo, or

35 (iii) a C₆₋₁₄ aryl or a 5- to 14-membered aromatic heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, each of which may be substituted by 1 to 3 substituents

selected from the group consisting of (1) halogen atoms, (2) C₁₋₃ alkylenedioxy, (3) nitro, (4) cyano, (5) optionally halogenated C₁₋₆ alkyl, (6) optionally halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) optionally halogenated C₁₋₆ alkoxy, (10) optionally halogenated C₁₋₆ alkylthio, (11) hydroxy, (12) amino, (13) mono-C₁₋₆ alkylamino, (14) di-C₁₋₆ alkylamino, (15) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (16) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (17) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (18) acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy, (19) sulfo, (20) C₆₋₁₄ aryl and (21) C₆₋₁₄ aryloxy; R⁴ is (i) a C₆₋₁₄ aryl or a 5- to 14-membered aromatic heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, each of which may be substituted by 1 to 3 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₃ alkylenedioxy, (3) nitro, (4) cyano, (5) optionally halogenated C₁₋₆ alkyl, (6) optionally

halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) optionally halogenated C₁₋₆ alkoxy, (10) optionally halogenated C₁₋₆ alkylthio, (11) hydroxy, (12) amino,
5 (13) mono-C₁₋₆ alkylamino, (14) di-C₁₋₆ alkylamino, (15) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (16) acyl
10 selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono-
15 C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (17) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido,
20 C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (18) acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy,
25 (19) sulfo, (20) C₆₋₁₄ aryl and (21) C₆₋₁₄ aryloxy,
(ii) an aliphatic hydrocarbon group selected from the group consisting of C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl and C₃₋₆ cycloalkyl, which hydrocarbon group substituted by 1 to 3 C₆₋₁₄ aryl or 5- to 14-membered aromatic heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, each of which may be substituted by 1 to 3 substituents
30 selected from the group consisting of (1) halogen atoms, (2) C₁₋₃ alkylenedioxy, (3) nitro, (4) cyano, (5) optionally halogenated C₁₋₆ alkyl, (6) optionally

halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) optionally halogenated C₁₋₆ alkoxy, (10) optionally halogenated C₁₋₆ alkylthio, (11) hydroxy, (12) amino,
5 (13) mono-C₁₋₆ alkylamino, (14) di-C₁₋₆ alkylamino, (15) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (16) acyl
10 selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono-
15 C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (17) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido,
20 C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (18) acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-
25 carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy, (19) sulfo, (20) C₆₋₁₄ aryl and (21) C₆₋₁₄ aryloxy, which hydrocarbon group may be further substituted by 1 to 5 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₃ alkylenedioxy, (3) nitro,
30 (4) cyano, (5) optionally halogenated C₁₋₆ alkyl, (6) optionally halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) C₆₋₁₄ aryl, (10) optionally halogenated C₁₋₆ alkoxy, (11) optionally halogenated C₁₋₆ alkylthio,
35 (12) hydroxy, (13) amino, (14) mono-C₁₋₆ alkylamino, (15) mono-C₆₋₁₄ arylamino, (16) di-C₁₋₆ alkylamino, (17) di-C₆₋₁₄ arylamino, (18) acyl selected from the group

consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl,

5 (19) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (20)

10 acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy,

15 (21) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (22) 5- to 10-membered aromatic heterocyclic group and (23) sulfo, or

20 (iii) an acyl of the formula: -(C=O)-R⁵, -(C=O)-OR⁵, -(C=O)-NR⁵R⁶, -(C=S)-NHR⁵, -SO₂-R^{5a} or -SO-R^{5a} wherein R⁵ is (a) a hydrogen atom,

25 (b) a C₆₋₁₄ aryl or a 5- to 14-membered aromatic heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, each of which may be substituted by 1 to 3 substituents

30 selected from the group consisting of (1) halogen atoms, (2) C₁₋₃ alkylenedioxy, (3) nitro, (4) cyano, (5) optionally halogenated C₁₋₆ alkyl, (6) optionally halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9)

35 optionally halogenated C₁₋₆ alkoxy, (10) optionally halogenated C₁₋₆ alkylthio, (11) hydroxy, (12) amino, (13) mono-C₁₋₆ alkylamino, (14) di-C₁₋₆ alkylamino, (15)

5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (16) acyl
5 selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono-
10 C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (17) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido,
15 C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (18) acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-
20 carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy, (19) sulfo, (20) C₆₋₁₄ aryl and (21) C₆₋₁₄ aryloxy, or
(c) a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₆ cycloalkyl group which may be substituted by 1 to 5 substituents selected from the group consisting of (1)
25 C₆₋₁₄ aryl or 5- to 14-membered aromatic heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, each of which may be substituted by 1 to 3 substituents selected from the
30 group consisting of (1') halogen atoms, (2') C₁₋₃ alkylenedioxy, (3') nitro, (4') cyano, (5') optionally halogenated C₁₋₆ alkyl, (6') optionally halogenated C₂₋₆ alkenyl, (7') optionally halogenated C₂₋₆ alkynyl, (8') optionally halogenated C₃₋₆ cycloalkyl, (9') optionally
35 halogenated C₁₋₆ alkoxy, (10') optionally halogenated C₁₋₆ alkylthio, (11') hydroxy, (12') amino, (13') mono-C₁₋₆ alkylamino, (14') di-C₁₋₆ alkylamino, (15') 5- to 7-

membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (16') acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, (17') acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (18') acyloxy selected from the group consisting of C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy, (19') sulfo, (20') C₆₋₁₄ aryl and (21') C₆₋₁₄ aryloxy, (2) halogen atoms, (3) C₁₋₃ alkylenedioxy, (4) nitro, (5) cyano, (6) optionally halogenated C₁₋₆ alkyl, (7) optionally halogenated C₂₋₆ alkenyl, (8) optionally halogenated C₂₋₆ alkynyl, (9) optionally halogenated C₃₋₆ cycloalkyl, (10) optionally halogenated C₁₋₆ alkoxy, (11) optionally halogenated C₁₋₆ alkylthio, (12) hydroxy, (13) amino, (14) mono-C₁₋₆ alkylamino, (15) di-C₁₋₆ alkylamino, (16) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic heterocyclic group, (17) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5- or 6-membered heterocycle

carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl,

5 (18) acylamino selected from the group consisting of formylamino, C₁₋₆ alkyl-carboxamido, C₆₋₁₄ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino and C₆₋₁₄ arylsulfonylamino, (19) acyloxy selected from the group consisting of C₁₋₆

10 alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy and nicotinoyloxy and (20) sulfo;

R^{5a} is (a) a C₆₋₁₄ aryl or a 5- to 14-membered aromatic heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, each of which may be substituted by 1 to 3 substituents selected from the group consisting of (1) halogen atoms,

15 (2) C₁₋₃ alkylenedioxy, (3) nitro, (4) cyano, (5) optionally halogenated C₁₋₆ alkyl, (6) optionally halogenated C₂₋₆ alkenyl, (7) optionally halogenated C₂₋₆ alkynyl, (8) optionally halogenated C₃₋₆ cycloalkyl, (9) optionally halogenated C₁₋₆ alkoxy, (10) optionally halogenated C₁₋₆ alkylthio, (11) hydroxy, (12) amino,

20 (13) mono-C₁₋₆ alkylamino, (14) di-C₁₋₆ alkylamino, (15) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-

25 membered aromatic heterocyclic group, (16) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-

30 carbonyl, 5- or 6-membered heterocycle carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C₁₋₆

alkylsulfonyl, C_{6-14} arylsulfonyl, C_{1-6} alkylsulfinyl and C_{6-14} arylsulfinyl, (17) acylamino selected from the group consisting of formylamino, C_{1-6} alkyl-carboxamido, C_{6-14} aryl-carboxamido, C_{1-6} alkoxy-carboxamido, C_{1-6} 5
alkylsulfonylamino and C_{6-14} arylsulfonylamino, (18) acyloxy selected from the group consisting of C_{1-6} alkyl-carbonyloxy, C_{6-14} aryl-carbonyloxy, C_{1-6} alkoxy-carbonyloxy, mono- C_{1-6} alkyl-carbamoyloxy, di- C_{1-6} alkyl-carbamoyloxy, C_{6-14} aryl-carbamoyloxy and nicotinoyloxy, 10 (19) sulfo, (20) C_{6-14} aryl and (21) C_{6-14} aryloxy, or (b) a C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{3-6} 15 cycloalkyl group which may be substituted by 1 to 5 substituents selected from the group consisting of (1) a C_{6-14} aryl or 5- to 14-membered aromatic heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, each of which may be substituted by 1 to 3 substituents selected from the group consisting of (1') halogen atoms, (2') C_{1-3} , 20 alkyleneoxy, (3') nitro, (4') cyano, (5') optionally halogenated C_{1-6} alkyl, (6') optionally halogenated C_{2-6} alkenyl, (7') optionally halogenated C_{2-6} alkynyl, (8') optionally halogenated C_{3-6} cycloalkyl, (9') optionally halogenated C_{1-6} alkoxy, (10') optionally halogenated C_{1-6} 25 alkylthio, (11') hydroxy, (12') amino, (13') mono- C_{1-6} alkylamino, (14') di- C_{1-6} alkylamino, (15') 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C_{1-6} alkyl, C_{6-14} aryl and 5- to 10- 30 membered aromatic heterocyclic group, (16') acyl selected from the group consisting of formyl, carboxy, carbamoyl, C_{1-6} alkyl-carbonyl, C_{3-6} cycloalkyl-carbonyl, C_{1-6} alkoxy-carbonyl, C_{6-14} aryl-carbonyl, C_{7-16} aralkyl-carbonyl, C_{6-14} aryloxy-carbonyl, C_{7-16} aralkyloxy-carbonyl, 35 5- or 6-membered heterocycle carbonyl, mono- C_{1-6} alkyl-carbamoyl, di- C_{1-6} alkyl-carbamoyl, C_{6-14} aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C_{1-6}

alkylsulfonyl, C_{6-14} arylsulfonyl, C_{1-6} alkylsulfinyl and C_{6-14} arylsulfinyl, (17') acylamino selected from the group consisting of formylamino, C_{1-6} alkyl-carboxamido, C_{6-14} aryl-carboxamido, C_{1-6} alkoxy-carboxamido, C_{1-6}

5 alkylsulfonylamino and C_{6-14} arylsulfonylamino, (18') acyloxy selected from the group consisting of C_{1-6} alkyl-carbonyloxy, C_{6-14} aryl-carbonyloxy, C_{1-6} alkoxy-carbonyloxy, mono- C_{1-6} alkyl-carbamoyloxy, di- C_{1-6} alkyl-carbamoyloxy, C_{6-14} aryl-carbamoyloxy and nicotinoyloxy,

10 (19') sulfo, (20') C_{6-14} aryl and (21') C_{6-14} aryloxy, (2) halogen atoms, (3) C_{1-3} alkylenedioxy, (4) nitro, (5) cyano, (6) optionally halogenated C_{1-6} alkyl, (7) optionally halogenated C_{2-6} alkenyl, (8) optionally halogenated C_{2-6} alkynyl, (9) optionally halogenated C_{3-6} cycloalkyl, (10) optionally halogenated C_{1-6} alkoxy,

15 (11) optionally halogenated C_{1-6} alkylthio, (12) hydroxy, (13) amino, (14) mono- C_{1-6} alkylamino, (15) di- C_{1-6} alkylamino, (16) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents

20 selected from the group consisting of C_{1-6} alkyl, C_{6-14} aryl and 5- to 10-membered aromatic heterocyclic group, (17) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C_{1-6} alkyl-carbonyl, C_{3-6} cycloalkyl-carbonyl, C_{1-6} alkoxy-carbonyl, C_{6-14} aryl-carbonyl, C_{7-16}

25 aralkyl-carbonyl, C_{6-14} aryloxy-carbonyl, C_{7-16} aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono- C_{1-6} alkyl-carbamoyl, di- C_{1-6} alkyl-carbamoyl, C_{6-14} aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C_{1-6} alkylsulfonyl, C_{6-14}

30 arylsulfonyl, C_{1-6} alkylsulfinyl and C_{6-14} arylsulfinyl, (18) acylamino selected from the group consisting of formylamino, C_{1-6} alkyl-carboxamido, C_{6-14} aryl-carboxamido, C_{1-6} alkoxy-carboxamido, C_{1-6} alkylsulfonylamino and C_{6-14} arylsulfonylamino, (19)

35 acyloxy selected from the group consisting of C_{1-6} alkyl-carbonyloxy, C_{6-14} aryl-carbonyloxy, C_{1-6} alkoxy-carbonyloxy, mono- C_{1-6} alkyl-carbamoyloxy, di- C_{1-6} alkyl-

carbamoyloxy, C_{6-14} aryl-carbamoyloxy and nicotinoyloxy and (20) sulfo; and

R^6 is a hydrogen atom or a C_{1-6} alkyl; and

ring A is a benzene ring which may be further

5 substituted by 1 to 3 substituents selected from the group consisting of (1) halogen atoms, (2) C_{1-3} alkylenedioxy, (3) nitro, (4) cyano, (5) optionally halogenated C_{1-6} alkyl, (6) optionally halogenated C_{2-6} alkenyl, (7) optionally halogenated C_{2-6} alkynyl, (8)

10 optionally halogenated C_{3-6} cycloalkyl, (9) optionally halogenated C_{1-6} alkoxy, (10) optionally halogenated C_{1-6} alkylthio, (11) hydroxy, (12) amino, (13) mono- C_{1-6} alkylamino, (14) di- C_{1-6} alkylamino, (15) 5- to 7-membered saturated cyclic amino which may be

15 substituted by 1 to 3 substituents selected from the group consisting of C_{1-6} alkyl, C_{6-14} aryl and 5- to 10-membered aromatic heterocyclic group, (16) acyl selected from the group consisting of formyl, carboxy, carbamoyl, C_{1-6} alkyl-carbonyl, C_{3-6} cycloalkyl-carbonyl,

20 C_{1-6} alkoxy-carbonyl, C_{6-14} aryl-carbonyl, C_{7-16} aralkyl-carbonyl, C_{6-14} aryloxy-carbonyl, C_{7-16} aralkyloxy-carbonyl, 5- or 6-membered heterocycle carbonyl, mono- C_{1-6} alkyl-carbamoyl, di- C_{1-6} alkyl-carbamoyl, C_{6-14} aryl-carbamoyl, 5- or 6-membered heterocycle carbamoyl, C_{1-6}


25 alkylsulfonyl, C_{6-14} arylsulfonyl, C_{1-6} alkylsulfinyl and C_{6-14} arylsulfinyl, (17) acylamino selected from the group consisting of formylamino, C_{1-6} alkyl-carboxamido, C_{6-14} aryl-carboxamido, C_{1-6} alkoxy-carboxamido, C_{1-6} alkylsulfonylamino and C_{6-14} arylsulfonylamino, (18)

30 acyloxy selected from the group consisting of C_{1-6} alkyl-carbonyloxy, C_{6-14} aryl-carbonyloxy, C_{1-6} alkoxy-carbonyloxy, mono- C_{1-6} alkyl-carbamoyloxy, di- C_{1-6} alkyl-carbamoyloxy, C_{6-14} aryl-carbamoyloxy and nicotinoyloxy, (19) sulfo, (20) C_{6-14} aryl and (21) C_{6-14} aryloxy.

35 3. A compound of Claim 1, wherein R^1 and R^2 each is a C_{1-6} alkyl which may be substituted, or R^1 and R^2 form, taken together with the adjacent carbon atom, a 3- to

8-membered carbo or heterocyclic ring which may be substituted.

4. A compound of Claim 1, R³ is an aromatic group which may be substituted.
5. A compound of Claim 1, wherein R⁴ is (i) an aliphatic hydrocarbon group substituted by an aromatic group which may be substituted, which hydrocarbon group may be further substituted or (ii) an acyl.
6. A compound of Claim 1, wherein X is an oxygen atom.
- 10 7. A compound of Claim 1, wherein Y is an oxygen atom.
8. A compound of Claim 7, wherein a group of the formula: -X-R⁴ is substituted on the 5-position of the benzofuran ring.
9. A compound of Claim 1, which is a compound of the
- 15 formula:



wherein each symbol is as defined in Claim 1, or a salt thereof.

10. A compound of Claim 1, wherein R¹ and R² each is a C₁₋₆ alkyl which may be substituted by 1 to 3 substituents selected from the group consisting of (1) C₆₋₁₄ aryl, (2) C₁₋₆ alkoxy, (3) C₁₋₆ alkylthio, (4) hydroxy, (5) amino, (6) mono-C₁₋₆ alkylamino, (7) mono-C₆₋₁₄ arylamino, (8) di-C₁₋₆ alkylamino, (9) di-C₆₋₁₄ arylamino, (10) carboxy, (11) C₁₋₆ alkylsulfonyl, (12) C₆₋₁₄ arylsulfonyl, (13) C₁₋₆ alkylsulfinyl, (14) C₆₋₁₄ arylsulfinyl and (15) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic group, or R¹ and R² form, taken together with the adjacent carbon atom, a 3- to 8-membered carbo or heterocyclic ring which may be substituted by 1 to 3 substituents

selected form the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl, C₇₋₁₆ aralkyl and 5- to 10-membered aromatic heterocyclic group;

R³ is a phenyl, 1-naphthyl, 2-naphthyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 1-isoquinolyl, 1-indolyl, 2-indolyl or 2-benzothiazolyl group, each of which may be substituted by 1 to 3 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₆ alkyl, (3) C₁₋₆ alkoxy, (4) mono-C₁₋₆ alkylamino, (5) di-C₁₋₆ alkylamino and (6) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected form the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic group;

R⁴ is (i) C₁₋₆ alkyl substituted by a phenyl, 1-naphthyl, 2-naphthyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 1-isoquinolyl, 1-indolyl, 2-indolyl or 2-benzothiazolyl group, each of which may be substituted by 1 to 3 substituents selected from the group consisting of (1) halogen atoms, (2) C₁₋₆ alkyl, (3) C₁₋₆ alkoxy, (4) hydroxy, (5) amino, (6) mono-C₁₋₆ alkylamino, (7) di-C₁₋₆ alkylamino, (8) carboxy and (9) 5- to 7-membered saturated cyclic amino which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and 5- to 10-membered aromatic group, which C₁₋₆ alkyl may be further substituted by carboxy or C₁₋₆ alkoxy-carbonyl, or (ii) a C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₆₋₁₄ aryl-carbonyl or C₇₋₁₆ aralkyl-carbonyl group, each of which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino and carboxy;

X is an oxygen atom;

Y is an oxygen atom; and


ring A is a benzene ring which may be further substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆

5 alkoxy, amino, mono-C₁₋₆ alkylamino and di-C₁₋₆ alkylamino.

11. A compound of Claim 1, wherein R¹ and R² each is a C₁₋₆ alkyl which may be substituted by 1 to 3 substituents selected from the group consisting of C₆₋₁₄
- 10 aryl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, mono-C₆₋₁₄ arylamino, di-C₁₋₆ alkylamino, di-C₆₋₁₄ arylamino, carboxy, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl and C₆₋₁₄ arylsulfinyl, or
- 15 R¹ and R² form, taken together with the adjacent carbon atom, a piperidine which may be substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl and C₇₋₁₆ aralkyl;
- R³ is a phenyl which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl, C₁₋₆ alkoxy, amino, mono-C₁₋₆ alkylamino and di-C₁₋₆ alkylamino;
- 20 R⁴ is (i) C₁₋₆ alkyl substituted by a phenyl or pyridyl, each of which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino and carboxy, or
- 25 (ii) an acyl of the formula: -(C=O)-R⁵' wherein R⁵' is a phenyl or phenyl-C₁₋₆ alkyl, each of which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino and carboxy;
- X is an oxygen atom;
- 30 Y is an oxygen atom; and
- 35 ring A is a benzene ring which may be further

substituted by 1 to 3 substituents selected from the group consisting of halogen atoms, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆ alkoxy, amino, mono-C₁₋₆ alkylamino and di-C₁₋₆ alkylamino.

5 12. A compound of Claim 1 which is a compound of the formula:




wherein R¹ and R² each is C₁₋₆ alkyl which may be
 10 substituted by 6-membered saturated cyclic amino
substituted by a phenyl, or
R¹ and R² form, taken together with the adjacent carbon
atom, a piperidine substituted by a C₁₋₆ alkyl or a C₇₋₁₆
aralkyl;

15 R³ is (i) a hydrogen atom, or
(ii) a phenyl which may be substituted by 1 to 3
substituents selected from the group consisting of (1)
C₁₋₆ alkyl, (2) di-C₁₋₆ alkylamino and (3) 6-membered
saturated cyclic amino which may be substituted by a
 20 C₁₋₆ alkyl,

R⁴ is (i) a phenyl which may be substituted by 1 to 3
substituents selected from the group consisting of
nitro and C₁₋₆ alkyl-carboxamido, (ii) a C₁₋₆ alkyl or C₂₋₆
alkenyl group substituted by 1 to 3 of phenyl,
 25 quinolyl or pyridyl, each of which may be substituted
by 1 to 3 substituents selected from the group
consisting of C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxy-
carbonyl, C₁₋₆ alkylsulfonyl and C₁₋₆ alkylsulfinyl,
which C₁₋₆ alkyl or C₂₋₆ alkenyl group may be further
 30 substituted by a phenyl, carboxy or C₁₋₆ alkoxy-carbonyl,
or
(iii) an acyl of the formula: -(C=O)-R^{5''}
wherein R^{5''} is phenyl substituted by a C₁₋₆ alkoxy; and


ring A' is a benzene ring which may be further substituted by 1 to 3 C₁₋₆ alkyl.

13. A compound of Claim 1 which is
 3-(4-isopropylphenyl)-5-(4-methoxybenzyloxy)-2,2,4,6,7-
 5 pentamethyl-2,3-dihydrobenzofuran,
 3-(4-isopropylphenyl)-2,4,6,7-tetramethylbenzofuran-5-
 yl 4-methoxybenzoate,
 3-(4-isopropylphenyl)-5-(4-methoxybenzyloxy)-2,4,6,7-
 tetramethylbenzofuran,
 10 3-(4-isopropylphenyl)-5-(4-methoxybenzyloxy)-1',4,6,7-
 tetramethylspiro[benzofuran-2(3H),4'-piperidine],
 or a salt thereof.
14. A process for producing of a compound of Claim 1, which comprises reacting a compound of the formula:




15 wherein each symbol is as defined in Claim 1, or a salt thereof with a compound of the formula: R⁴-L wherein L represents a leaving group and R⁴ is as defined in Claim 1, or salt thereof.


- 20 15. A pharmaceutical composition which comprises a compound of Claim 1.
16. A composition of Claim 15 which is an agent for suppressing neurodegeneration.
17. A composition of Claim 15 which is an agent for suppressing β-amyloid toxicity.
- 25 18. A composition of Claim 15 which is an agent for preventing and/or treating neurodegenerative diseases.
19. An agent for preventing and/or treating neurodegenerative diseases which comprises a compound
 30 of the formula:



- wherein R¹ and R² each represents a hydrogen atom or a hydrocarbon group which may be substituted, or R¹ and R² form, taken together with the adjacent carbon atom, a 3- to 8-membered carbo or heterocyclic ring which may be substituted;
- R³ represents a hydrogen atom, a lower alkyl which may be substituted or an aromatic group which may be substituted;
- 5 R^{4a} represents an aromatic group which may be substituted, an aliphatic hydrocarbon group which may be substituted or an acyl;
- Xa represents an oxygen atom or a sulfur atom which may be oxidized;
- 10 Ya represents an oxygen atom, a sulfur atom which may be oxidized or an imino which may be substituted;
- represents a single bond or a double bond;
- ring Aa represents a benzene ring which may be further substituted apart from (i) the group of the formula:
- 15 -Xa-R^{4a} wherein each symbol is as defined above, and (ii) an amino which may be substituted,
- provided that when Xa and Ya are oxygen atoms and ----- is a single bond, R⁴ is not an acyl,
- 20 or a salt thereof.
- 25 20. An agent of Claim 19 which is an agent for suppressing β-amyloid toxicity.
21. An agent of Claim 19 which is an agent for preventing and/or treating neurodegenerative diseases.
22. A method for suppressing neurodegeneration in
- 30 mammal, which comprises administering to said mammal an effective amount of a compound of the formula:



- wherein R¹ and R² each represents a hydrogen atom or a hydrocarbon group which may be substituted, or R¹ and R² form, taken together with the adjacent carbon atom, a 3- to 8-membered carbo or heterocyclic ring which may be substituted;
- R³ represents a hydrogen atom, a lower alkyl which may be substituted or an aromatic group which may be substituted;
- 10 R^{4a} represents an aromatic group which may be substituted, an aliphatic hydrocarbon group which may be substituted or an acyl;
- Xa represents an oxygen atom or a sulfur atom which may be oxidized;
- 15 Ya represents an oxygen atom, a sulfur atom which may be oxidized or an imino which may be substituted;
- represents a single bond or a double bond;
- ring Aa represents a benzene ring which may be further substituted apart from (i) the group of the formula:
- 20 -Xa-R^{4a} wherein each symbol is as defined above, and (ii) an amino which may be substituted, provided that when Xa and Ya are oxygen atoms and ---- is a single bond, R⁴ is not an acyl,
- or a pharmaceutically acceptable salt thereof with a
- 25 pharmaceutically acceptable excipient, carrier or diluent.
23. Use of a compound of the formula:



- wherein R¹ and R² each represents a hydrogen atom or a hydrocarbon group which may be substituted, or
- 30

R¹ and R² form, taken together with the adjacent carbon atom, a 3- to 8-membered carbo or heterocyclic ring which may be substituted;

5 R³ represents a hydrogen atom, a lower alkyl which may be substituted or an aromatic group which may be substituted;

R^{4a} represents an aromatic group which may be substituted, an aliphatic hydrocarbon group which may be substituted or an acyl;

10 Xa represents an oxygen atom or a sulfur atom which may be oxidized;

Ya represents an oxygen atom, a sulfur atom which may be oxidized or an imino which may be substituted;

---- represents a single bond or a double bond;

15 ring Aa represents a benzene ring which may be further substituted apart from (i) the group of the formula:

-Xa-R^{4a} wherein each symbol is as defined above, and
(ii) an amino which may be substituted,

provided that when Xa and Ya are oxygen atoms and ----

20 is a single bond, R⁴ is not an acyl,
or a salt thereof for manufacturing a pharmaceutical composition for suppressing neurodegeneration.

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 307/79, 307/81, 405/06, 413/06, A61K 31/34		A3	(11) International Publication Number: WO 98/55454 (43) International Publication Date: 10 December 1998 (10.12.98)
(21) International Application Number:	PCT/JP98/02482		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	4 June 1998 (04.06.98)		
(30) Priority Data:	9/148325 5 June 1997 (05.06.97)	JP	
(71) Applicant (for all designated States except US):	TAKEDA CHEMICAL INDUSTRIES, LTD. [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP).		Published With international search report.
(72) Inventors; and			
(75) Inventors/Applicants (for US only):	OHKAWA, Shigenori [JP/JP]; 45-20, Makamicho 6-chome, Takatsuki-shi, Osaka 569-1121 (JP). SETOH, Masaki [JP/JP]; 18-D73-302, Tsukumodai 5-chome, Suita-shi, Osaka 565-0862 (JP). KAKIHANA, Mitsuru [JP/JP]; 4-2, Tsukushigaoka 9-chome, Kita-ku, Kobe-shi, Hyogo 651-1212 (JP). OKURA, Masahiro [JP/JP]; 6-3-A, Shibuya 2-chome, Ikeda-shi, Osaka 563-0028 (JP).		(88) Date of publication of the international search report: 4 March 1999 (04.03.99)
(74) Agents:	ASAHINA, Tadao et al.; Osaka Plant of Takeda Chemical Industries, Ltd., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-0024 (JP).		

(54) Title: BENZOFURANS AND BENZOTOPHENES AS SUPPRESSORS OF NEURODEGENERATION



(57) Abstract

A compound of formula (I): wherein R¹ and R² each is H or a hydrocarbon group which may be substituted, or R¹ and R² form a 3- to 8-membered carbo or heterocyclic ring which may be substituted; R³ is H, a lower alkyl which may be substituted or an aromatic group which may be substituted; R⁴ is (1) an aromatic group which may be substituted, (2) an aliphatic hydrocarbon group substituted by an aromatic group which may be substituted, which hydrocarbon group may be further substituted or (3) an acyl; X and Y each is oxygen or sulfur which may be oxidized; and ring A is a benzene ring which may be further substituted, or a salt thereof, is useful for an agent for suppressing neurodegeneration.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 98/02482

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D307/79 C07D307/81 C07D405/06 C07D413/06 A61K31/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHEMICAL ABSTRACTS, vol. 110, no. 19, 8 May 1989 Columbus, Ohio, US; abstract no. 173099g, page 762; XP002074285 see abstract & CN 88 100 659 A (MITSUI PETROCHEMICAL INDUSTRIES) 14 September 1988</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-12,14

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 October 1998

Date of mailing of the international search report

02.12.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT

Intell. Application No
PCT/JP 98/02482

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 126, no. 17, 28 April 1997 Columbus, Ohio, US; abstract no. 225226y, page 570; XP002074286 see abstract & ZA 9 509 262 A (ABBOTT ALBORATORIES) 29 May 1996 ---	1-12,14
P,X	DE 196 02 095 A (BAYER AG) 24 July 1997 see claim 1; example 42 ---	1-12,14
X	PATENT ABSTRACTS OF JAPAN vol. 096, no. 001, 31 January 1996 & JP 07 247263 A (NIPPON SODA CO., LTD.), 26 September 1995 see abstract ---	1-12,14
X	US 4 659 360 A (J. S. BAUM, T. M. CHEN) 21 April 1987 see claim 1; examples 100,101 ---	1-12,14
X	EP 0 165 810 A (MERCK FROSST CANADA INC.) 27 December 1985 see claim 1; example 34A ---	1-12,14
X	US 4 426 385 A (P. A. CAIN) 17 January 1984 see column 15, line 20-21 ---	1-12,14
X	EP 0 054 924 A (THE WELLCOME FOUNDATION LTD.) 30 June 1982 * Compounds of formula V * see example 5A ---	1-12,14
P,X	US 5 681 842 A (J. F. DELLARIA, T. H. GANE) 28 October 1997 see claim 1; example 3 ---	1-12,14
X	EP 0 733 631 A (TAKEDA CHEMICAL INDUSTRIES, LTD.) 25 September 1996 see claim 1 ---	1-12,14
X	PATENT ABSTRACTS OF JAPAN vol. 095, no. 009, 31 October 1995 & JP 07 145147 A (YAMANOUCHI PHARMACEUT. CO., LTD.), 6 June 1995 see abstract ---	1-12,14
X	PATENT ABSTRACTS OF JAPAN vol. 095, no. 002, 31 March 1995 & JP 06 312976 A (YAMANOUCHI PHARMACEUT. CO., LTD.), 8 November 1994 see abstract ---	1-12,14

INTERNATIONAL SEARCH REPORT

Intern'l Application No.
PCT/JP 98/02482

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 015, no. 392, 4 October 1991 & JP 03 161405 A (MITSUI PETROCHEM. IND., LTD.), 11 July 1991 see abstract ---	1-12,14
X	EP 0 394 043 A (SUMITOMO CHEMICAL COMPANY, LIMITED) 24 October 1990 see claim 1; examples 1-619 ---	1-12,14
X	EP 0 365 925 A (MITSUBISHI KASEI CORPORATION) 2 May 1990 see claim 1; example 67 ---	1-12,14
X	EP 0 729 956 A (ELI LILLY AND COMPANY) 4 September 1996 * Examples * see claim 1 ---	1-12,14
X	WO 91 05474 A (MITSUI PETROCHEMICAL INDUSTRIES, LTD.) 2 May 1991 see claim 1 ---	1-12,14
X	PATENT ABSTRACTS OF JAPAN vol. 015, no. 377, 24 September 1991 & JP 03 151311 A (MITSUI PETROCHEM. IND., LTD.), 27 June 1991 see abstract ---	1-12,14
X	PATENT ABSTRACTS OF JAPAN vol. 016, no. 066, 19 February 1992 & JP 03 261778 A (KOTOBUKI SEIYAKU K.K.), 21 November 1991 see abstract ---	1-12,14
X	PATENT ABSTRACTS OF JAPAN vol. 016, no. 518, 26 October 1992 & JP 04 193803 A (MITSUI PETROCHEM. IND. LTD.), 13 July 1992 see abstract ---	1-12,14
X	EP 0 526 951 A (SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B. V.) 10 February 1993 see claim 1; example 76 ---	1-12,14
X	PATENT ABSTRACTS OF JAPAN vol. 018, no. 625, 29 November 1994 & JP 06 239853 A (MITSUI PETROCHEM. IND. LTD.), 30 August 1994 see abstract ---	1-12,14
X	WO 95 09159 A (OTSUKA PHARMACEUTICAL CO., LTD.) 6 April 1995 see claim 1 ---	1-12,14

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 98/02482

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 095, no. 010, 30 November 1995 & JP 07 179856 A (CANON K. K.), 18 July 1995 * page 8, scheme B; page 9, groups Cm2, Hα1, Hα2, Hb1, Hb2 * see abstract; claim 1 ---	1-12,14
P,X	WO 97 34869 A (EISAI CO., LTD.) 25 September 1997 see claim 3; example 41 ---	1-12,14
X	WO 95 29907 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 9 November 1995 see claim 1; examples 10-1,10-2 ---	1-12,14
X	WO 96 04251 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 15 February 1996 see claim 1 ---	1-12,14
X	WO 96 20925 A (TORAY INDUSTRIES, INC.) 11 July 1996 see claim 1; examples 9,10,37,42 ---	1-12,14
P,X	EP 0 778 274 A (HELOPHARM G. PETRIK GMBH) 11 June 1997 see claim 1; example 120 ---	1-12,14
X	WO 87 00840 A (MITSUI PETROCHEMICAL INDUSTRIES, LTD.) 12 February 1987 see claim 1; tables 1,2,6,7 ---	1-12,14
X	EP 0 224 816 A (MITSUBISHI CHEMICAL INDUSTRIES LIMITED) 10 June 1987 see claim 1 ---	1-12,14
X	EP 0 277 842 A (MITSUBISHI PETROCHEMICAL INDUSTRIES LTD.) 10 August 1988 see claim 1; table 1 ---	1-12,14
X	PATENT ABSTRACTS OF JAPAN vol. 014, no. 548, 5 December 1990 & JP 02 233679 A (MITSUBISHI KSEI CORP.), 17 September 1990 see abstract ---	1-12,14
P,X	WO 97 25033 A (J. A. BASTIAN ET AL.) 17 July 1997 see claims 1,17 ---	1-12,14
Y	WO 95 17095 A (ELI LILLY AND COMPANY) 29 June 1995 cited in the application see page 6, line 16 - page 7, line 2; claims 1-7 ---	1-23

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/JP 98/02482

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^a	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 281 261 A (H. LUNDBECK A/S) 7 September 1988 see page 1, line 48-50; claims 1-8 ----	1-23
P,Y	WO 98 05292 A (SCHERING CORPORATION) 12 February 1998 see claims 1,10 ----	1-23
Y	EP 0 383 281 A (TOYAMA CHEMICAL CO., LTD.) 22 August 1990 see claims 1,18 ----	1-23
X	WO 96 10999 A (G. D. SEARLE & CO.) 18 April 1996 see claim 1 ----	1-12,14
X	WO 96 11192 A (G. D. SEARLE & CO.) 18 April 1996 see claim 1 ----	1-12,14
X	PATENT ABSTRACTS OF JAPAN vol. 013, no. 501, 10 November 1989 & JP 01 199957 A (DAINIPPON PHARMACEUT. CO., LTD.) see abstract ----	1-12,14
X	EP 0 445 073 A (CIBA-GEIGY AG) 4 September 1991 see claims 1,13,16 ----	1-12,14
Y	EP 0 686 637 A (ADIR ET COMPAGNIE) 13 December 1995 see claims 1,4 ----	1-23
Y	PATENT ABSTRACTS OF JAPAN vol. 016, no. 329, 17 July 1992 & JP 04 095070 A (TOYAMA CHEM. CO., LTD.), 27 March 1992 see abstract ----	1-23
X	M. DAVID ET AL.: "Evaluation of Antiviral Activity of Chromane Diols and their Synthetic Analogues" PHARM. SCI., vol. 3, no. 5/6, 1997, pages 305-309, XP002082798 * Scheme I * ----	1-12,14
		-/-

INTERNATIONAL SEARCH REPORT

Intell. Final Application No

PCT/JP 98/02482

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	B. SNIDER ET AL.: "Synthesis of 2,3-Dihydrobenzofurans by Mn(OAc) ₃ -Based Oxidative Cycloaddition of 2-Cyclohexenones with Alkenes. Synthesis of (+/-)-Conocarpan" J. ORG. CHEM., vol. 62, no. 20, 1997, pages 6978-6984, XP002082799 see page 6597 ---	1-12,14
X	M. MIYAKE ET AL.: "Synthesis and biological activity of arthrographol and related compounds" HETEROCYCLES, vol. 43, no. 3, 1996, pages 665-674, XP002082800 * Scheme 1 * ---	1-12,14
X	H. MATSUTANI ET AL.: "Synthesis of ferroelectric liquid crystals having chiral nitrodihydrobenzofuran structure" MOL. CRYST. LIQ. CRYST. SCI. TECHNOL., SECT. A, vol. 263, 1995, pages 2063-2070, XP002082801 see page 2065 ---	1-12,14
X	M. DAVID ET AL.: "Une nouvelle voie d'accès courte à des chromane diols, des dihydrobenzo[b]furane diols. Différenciations par RMN ¹ H et ¹³ C" BULL. SOC. CHIM. FR., vol. 130, no. 4, 1993, pages 527-534, XP002082802 see table I ---	1-12,14
X	M. M. PONPIPOM ET AL.: "Structure-Activity Relationships of Kadsurenone Analogues" J. MED. CHEM., vol. 30, no. 1, 1987, pages 136-142, XP002082803 * Scheme I, chart II, III * ---	1-12,14
X	R. E. CLINE ET AL.: "Gas Chromatographic and Spectral Properties of Pentafluorobenzyl Derivatives of 2,4-Dichlorophenoxyacetic Acid and Phenolic Pesticides and Metabolites" J. CHROMATOGR. SCI., vol. 28, no. 4, 1990, pages 167-172, XP002082804 see table V ---	1-12,14
		-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 98/02482

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	A. RATNAKAR ET AL.: "Synthesis of a New Type of 5-Heteroaryl-3-Mercapto-4-Amino-1,2,4-Triazoles and their Derivatives" ASIAN J. CHEM., vol. 4, no. 2, 1992, pages 197-200, XP002082805 see table 1 ---	1-12,14
X	Z. M. WANG ET AL.: "The revised structure of gnetifolin A" CHIN. CHEM. LETT., vol. 6, no. 8, 1995, pages 683-686, XP002082806 see figures I,II ---	1-12,14
X	K. CLARKE ET AL.: "Substitution Reactions of Benzo[b]thiophen Derivatives. Part VII. Reactions of 4-Hydroxybenzo[b]thiophen, its 3-Methyl Derivative, and Related Compounds" J. CHEM. SOC., PERKIN TRANS. 1, no. 11, 1973, pages 1196-1200, XP002082807 see page 1197 ---	1-12,14
X	D. S. KEMP, D. R. BUCKLER: "New templates for prior thiol capture from xanthene, dibenzo[c,h]xanthen-7-one and 2-methylenedihydrobenzofuran" TETRAHEDRON LETT., vol. 32, no. 26, 1991, pages 3009-3012, XP002082808 see page 3011 ---	1-12,14
X	M. IWASAKI ET AL.: "Palladium-Catalyzed Cyclocarbonylation of 3-(Heteroaryl)allyl Acetates" J. ORG. CHEM., vol. 56, no. 5, 1991, pages 1922-1927, XP002082809 * Chart I, II * ---	1-12,14
X	M. SHIPCHANDLER ET AL.: "Coumarins. XI. Total synthesis of (+/-)-columbianetin" J. PHARM. SCI., vol. 59, no. 1, 1970, pages 67-71, XP002082810 * Scheme I, II * ---	1-12,14
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 98/02482

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	E. CAMPAIGNE, R. B. ROGERS: "Benzo[b]thiophene Derivatives. XIX. The Sulfur Isosteres of Psilocin and Related Isomers (1)" J. HETEROCYCL. CHEM., vol. 10, no. 3, 1973, pages 297-305, XP002082811 see page 298 ---	1-12,14
X	J. S. KALTENBRONN ET AL.: "Benzofuran derivatives as ET(A)-selective, non-peptide endothelin antagonists" EUR. J. MED. CHEM., vol. 32, no. 5, 1997, pages 425-431, XP002082812 see tables I,II -----	1-12,14

INTERNATIONAL SEARCH REPORT

In. national application No.
PCT/JP 98/02482

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 1-12,14-23(all partly)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos.: 1-12,14-23(all partly)

The open-ended definitions given in the claims are too general and/or encompass too broad a range of totally different chemical groups, only partly supported by examples given in the specification. In view of the exceedingly large number of compounds which are defined by these definitions the search had to be limited to the compounds for which experimental data was given and/or the compounds mentioned in the claims and to the general idea underlying the application. (see Guidelines, Chapter III, paragraph 2.3). However, as the number of documents disclosing compounds which fall under the scope of the present claims still amounts to several hundreds a selection of relevant patent documents is only cited.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern:	1st Application No
PCT/JP 98/02482	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
DE 19602095 A	24-07-1997	AU 1312197 A WO 9727189 A		20-08-1997 31-07-1997
US 4659360 A	21-04-1987	NONE		
EP 165810 A	27-12-1985	AU 4377585 A CA 1281325 A DK 276985 A GR 851493 A JP 61017579 A PT 80660 B US 4863958 A US 5087638 A		02-01-1986 12-03-1991 21-12-1985 25-11-1985 25-01-1986 04-05-1987 05-09-1989 11-02-1992
US 4426385 A	17-01-1984	AR 231972 A AT 15036 T AU 7625081 A BR 8106662 A CA 1190553 A DD 202377 A DK 457781 A EP 0050321 A GR 75828 A IN 155350 A IN 160602 A OA 6932 A PT 73826 B SU 1425190 A JP 1381222 C JP 57158753 A JP 61050940 B ZA 8107110 A		30-04-1985 15-09-1985 22-04-1982 29-06-1982 16-07-1985 14-09-1983 17-04-1982 28-04-1982 02-08-1984 19-01-1985 18-07-1987 31-07-1983 17-01-1983 23-09-1988 28-05-1987 30-09-1982 06-11-1986 29-09-1982
EP 54924 A	30-06-1982	DK 561881 A,B, FI 814058 A,B, GB 2090830 A,B GR 76950 A JP 1623021 C JP 2049294 B JP 57145844 A		19-06-1982 19-06-1982 21-07-1982 04-09-1984 25-10-1991 29-10-1990 09-09-1982

INTERNATIONAL SEARCH REPORT

Information on patent family members			International Application No
Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 54924 A		KE 3745 A OA 6998 A US 4535183 A ZA 8108741 A	04-09-1987 31-08-1983 13-08-1985 27-07-1983
US 5681842 A	28-10-1997	US 5776984 A	07-07-1998
EP 733631 A	25-09-1996	CA 2171702 A JP 8311065 A US 5723479 A	15-09-1996 26-11-1996 03-03-1998
EP 394043 A	24-10-1990	AU 626402 B AU 5298790 A CA 2014763 A EG 19427 A JP 3223256 A US 5206259 A US 5264448 A	30-07-1992 25-10-1990 19-10-1990 28-02-1995 02-10-1991 27-04-1993 23-11-1993
EP 365925 A	02-05-1990	JP 3081266 A DE 68923528 D DE 68923528 T ES 2075026 T KR 9610341 B US 5039693 A	05-04-1991 24-08-1995 28-03-1996 01-10-1995 30-07-1996 13-08-1991
EP 729956 A	04-09-1996	US 5510357 A AU 4579796 A BR 9600829 A CA 2170479 A CN 1159448 A CZ 9600588 A FI 960909 A HU 9600448 A JP 9183776 A NO 960796 A NZ 286079 A PL 312955 A US 5492922 A US 5488058 A	23-04-1996 05-09-1996 30-12-1997 29-08-1996 17-09-1997 11-09-1996 29-08-1996 28-09-1998 15-07-1997 29-08-1996 19-12-1997 02-09-1996 20-02-1996 30-01-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No

PCT/JP 98/02482

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
EP 729956 A		US	5510498 A		23-04-1996
		US	5510358 A		23-04-1996
		US	5723474 A		03-03-1998
WO 9105474 A	02-05-1991	JP	3215404 A		20-09-1991
		JP	3130205 A		04-06-1991
		CA	2042585 A		17-04-1991
		EP	0448723 A		02-10-1991
		US	5223016 A		29-06-1993
EP 526951 A	10-02-1993	CN	1070643 A		07-04-1993
		JP	5213702 A		24-08-1993
WO 9509159 A	06-04-1995	AU	674613 B		02-01-1997
		AU	7666094 A		18-04-1995
		CA	2150345 A		06-04-1995
		CN	1114834 A		10-01-1996
		EP	0670831 A		13-09-1995
		JP	2759257 B		28-05-1998
		JP	8012579 A		16-01-1996
WO 9734869 A	25-09-1997	AU	1942397 A		10-10-1997
WO 9529907 A	09-11-1995	AU	2267395 A		29-11-1995
		EP	0757682 A		12-02-1997
		JP	9512795 T		22-12-1997
		ZA	9503469 A		17-01-1996
WO 9604251 A	15-02-1996	AU	2991595 A		04-03-1996
		EP	0774462 A		21-05-1997
WO 9620925 A	11-07-1996	AU	4357296 A		24-07-1996
		CN	1148381 A		23-04-1997
		EP	0751126 A		02-01-1997
		FI	963477 A		04-11-1996
		NO	963706 A		06-11-1996
EP 778274 A	11-06-1997	DE	19547263 A		12-06-1997
		AU	7411796 A		12-06-1997
		CA	2192044 A		08-06-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No
PCT/JP 98/02482

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 778274	A	JP 9169755 A US 5747508 A		30-06-1997 05-05-1998
WO 8700840	A 12-02-1987	CA 1324147 A CA 1324148 A DE 3684445 A EP 0230475 A US 4838924 A JP 1690863 C JP 3060829 B JP 63010779 A		09-11-1993 09-11-1993 23-04-1992 05-08-1987 13-06-1989 27-08-1992 17-09-1991 18-01-1988
EP 224816	A 10-06-1987	JP 62228070 A US 4705554 A		06-10-1987 10-11-1987
EP 277842	A 10-08-1988	JP 2514945 B JP 63192768 A CA 1302414 A US 5011950 A US 5189183 A		10-07-1996 10-08-1988 02-06-1992 30-04-1991 23-02-1993
WO 9725033	A 17-07-1997	AU 7725596 A EP 0863755 A		01-08-1997 16-09-1998
WO 9517095	A 29-06-1995	AU 1440395 A CA 2176127 A EP 0735821 A JP 9507071 T ZA 9410036 A		10-07-1995 29-06-1995 09-10-1996 15-07-1997 18-06-1996
EP 281261	A 07-09-1988	AU 608293 B AU 1216788 A CA 1338934 A DE 3870666 A DK 91488 A FI 880906 A,B, GR 3004984 T IE 61257 B JP 2677588 B JP 63264557 A		28-03-1991 01-09-1988 25-02-1997 11-06-1992 27-08-1988 27-08-1988 28-04-1993 19-10-1994 17-11-1997 01-11-1988

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 98/02482

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 281261	A	PT	86836 B	29-05-1992
		US	4847254 A	11-07-1989
		US	4946863 A	07-08-1990
-----	-----	-----	-----	-----
WO 9805292	A	12-02-1998	AU 3899997 A	25-02-1998
-----	-----	-----	-----	-----
EP 383281	A	22-08-1990	JP 3232830 A	16-10-1991
			AT 110054 T	15-09-1994
			AT 147065 T	15-01-1997
			AT 154009 T	15-06-1997
			AT 144243 T	15-11-1996
			AU 633539 B	04-02-1993
			AU 4939290 A	23-08-1990
			BE 1003168 A	17-12-1991
			CA 2009886 A,C	14-08-1990
			CA 2160270 A	15-08-1990
			CZ 278503 B	16-02-1994
			DE 69011547 D	22-09-1994
			DE 69011547 T	09-03-1995
			DE 69028930 D	21-11-1996
			DE 69028930 T	20-03-1997
			DE 69029590 D	13-02-1997
			DE 69029590 T	10-07-1997
			DE 69030887 D	10-07-1997
			DE 69030887 T	25-09-1997
			DK 383281 T	12-12-1994
			DK 587193 T	02-06-1997
			DK 587194 T	01-09-1997
			DK 589484 T	18-11-1996
			EP 0587193 A	16-03-1994
			EP 0587194 A	16-03-1994
			EP 0589484 A	30-03-1994
			FR 2643079 A	17-08-1990
			HU 9500675 A	28-12-1995
			IT 1240762 B	17-12-1993
			KR 9312005 B	23-12-1993
			PL 166611 B	30-06-1995
			PL 166607 B	30-06-1995
			SK 68090 A	13-09-1995
			US 5472984 A	05-12-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 98/02482

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 383281 A		US 5658904 A		19-08-1997
		US 5612381 A		18-03-1997
		US 5719150 A		17-02-1998
		US 5280032 A		18-01-1994
		JP 3197422 A		28-08-1991
		JP 3047158 A		28-02-1991

WO 9610999 A	18-04-1996	AU 3686695 A		02-05-1996
		CA 2202368 A		18-04-1996
		EP 0786992 A		06-08-1997
		US 5723492 A		03-03-1998

WO 9611192 A	18-04-1996	US 5585492 A		17-12-1996
		AU 3686595 A		02-05-1996
		CA 2202371 A		18-04-1996
		EP 0804427 A		05-11-1997
		US 5719306 A		17-02-1998

EP 445073 A	04-09-1991	AU 7124691 A		29-08-1991
		CA 2036975 A		28-08-1991
		JP 4211684 A		03-08-1992
		PT 96864 A		31-10-1991

EP 686637 A	13-12-1995	FR 2721027 A		15-12-1995
		AU 681780 B		04-09-1997
		AU 2052395 A		14-12-1995
		CA 2151096 A		09-12-1995
		CN 1120541 A		17-04-1996
		FI 952802 A		09-12-1995
		JP 7330778 A		19-12-1995
		NO 952249 A		11-12-1995
		NZ 272298 A		28-05-1996
		US 5593989 A		14-01-1997
		US 5668142 A		16-09-1997
		ZA 9504738 A		26-01-1996
